GENE	ONTOLOGY	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count	gene_names
AR	BP	GO:0030518	intracellular steroid hormone receptor signaling pathway	May-29	115/18614	8.70E-07	9.37E-05	4.98E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
AR	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
AR	BP	GO:0043401	steroid hormone mediated signaling pathway	May-29	135/18614	1.92E-06	1.81E-04	9.62E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
AR	BP	GO:0061180	mammary gland epithelium development	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
AR	BP	GO:1902893	regulation of miRNA transcription	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
AR	BP	GO:0061614	miRNA transcription	Apr-29	69/18614	3.83E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
AR	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
AR	BP	GO:0033143	regulation of intracellular steroid hormone receptor signaling pathway	Apr-29	72/18614	4.54E-06	3.19E-04	1.70E-04	367/2033/3065/6714	4	AR/EP300/HDAC1/SRC
AR	BP	GO:0060444	branching involved in mammary gland duct morphogenesis	Mar-29	22/18614	5.13E-06	3.46E-04	1.84E-04	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:2000628	regulation of miRNA metabolic process	Apr-29	81/18614	7.27E-06	4.05E-04	2.15E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
AR	BP	GO:0009755	hormone-mediated signaling pathway	May-29	192/18614	1.08E-05	4.97E-04	2.64E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
AR	BP	GO:0060603	mammary gland duct morphogenesis	Mar-29	30/18614	1.34E-05	5.71E-04	3.03E-04	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0010586	miRNA metabolic process	Apr-29	97/18614	1.49E-05	6.17E-04	3.28E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
AR	BP	GO:0071383	cellular response to steroid hormone stimulus	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
AR	BP	GO:2001234	negative regulation of apoptotic signaling pathway	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	367/1457/3065/9821/6714	5	AR/CSNK2A1/HDAC1/RB1CC1/SRC
AR	BP	GO:0001701	in utero embryonic development	Jun-29	398/18614	2.88E-05	0.001012157	5.38E-04	367/2885/5594/4087/4088/7157	6	AR/GRB2/MAPK1/SMAD2/SMAD3/TP53
AR	BP	GO:0060443	mammary gland morphogenesis	Mar-29	45/18614	4.62E-05	0.001492153	7.93E-04	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0030521	androgen receptor signaling pathway	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	367/2033/3065	3	AR/EP300/HDAC1
AR	BP	GO:0030879	mammary gland development	Apr-29	136/18614	5.62E-05	0.001650943	8.78E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
AR	BP	GO:0048009	insulin-like growth factor receptor signaling pathway	Mar-29	50/18614	6.34E-05	0.001830608	9.73E-04	367/2885/5594	3	AR/GRB2/MAPK1
AR	BP	GO:1902895	positive regulation of miRNA transcription	Mar-29	51/18614	6.73E-05	0.001908899	0.001014631	367/4088/7157	3	AR/SMAD3/TP53
AR	BP	GO:0030520	intracellular estrogen receptor signaling pathway	Mar-29	54/18614	7.99E-05	0.00221531	0.001177497	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0030522	intracellular receptor signaling pathway	May-29	299/18614	8.95E-05	0.002336435	0.001241878	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
AR	BP	GO:2000630	positive regulation of miRNA metabolic process	Mar-29	60/18614	1.10E-04	0.002566918	0.001364386	367/4088/7157	3	AR/SMAD3/TP53
AR	BP	GO:0060736	prostate gland growth	Feb-29	11/18614	1.28E-04	0.002908472	0.001545931	367/2099	2	AR/ESR1
AR	BP	GO:0048545	response to steroid hormone	May-29	339/18614	1.61E-04	0.003257009	0.001731188	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
AR	BP	GO:0043627	response to estrogen	Mar-29	70/18614	1.74E-04	0.00341922	0.001817407	367/2033/2099	3	AR/EP300/ESR1
AR	BP	GO:0061138	morphogenesis of a branching epithelium	Apr-29	188/18614	1.96E-04	0.003691252	0.001961999	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
AR	BP	GO:0001763	morphogenesis of a branching structure	Apr-29	203/18614	2.63E-04	0.004433918	0.002356747	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
AR	BP	GO:2000241	regulation of reproductive process	Apr-29	206/18614	2.79E-04	0.004593103	0.002441358	367/246184/2099/6714	4	AR/CDC26/ESR1/SRC
AR	BP	GO:0071391	cellular response to estrogen stimulus	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	367/2099	2	AR/ESR1
AR	BP	GO:0097191	extrinsic apoptotic signaling pathway	Apr-29	227/18614	4.03E-04	0.005609047	0.002981359	367/9821/4088/6714	4	AR/RB1CC1/SMAD3/SRC
AR	BP	GO:0060749	mammary gland alveolus development	Feb-29	20/18614	4.38E-04	0.005893251	0.003132421	367/2099	2	AR/ESR1
AR	BP	GO:0061377	mammary gland lobule development	Feb-29	20/18614	4.38E-04	0.005893251	0.003132421	367/2099	2	AR/ESR1
AR	BP	GO:0003002	regionalization	May-29	422/18614	4.43E-04	0.005919313	0.003146274	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
AR	BP	GO:2001237	negative regulation of extrinsic apoptotic signaling pathway	Mar-29	99/18614	4.82E-04	0.006234977	0.003314057	367/9821/6714	3	AR/RB1CC1/SRC
AR	BP	GO:0042659	regulation of cell fate specification	Feb-29	25/18614	6.88E-04	0.007825603	0.004159518	367/3065	2	AR/HDAC1
AR	BP	GO:0007389	pattern specification process	May-29	467/18614	7.02E-04	0.007936074	0.004218236	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
AR	BP	GO:0060740	prostate gland epithelium morphogenesis	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	367/2099	2	AR/ESR1
AR	BP	GO:0051091	positive regulation of DNA-binding transcription factor activity	Apr-29	271/18614	7.83E-04	0.008440626	0.004486419	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
AR	BP	GO:0060512	prostate gland morphogenesis	Feb-29	28/18614	8.64E-04	0.0089494	0.004756846	367/2099	2	AR/ESR1
AR	BP	GO:0045165	cell fate commitment	Apr-29	281/18614	8.97E-04	0.00907924	0.00482586	367/3065/4087/7157	4	AR/HDAC1/SMAD2/TP53
AR	BP	GO:0022612	gland morphogenesis	Mar-29	123/18614	9.07E-04	0.00907924	0.00482586	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0033146	regulation of intracellular estrogen receptor signaling pathway	Feb-29	35/18614	0.001350728	0.011549078	0.006138645	367/6714	2	AR/SRC
AR	BP	GO:0035264	multicellular organism growth	Mar-29	145/18614	0.001458362	0.012274545	0.00652425	367/2033/7157	3	AR/EP300/TP53
AR	BP	GO:0060562	epithelial tube morphogenesis	Apr-29	334/18614	0.001696541	0.013439265	0.00714333	367/2099/4088/6714	4	AR/ESR1/SMAD3/SRC
AR	BP	GO:2001236	regulation of extrinsic apoptotic signaling pathway	Mar-29	156/18614	0.001797997	0.014036539	0.007460797	367/9821/6714	3	AR/RB1CC1/SRC
AR	BP	GO:0048754	branching morphogenesis of an epithelial tube	Mar-29	157/18614	0.001831111	0.014226325	0.007561674	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0010453	regulation of cell fate commitment	Feb-29	42/18614	0.001941427	0.014939743	0.007940874	367/3065	2	AR/HDAC1
AR	BP	GO:0048806	genitalia development	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	367/2099	2	AR/ESR1
AR	BP	GO:0030850	prostate gland development	Feb-29	48/18614	0.0025288	0.017962061	0.009547318	367/2099	2	AR/ESR1
AR	BP	GO:0035265	organ growth	Mar-29	180/18614	0.002700744	0.018893519	0.010042412	367/2099/4087	3	AR/ESR1/SMAD2
AR	BP	GO:0060688	regulation of morphogenesis of a branching structure	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	367/2099	2	AR/ESR1
AR	BP	GO:0060135	maternal process involved in female pregnancy	Feb-29	61/18614	0.00405151	0.024012739	0.012763415	367/2099	2	AR/ESR1
AR	BP	GO:1901654	response to ketone	Mar-29	208/18614	0.004056608	0.024012739	0.012763415	367/978/6714	3	AR/CDA/SRC
AR	BP	GO:0002064	epithelial cell development	Mar-29	210/18614	0.004166641	0.024484695	0.013014272	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:1905330	regulation of morphogenesis of an epithelium	Feb-29	65/18614	0.004587294	0.025829504	0.013729074	367/2099	2	AR/ESR1
AR	BP	GO:0001655	urogenital system development	Feb-29	66/18614	0.004726096	0.026518648	0.014095373	367/2099	2	AR/ESR1
AR	BP	GO:0048645	animal organ formation	Feb-29	68/18614	0.005009484	0.027723717	0.0147359	367/5594	2	AR/MAPK1
AR	BP	GO:0008406	gonad development	Mar-29	228/18614	0.005239432	0.028508155	0.015152849	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0045137	development of primary sexual characteristics	Mar-29	233/18614	0.005564295	0.029569806	0.015717146	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0051090	regulation of DNA-binding transcription factor activity	Apr-29	465/18614	0.005565604	0.029569806	0.015717146	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
AR	BP	GO:0050673	epithelial cell proliferation	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	367/2099/5594/4088	4	AR/ESR1/MAPK1/SMAD3
AR	BP	GO:2000243	positive regulation of reproductive process	Feb-29	87/18614	0.008077782	0.037403141	0.019880773	367/6714	2	AR/SRC
AR	BP	GO:0007548	sex differentiation	Mar-29	283/18614	0.00948657	0.042466197	0.022571923	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0048608	reproductive structure development	Mar-29	301/18614	0.011209976	0.047546773	0.025272386	367/2099/6714	3	AR/ESR1/SRC
AR	BP	GO:0061458	reproductive system development	Mar-29	305/18614	0.011616029	0.049011756	0.026051064	367/2099/6714	3	AR/ESR1/SRC
AR	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
AR	MF	GO:0001223	transcription coactivator binding	May-32	43/18369	1.06E-08	9.45E-07	4.03E-07	367/1387/2033/2099/4088	5	AR/CREBBP/EP300/ESR1/SMAD3
AR	MF	GO:0001221	transcription coregulator binding	Jun-32	111/18369	3.39E-08	2.01E-06	8.56E-07	367/1387/2033/2099/3065/4088	6	AR/CREBBP/EP300/ESR1/HDAC1/SMAD3
AR	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
AR	MF	GO:0001091	RNA polymerase II general transcription initiation factor binding	Mar-32	26/18369	1.22E-05	3.37E-04	1.43E-04	367/2099/7157	3	AR/ESR1/TP53
AR	MF	GO:0008013	beta-catenin binding	Apr-32	88/18369	1.60E-05	3.37E-04	1.43E-04	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
AR	MF	GO:0140296	general transcription initiation factor binding	Mar-32	53/18369	1.06E-04	0.001348122	5.74E-04	367/2099/7157	3	AR/ESR1/TP53
AR	MF	GO:0001098	basal transcription machinery binding	Mar-32	61/18369	1.61E-04	0.001689597	7.19E-04	367/2099/7157	3	AR/ESR1/TP53
AR	MF	GO:0001099	basal RNA polymerase II transcription machinery binding	Mar-32	61/18369	1.61E-04	0.001689597	7.19E-04	367/2099/7157	3	AR/ESR1/TP53
AR	MF	GO:0051117	ATPase binding	Mar-32	86/18369	4.45E-04	0.003776103	0.001607803	367/2099/6714	3	AR/ESR1/SRC
AR	MF	GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	May-32	468/18369	0.001198605	0.007136975	0.003038807	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
AR	MF	GO:0001216	DNA-binding transcription activator activity	May-32	472/18369	0.001244795	0.007145292	0.003042348	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
AR	MF	GO:0004879	nuclear receptor activity	Feb-32	46/18369	0.002900871	0.010757398	0.004580323	367/2099	2	AR/ESR1
AR	MF	GO:0098531	ligand-activated transcription factor activity	Feb-32	46/18369	0.002900871	0.010757398	0.004580323	367/2099	2	AR/ESR1
AR	MF	GO:0005496	steroid binding	Feb-32	99/18369	0.012838451	0.037463021	0.015951139	367/2099	2	AR/ESR1
AR	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
AR	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
AR	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
AR	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
AR	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
AR	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
BNIP1	BP	GO:0097194	execution phase of apoptosis	Feb-29	87/18614	0.008077782	0.037403141	0.019880773	662/7157	2	BNIP1/TP53
BOLA2	BP	GO:0051604	protein maturation	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	552900/1387/2033/6714	4	BOLA2/CREBBP/EP300/SRC
BTN3A1	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
BTN3A1	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
BTN3A1	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
BTN3A1	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
BTN3A1	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
BTN3A1	BP	GO:0070661	leukocyte proliferation	May-29	348/18614	1.82E-04	0.003463376	0.001840877	11119/1026/2534/5594/7157	5	BTN3A1/CDKN1A/FYN/MAPK1/TP53
BTN3A1	BP	GO:0050851	antigen receptor-mediated signaling pathway	Apr-29	201/18614	2.54E-04	0.004314593	0.002293322	11119/2534/2885/5594	4	BTN3A1/FYN/GRB2/MAPK1
BTN3A1	BP	GO:0046651	lymphocyte proliferation	Apr-29	306/18614	0.001229728	0.011040225	0.005868176	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
BTN3A1	BP	GO:0050852	T cell receptor signaling pathway	Mar-29	140/18614	0.001318524	0.01145556	0.006088937	11119/2534/5594	3	BTN3A1/FYN/MAPK1
BTN3A1	BP	GO:0032943	mononuclear cell proliferation	Apr-29	313/18614	0.001336677	0.011549078	0.006138645	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
BTN3A1	BP	GO:0050798	activated T cell proliferation	Feb-29	48/18614	0.0025288	0.017962061	0.009547318	11119/2534	2	BTN3A1/FYN
BTN3A1	BP	GO:0042098	T cell proliferation	Mar-29	213/18614	0.004335086	0.0249306	0.013251283	11119/2534/7157	3	BTN3A1/FYN/TP53
CDA	BP	GO:0030308	negative regulation of cell growth	Apr-29	191/18614	2.09E-04	0.003876813	0.00206063	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
CDA	BP	GO:0006206	pyrimidine nucleobase metabolic process	Feb-29	15/18614	2.43E-04	0.004222673	0.002244464	978/5594	2	CDA/MAPK1
CDA	BP	GO:0006140	regulation of nucleotide metabolic process	Mar-29	94/18614	4.14E-04	0.005722622	0.003041727	978/2033/7157	3	CDA/EP300/TP53
CDA	BP	GO:0001558	regulation of cell growth	May-29	420/18614	4.34E-04	0.005893251	0.003132421	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
CDA	BP	GO:0045926	negative regulation of growth	Apr-29	252/18614	5.97E-04	0.007092315	0.003769756	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
CDA	BP	GO:0062014	negative regulation of small molecule metabolic process	Mar-29	107/18614	6.05E-04	0.007094243	0.003770781	978/2033/7157	3	CDA/EP300/TP53
CDA	BP	GO:0045980	negative regulation of nucleotide metabolic process	Feb-29	25/18614	6.88E-04	0.007825603	0.004159518	978/7157	2	CDA/TP53
CDA	BP	GO:0071216	cellular response to biotic stimulus	Apr-29	264/18614	7.11E-04	0.007973549	0.004238155	978/5594/6714/7157	4	CDA/MAPK1/SRC/TP53
CDA	BP	GO:0016049	cell growth	May-29	495/18614	9.13E-04	0.00907924	0.00482586	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
CDA	BP	GO:0009112	nucleobase metabolic process	Feb-29	34/18614	0.001274773	0.011135312	0.005918717	978/5594	2	CDA/MAPK1
CDA	BP	GO:0071496	cellular response to external stimulus	Apr-29	327/18614	0.001569882	0.012877816	0.006844905	978/1026/5594/7157	4	CDA/CDKN1A/MAPK1/TP53
CDA	BP	GO:0062012	regulation of small molecule metabolic process	Apr-29	331/18614	0.001641417	0.013354479	0.007098264	978/2033/6714/7157	4	CDA/EP300/SRC/TP53
CDA	BP	GO:1901654	response to ketone	Mar-29	208/18614	0.004056608	0.024012739	0.012763415	367/978/6714	3	AR/CDA/SRC
CDA	BP	GO:0045936	negative regulation of phosphate metabolic process	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
CDA	BP	GO:0010563	negative regulation of phosphorus metabolic process	Apr-29	440/18614	0.004579782	0.025829504	0.013729074	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
CDA	BP	GO:0097305	response to alcohol	Mar-29	252/18614	0.006908455	0.034036777	0.01809146	978/2534/4087	3	CDA/FYN/SMAD2
CDA	BP	GO:0072527	pyrimidine-containing compound metabolic process	Feb-29	83/18614	0.007376253	0.035266347	0.01874501	978/5594	2	CDA/MAPK1
CDA	MF	GO:0019239	deaminase activity	Feb-32	32/18369	0.001411467	0.007389446	0.003146304	23536/978	2	ADAT1/CDA
CDA	MF	GO:0016810	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	Mar-32	131/18369	0.001511415	0.007686625	0.003272839	23536/978/3065	3	ADAT1/CDA/HDAC1
CDA	MF	GO:0016814	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines	Feb-32	35/18369	0.001687683	0.008147008	0.003468862	23536/978	2	ADAT1/CDA
CDC26	BP	GO:2000241	regulation of reproductive process	Apr-29	206/18614	2.79E-04	0.004593103	0.002441358	367/246184/2099/6714	4	AR/CDC26/ESR1/SRC
CDC26	BP	GO:0033044	regulation of chromosome organization	Mar-29	250/18614	0.006758672	0.033503111	0.017807803	246184/5594/6714	3	CDC26/MAPK1/SRC
CDC26	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
CDC26	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
CDC26	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
CDC26	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
CDC26	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
CDC26	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
CDKN1A	BP	GO:0097193	intrinsic apoptotic signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1026/1984/2033/3065/6714/7157	6	CDKN1A/EIF5A/EP300/HDAC1/SRC/TP53
CDKN1A	BP	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
CDKN1A	BP	GO:0071478	cellular response to radiation	May-29	191/18614	1.05E-05	4.97E-04	2.64E-04	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CDKN1A	BP	GO:0034644	cellular response to UV	Apr-29	93/18614	1.26E-05	5.62E-04	2.99E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CDKN1A	BP	GO:2000279	negative regulation of DNA biosynthetic process	Mar-29	37/18614	2.55E-05	9.58E-04	5.09E-04	1026/6714/7157	3	CDKN1A/SRC/TP53
CDKN1A	BP	GO:2000278	regulation of DNA biosynthetic process	Apr-29	121/18614	3.56E-05	0.001223397	6.50E-04	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
CDKN1A	BP	GO:0071482	cellular response to light stimulus	Apr-29	127/18614	4.30E-05	0.001422587	7.56E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CDKN1A	BP	GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Mar-29	44/18614	4.31E-05	0.001422587	7.56E-04	1026/2033/7157	3	CDKN1A/EP300/TP53
CDKN1A	BP	GO:2000377	regulation of reactive oxygen species metabolic process	Apr-29	150/18614	8.23E-05	0.00221531	0.001177497	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
CDKN1A	BP	GO:0009411	response to UV	Apr-29	154/18614	9.11E-05	0.002336435	0.001241878	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CDKN1A	BP	GO:0034504	protein localization to nucleus	May-29	304/18614	9.68E-05	0.002443574	0.001298825	1026/2534/4088/6714/7157	5	CDKN1A/FYN/SMAD3/SRC/TP53
CDKN1A	BP	GO:0072331	signal transduction by p53 class mediator	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
CDKN1A	BP	GO:0071214	cellular response to abiotic stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CDKN1A	BP	GO:0104004	cellular response to environmental stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CDKN1A	BP	GO:2000379	positive regulation of reactive oxygen species metabolic process	Mar-29	70/18614	1.74E-04	0.00341922	0.001817407	1026/2885/7157	3	CDKN1A/GRB2/TP53
CDKN1A	BP	GO:0070661	leukocyte proliferation	May-29	348/18614	1.82E-04	0.003463376	0.001840877	11119/1026/2534/5594/7157	5	BTN3A1/CDKN1A/FYN/MAPK1/TP53
CDKN1A	BP	GO:0030308	negative regulation of cell growth	Apr-29	191/18614	2.09E-04	0.003876813	0.00206063	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
CDKN1A	BP	GO:0071479	cellular response to ionizing radiation	Mar-29	75/18614	2.13E-04	0.003909723	0.002078123	1026/2885/7157	3	CDKN1A/GRB2/TP53
CDKN1A	BP	GO:0051098	regulation of binding	May-29	369/18614	2.39E-04	0.004206819	0.002236037	1026/2033/4087/4088/6714	5	CDKN1A/EP300/SMAD2/SMAD3/SRC
CDKN1A	BP	GO:0071897	DNA biosynthetic process	Apr-29	198/18614	2.39E-04	0.004206819	0.002236037	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
CDKN1A	BP	GO:0090399	replicative senescence	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0048145	regulation of fibroblast proliferation	Mar-29	87/18614	3.30E-04	0.004984416	0.002649351	1026/2099/7157	3	CDKN1A/ESR1/TP53
CDKN1A	BP	GO:0006977	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0006978	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0042772	DNA damage response, signal transduction resulting in transcription	Feb-29	19/18614	3.94E-04	0.005539882	0.002944596	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0001558	regulation of cell growth	May-29	420/18614	4.34E-04	0.005893251	0.003132421	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
CDKN1A	BP	GO:0072593	reactive oxygen species metabolic process	Apr-29	237/18614	4.74E-04	0.006174999	0.003282178	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
CDKN1A	BP	GO:0008630	intrinsic apoptotic signaling pathway in response to DNA damage	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	1026/2033/7157	3	CDKN1A/EP300/TP53
CDKN1A	BP	GO:0048144	fibroblast proliferation	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	1026/2099/7157	3	CDKN1A/ESR1/TP53
CDKN1A	BP	GO:0045926	negative regulation of growth	Apr-29	252/18614	5.97E-04	0.007092315	0.003769756	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
CDKN1A	BP	GO:0009314	response to radiation	May-29	452/18614	6.06E-04	0.007094243	0.003770781	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CDKN1A	BP	GO:0051348	negative regulation of transferase activity	Apr-29	279/18614	8.73E-04	0.00898774	0.004777225	1026/6714/7157/7532	4	CDKN1A/SRC/TP53/YWHAG
CDKN1A	BP	GO:0016049	cell growth	May-29	495/18614	9.13E-04	0.00907924	0.00482586	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
CDKN1A	BP	GO:0031571	mitotic G1 DNA damage checkpoint signaling	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0044819	mitotic G1/S transition checkpoint signaling	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0071480	cellular response to gamma radiation	Feb-29	30/18614	9.92E-04	0.009519221	0.005059721	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0046651	lymphocyte proliferation	Apr-29	306/18614	0.001229728	0.011040225	0.005868176	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
CDKN1A	BP	GO:0032943	mononuclear cell proliferation	Apr-29	313/18614	0.001336677	0.011549078	0.006138645	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
CDKN1A	BP	GO:0010212	response to ionizing radiation	Mar-29	143/18614	0.001401358	0.011856515	0.006302056	1026/2885/7157	3	CDKN1A/GRB2/TP53
CDKN1A	BP	GO:0009416	response to light stimulus	Apr-29	323/18614	0.001500559	0.0124354	0.006609749	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CDKN1A	BP	GO:0051053	negative regulation of DNA metabolic process	Mar-29	148/18614	0.001546573	0.012751337	0.006777678	1026/6714/7157	3	CDKN1A/SRC/TP53
CDKN1A	BP	GO:0071496	cellular response to external stimulus	Apr-29	327/18614	0.001569882	0.012877816	0.006844905	978/1026/5594/7157	4	CDA/CDKN1A/MAPK1/TP53
CDKN1A	BP	GO:0007265	Ras protein signal transduction	Apr-29	333/18614	0.001678025	0.013358069	0.007100172	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
CDKN1A	BP	GO:0006606	protein import into nucleus	Mar-29	163/18614	0.00203783	0.015460723	0.008217789	1026/4088/7157	3	CDKN1A/SMAD3/TP53
CDKN1A	BP	GO:0051170	import into nucleus	Mar-29	168/18614	0.002220791	0.016424566	0.008730098	1026/4088/7157	3	CDKN1A/SMAD3/TP53
CDKN1A	BP	GO:0009267	cellular response to starvation	Mar-29	170/18614	0.002296745	0.016870633	0.008967194	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	BP	GO:0048660	regulation of smooth muscle cell proliferation	Mar-29	176/18614	0.002534251	0.017962061	0.009547318	1026/3065/6714	3	CDKN1A/HDAC1/SRC
CDKN1A	BP	GO:0034198	cellular response to amino acid starvation	Feb-29	49/18614	0.002633868	0.018586598	0.009879276	1026/5594	2	CDKN1A/MAPK1
CDKN1A	BP	GO:0048659	smooth muscle cell proliferation	Mar-29	180/18614	0.002700744	0.018893519	0.010042412	1026/3065/6714	3	CDKN1A/HDAC1/SRC
CDKN1A	BP	GO:0042770	signal transduction in response to DNA damage	Mar-29	184/18614	0.002873867	0.019350706	0.010285419	1026/2885/7157	3	CDKN1A/GRB2/TP53
CDKN1A	BP	GO:1990928	response to amino acid starvation	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	1026/5594	2	CDKN1A/MAPK1
CDKN1A	BP	GO:0048146	positive regulation of fibroblast proliferation	Feb-29	53/18614	0.00307441	0.019872984	0.010563024	1026/2099	2	CDKN1A/ESR1
CDKN1A	BP	GO:0010332	response to gamma radiation	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0043393	regulation of protein binding	Mar-29	201/18614	0.003685608	0.022489469	0.011953756	1026/2033/6714	3	CDKN1A/EP300/SRC
CDKN1A	BP	GO:0042594	response to starvation	Mar-29	207/18614	0.004002267	0.024012739	0.012763415	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	BP	GO:0042060	wound healing	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	1026/4087/4088/6714	4	CDKN1A/SMAD2/SMAD3/SRC
CDKN1A	BP	GO:0045936	negative regulation of phosphate metabolic process	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
CDKN1A	BP	GO:0010563	negative regulation of phosphorus metabolic process	Apr-29	440/18614	0.004579782	0.025829504	0.013729074	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
CDKN1A	BP	GO:0031669	cellular response to nutrient levels	Mar-29	230/18614	0.005367955	0.02901209	0.015420705	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	BP	GO:0030330	DNA damage response, signal transduction by p53 class mediator	Feb-29	72/18614	0.005599233	0.029569806	0.015717146	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0031667	response to nutrient levels	Apr-29	477/18614	0.006085872	0.03122149	0.01659506	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
CDKN1A	BP	GO:0007264	small GTPase mediated signal transduction	Apr-29	483/18614	0.006357843	0.032384911	0.017213449	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
CDKN1A	BP	GO:0033002	muscle cell proliferation	Mar-29	249/18614	0.006684519	0.033237488	0.017666617	1026/3065/6714	3	CDKN1A/HDAC1/SRC
CDKN1A	BP	GO:0044773	mitotic DNA damage checkpoint signaling	Feb-29	81/18614	0.007036453	0.034457298	0.018314979	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0031668	cellular response to extracellular stimulus	Mar-29	261/18614	0.007607017	0.036049677	0.019161371	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	BP	GO:0044774	mitotic DNA integrity checkpoint signaling	Feb-29	85/18614	0.007723378	0.036281916	0.019284812	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:2000134	negative regulation of G1/S transition of mitotic cell cycle	Feb-29	86/18614	0.007899673	0.036789256	0.019554477	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:0042113	B cell activation	Mar-29	276/18614	0.00886175	0.040568238	0.021563107	1026/2033/7157	3	CDKN1A/EP300/TP53
CDKN1A	BP	GO:1904705	regulation of vascular associated smooth muscle cell proliferation	Feb-29	95/18614	0.009567286	0.042521627	0.022601386	1026/6714	2	CDKN1A/SRC
CDKN1A	BP	GO:1902807	negative regulation of cell cycle G1/S phase transition	Feb-29	97/18614	0.009957409	0.043607514	0.023178564	1026/7157	2	CDKN1A/TP53
CDKN1A	BP	GO:1990874	vascular associated smooth muscle cell proliferation	Feb-29	97/18614	0.009957409	0.043607514	0.023178564	1026/6714	2	CDKN1A/SRC
CDKN1A	CC	GO:1902554	serine/threonine protein kinase complex	Mar-30	121/19518	8.35E-04	0.019706033	0.012656864	1026/1457/9821	3	CDKN1A/CSNK2A1/RB1CC1
CDKN1A	CC	GO:1902911	protein kinase complex	Mar-30	142/19518	0.001325491	0.026067996	0.016743049	1026/1457/9821	3	CDKN1A/CSNK2A1/RB1CC1
CDKN1A	MF	GO:0031625	ubiquitin protein ligase binding	Apr-32	301/18369	0.001769913	0.008147008	0.003468862	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
CDKN1A	MF	GO:0030291	protein serine/threonine kinase inhibitor activity	Feb-32	36/18369	0.001785019	0.008147008	0.003468862	1026/7532	2	CDKN1A/YWHAG
CDKN1A	MF	GO:0044389	ubiquitin-like protein ligase binding	Apr-32	320/18369	0.002211874	0.009602771	0.004088702	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
CDKN1A	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
CDKN1A	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
CDKN1A	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
CDKN1A	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
CDKN1A	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
CDKN1A	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
CDKN1A	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
CDKN1A	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
CDKN1A	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
CDKN1A	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CDKN1A	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CDKN1A	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
CDKN1A	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
CDKN1A	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
CDKN1A	NA	hsa05216	Thyroid cancer	Mar-22	37/8848	9.82E-05	5.12E-04	1.90E-04	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
CDKN1A	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
CDKN1A	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
CDKN1A	NA	hsa05218	Melanoma	Mar-22	73/8848	7.41E-04	0.002691655	0.001000994	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	NA	hsa01524	Platinum drug resistance	Mar-22	75/8848	8.02E-04	0.002850907	0.001060217	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
CDKN1A	NA	hsa04921	Oxytocin signaling pathway	Mar-22	154/8848	0.006246197	0.015339925	0.005704731	1026/5594/6714	3	CDKN1A/MAPK1/SRC
CDKN1A	NA	hsa05217	Basal cell carcinoma	Feb-22	63/8848	0.010516467	0.02405822	0.008946958	1026/7157	2	CDKN1A/TP53
CDKN1A	NA	hsa05202	Transcriptional misregulation in cancer	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	1026/3065/7157	3	CDKN1A/HDAC1/TP53
CDKN1A	NA	hsa05169	Epstein-Barr virus infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	1026/3065/7157	3	CDKN1A/HDAC1/TP53
CDKN1A	NA	hsa04115	p53 signaling pathway	Feb-22	75/8848	0.014676616	0.02849994	0.01059878	1026/7157	2	CDKN1A/TP53
CDKN1A	NA	hsa05222	Small cell lung cancer	Feb-22	93/8848	0.022025036	0.039980229	0.01486816	1026/7157	2	CDKN1A/TP53
CDKN1A	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
CDKN1A	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
CDKN1A	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
CDKN1A	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
CDKN1A	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
CDKN1A	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
CDKN1A	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
CDKN1A	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
CDKN1A	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
CDKN1A	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
CDKN1A	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CDKN1A	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CDKN1A	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
CDKN1A	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
CDKN1A	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
CDKN1A	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
CDKN1A	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
CDKN1A	NA	hsa05216	Thyroid cancer	Mar-22	37/8848	9.82E-05	5.12E-04	1.90E-04	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
CDKN1A	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
CDKN1A	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
CDKN1A	NA	hsa05218	Melanoma	Mar-22	73/8848	7.41E-04	0.002691655	0.001000994	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	NA	hsa01524	Platinum drug resistance	Mar-22	75/8848	8.02E-04	0.002850907	0.001060217	1026/5594/7157	3	CDKN1A/MAPK1/TP53
CDKN1A	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
CDKN1A	NA	hsa04921	Oxytocin signaling pathway	Mar-22	154/8848	0.006246197	0.015339925	0.005704731	1026/5594/6714	3	CDKN1A/MAPK1/SRC
CDKN1A	NA	hsa05217	Basal cell carcinoma	Feb-22	63/8848	0.010516467	0.02405822	0.008946958	1026/7157	2	CDKN1A/TP53
CDKN1A	NA	hsa05202	Transcriptional misregulation in cancer	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	1026/3065/7157	3	CDKN1A/HDAC1/TP53
CDKN1A	NA	hsa05169	Epstein-Barr virus infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	1026/3065/7157	3	CDKN1A/HDAC1/TP53
CDKN1A	NA	hsa04115	p53 signaling pathway	Feb-22	75/8848	0.014676616	0.02849994	0.01059878	1026/7157	2	CDKN1A/TP53
CDKN1A	NA	hsa05222	Small cell lung cancer	Feb-22	93/8848	0.022025036	0.039980229	0.01486816	1026/7157	2	CDKN1A/TP53
CERS4	MF	GO:0016410	N-acyltransferase activity	Mar-32	93/18369	5.60E-04	0.004335707	0.001846073	79603/1387/2033	3	CERS4/CREBBP/EP300
CERS4	MF	GO:0016747	acyltransferase activity, transferring groups other than amino-acyl groups	Mar-32	226/18369	0.007007449	0.022273676	0.009483765	79603/1387/2033	3	CERS4/CREBBP/EP300
CERS4	MF	GO:0016746	acyltransferase activity	Mar-32	253/18369	0.009537861	0.029271365	0.012463266	79603/1387/2033	3	CERS4/CREBBP/EP300
CERS4	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
CERS4	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
CREBBP	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
CREBBP	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
CREBBP	BP	GO:0002223	stimulatory C-type lectin receptor signaling pathway	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
CREBBP	BP	GO:1990840	response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
CREBBP	BP	GO:1990858	cellular response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
CREBBP	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
CREBBP	BP	GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	Jun-29	148/18614	9.32E-08	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
CREBBP	BP	GO:1903844	regulation of cellular response to transforming growth factor beta stimulus	Jun-29	151/18614	1.05E-07	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
CREBBP	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
CREBBP	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
CREBBP	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
CREBBP	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
CREBBP	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
CREBBP	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
CREBBP	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
CREBBP	BP	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
CREBBP	BP	GO:0002220	innate immune response activating cell surface receptor signaling pathway	Apr-29	78/18614	6.26E-06	3.74E-04	1.99E-04	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
CREBBP	BP	GO:0031647	regulation of protein stability	Jun-29	322/18614	8.69E-06	4.25E-04	2.26E-04	1387/2033/5594/4088/6714/7157	6	CREBBP/EP300/MAPK1/SMAD3/SRC/TP53
CREBBP	BP	GO:0071478	cellular response to radiation	May-29	191/18614	1.05E-05	4.97E-04	2.64E-04	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CREBBP	BP	GO:0034644	cellular response to UV	Apr-29	93/18614	1.26E-05	5.62E-04	2.99E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CREBBP	BP	GO:0090287	regulation of cellular response to growth factor stimulus	Jun-29	345/18614	1.29E-05	5.62E-04	2.99E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
CREBBP	BP	GO:0002758	innate immune response-activating signaling pathway	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0002218	activation of innate immune response	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0071482	cellular response to light stimulus	Apr-29	127/18614	4.30E-05	0.001422587	7.56E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CREBBP	BP	GO:0031648	protein destabilization	Mar-29	48/18614	5.61E-05	0.001650943	8.78E-04	1387/2033/6714	3	CREBBP/EP300/SRC
CREBBP	BP	GO:0001666	response to hypoxia	May-29	293/18614	8.13E-05	0.00221531	0.001177497	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
CREBBP	BP	GO:0045089	positive regulation of innate immune response	May-29	300/18614	9.09E-05	0.002336435	0.001241878	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0009411	response to UV	Apr-29	154/18614	9.11E-05	0.002336435	0.001241878	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CREBBP	BP	GO:0036293	response to decreased oxygen levels	May-29	306/18614	9.98E-05	0.002481349	0.001318903	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
CREBBP	BP	GO:0002833	positive regulation of response to biotic stimulus	May-29	327/18614	1.36E-04	0.003058239	0.001625536	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0070482	response to oxygen levels	May-29	333/18614	1.48E-04	0.003154276	0.001676583	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
CREBBP	BP	GO:0071214	cellular response to abiotic stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CREBBP	BP	GO:0104004	cellular response to environmental stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CREBBP	BP	GO:0045088	regulation of innate immune response	May-29	373/18614	2.51E-04	0.004314593	0.002293322	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0006474	N-terminal protein amino acid acetylation	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	1387/2033	2	CREBBP/EP300
CREBBP	BP	GO:1900034	regulation of cellular response to heat	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	1387/2033	2	CREBBP/EP300
CREBBP	BP	GO:0031349	positive regulation of defense response	May-29	441/18614	5.42E-04	0.006631889	0.003525027	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0009314	response to radiation	May-29	452/18614	6.06E-04	0.007094243	0.003770781	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
CREBBP	BP	GO:0002831	regulation of response to biotic stimulus	May-29	463/18614	6.75E-04	0.00779709	0.004144362	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
CREBBP	BP	GO:0090100	positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Mar-29	122/18614	8.86E-04	0.009064455	0.004818001	1387/2033/4087	3	CREBBP/EP300/SMAD2
CREBBP	BP	GO:0031365	N-terminal protein amino acid modification	Feb-29	30/18614	9.92E-04	0.009519221	0.005059721	1387/2033	2	CREBBP/EP300
CREBBP	BP	GO:0030511	positive regulation of transforming growth factor beta receptor signaling pathway	Feb-29	34/18614	0.001274773	0.011135312	0.005918717	1387/2033	2	CREBBP/EP300
CREBBP	BP	GO:1903846	positive regulation of cellular response to transforming growth factor beta stimulus	Feb-29	34/18614	0.001274773	0.011135312	0.005918717	1387/2033	2	CREBBP/EP300
CREBBP	BP	GO:0009416	response to light stimulus	Apr-29	323/18614	0.001500559	0.0124354	0.006609749	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
CREBBP	BP	GO:0051604	protein maturation	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	552900/1387/2033/6714	4	BOLA2/CREBBP/EP300/SRC
CREBBP	BP	GO:0042733	embryonic digit morphogenesis	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	1387/3065	2	CREBBP/HDAC1
CREBBP	BP	GO:0034605	cellular response to heat	Feb-29	67/18614	0.004866828	0.027213818	0.014464874	1387/2033	2	CREBBP/EP300
CREBBP	BP	GO:0016570	histone modification	Apr-29	475/18614	0.005996982	0.031161166	0.016562996	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
CREBBP	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
CREBBP	MF	GO:0001223	transcription coactivator binding	May-32	43/18369	1.06E-08	9.45E-07	4.03E-07	367/1387/2033/2099/4088	5	AR/CREBBP/EP300/ESR1/SMAD3
CREBBP	MF	GO:0001221	transcription coregulator binding	Jun-32	111/18369	3.39E-08	2.01E-06	8.56E-07	367/1387/2033/2099/3065/4088	6	AR/CREBBP/EP300/ESR1/HDAC1/SMAD3
CREBBP	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
CREBBP	MF	GO:0002039	p53 binding	Apr-32	67/18369	5.38E-06	1.92E-04	8.16E-05	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
CREBBP	MF	GO:0031490	chromatin DNA binding	Apr-32	118/18369	5.06E-05	8.19E-04	3.49E-04	1387/2033/3065/4088	4	CREBBP/EP300/HDAC1/SMAD3
CREBBP	MF	GO:0016410	N-acyltransferase activity	Mar-32	93/18369	5.60E-04	0.004335707	0.001846073	79603/1387/2033	3	CERS4/CREBBP/EP300
CREBBP	MF	GO:0043425	bHLH transcription factor binding	Feb-32	31/18369	0.001324689	0.007145292	0.003042348	1387/4088	2	CREBBP/SMAD3
CREBBP	MF	GO:0004402	histone acetyltransferase activity	Feb-32	43/18369	0.002539157	0.010272045	0.004373668	1387/2033	2	CREBBP/EP300
CREBBP	MF	GO:0061733	peptide-lysine-N-acetyltransferase activity	Feb-32	46/18369	0.002900871	0.010757398	0.004580323	1387/2033	2	CREBBP/EP300
CREBBP	MF	GO:0034212	peptide N-acetyltransferase activity	Feb-32	51/18369	0.003554209	0.012404887	0.005281797	1387/2033	2	CREBBP/EP300
CREBBP	MF	GO:0008080	N-acetyltransferase activity	Feb-32	67/18369	0.006057486	0.019967267	0.008501734	1387/2033	2	CREBBP/EP300
CREBBP	MF	GO:0003684	damaged DNA binding	Feb-32	71/18369	0.00677875	0.0219385	0.009341053	1387/2033	2	CREBBP/EP300
CREBBP	MF	GO:0016747	acyltransferase activity, transferring groups other than amino-acyl groups	Mar-32	226/18369	0.007007449	0.022273676	0.009483765	79603/1387/2033	3	CERS4/CREBBP/EP300
CREBBP	MF	GO:0016746	acyltransferase activity	Mar-32	253/18369	0.009537861	0.029271365	0.012463266	79603/1387/2033	3	CERS4/CREBBP/EP300
CREBBP	MF	GO:0016407	acetyltransferase activity	Feb-32	94/18369	0.011630709	0.034504438	0.014691422	1387/2033	2	CREBBP/EP300
CREBBP	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
CREBBP	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
CREBBP	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
CREBBP	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
CREBBP	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
CREBBP	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
CREBBP	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
CREBBP	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
CREBBP	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
CREBBP	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
CREBBP	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
CREBBP	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CREBBP	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CREBBP	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
CREBBP	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
CREBBP	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
CREBBP	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
CREBBP	NA	hsa04330	Notch signaling pathway	Mar-22	62/8848	4.59E-04	0.001824653	6.79E-04	1387/2033/3065	3	CREBBP/EP300/HDAC1
CREBBP	NA	hsa04720	Long-term potentiation	Mar-22	67/8848	5.77E-04	0.002239357	8.33E-04	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
CREBBP	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
CREBBP	NA	hsa03083	Polycomb repressive complex	Mar-22	83/8848	0.001077785	0.0035998	0.001338722	1387/2033/3065	3	CREBBP/EP300/HDAC1
CREBBP	NA	hsa04916	Melanogenesis	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa05164	Influenza A	Mar-22	172/8848	0.008471789	0.020211268	0.007516324	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa03250	Viral life cycle - HIV-1	Feb-22	64/8848	0.010839453	0.024135849	0.008975828	1387/2033	2	CREBBP/EP300
CREBBP	NA	hsa04024	cAMP signaling pathway	Mar-22	226/8848	0.017697314	0.033584675	0.012489731	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa04922	Glucagon signaling pathway	Feb-22	107/8848	0.028593175	0.048725104	0.018120272	1387/2033	2	CREBBP/EP300
CREBBP	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
CREBBP	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
CREBBP	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
CREBBP	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
CREBBP	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
CREBBP	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
CREBBP	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
CREBBP	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
CREBBP	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
CREBBP	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
CREBBP	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
CREBBP	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CREBBP	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
CREBBP	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
CREBBP	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
CREBBP	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
CREBBP	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
CREBBP	NA	hsa04330	Notch signaling pathway	Mar-22	62/8848	4.59E-04	0.001824653	6.79E-04	1387/2033/3065	3	CREBBP/EP300/HDAC1
CREBBP	NA	hsa04720	Long-term potentiation	Mar-22	67/8848	5.77E-04	0.002239357	8.33E-04	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
CREBBP	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
CREBBP	NA	hsa03083	Polycomb repressive complex	Mar-22	83/8848	0.001077785	0.0035998	0.001338722	1387/2033/3065	3	CREBBP/EP300/HDAC1
CREBBP	NA	hsa04916	Melanogenesis	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa05164	Influenza A	Mar-22	172/8848	0.008471789	0.020211268	0.007516324	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa03250	Viral life cycle - HIV-1	Feb-22	64/8848	0.010839453	0.024135849	0.008975828	1387/2033	2	CREBBP/EP300
CREBBP	NA	hsa04024	cAMP signaling pathway	Mar-22	226/8848	0.017697314	0.033584675	0.012489731	1387/2033/5594	3	CREBBP/EP300/MAPK1
CREBBP	NA	hsa04922	Glucagon signaling pathway	Feb-22	107/8848	0.028593175	0.048725104	0.018120272	1387/2033	2	CREBBP/EP300
CSNK2A1	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
CSNK2A1	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
CSNK2A1	BP	GO:2001234	negative regulation of apoptotic signaling pathway	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	367/1457/3065/9821/6714	5	AR/CSNK2A1/HDAC1/RB1CC1/SRC
CSNK2A1	BP	GO:0052548	regulation of endopeptidase activity	May-29	336/18614	1.55E-04	0.003246445	0.001725573	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
CSNK2A1	BP	GO:0001558	regulation of cell growth	May-29	420/18614	4.34E-04	0.005893251	0.003132421	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
CSNK2A1	BP	GO:2000116	regulation of cysteine-type endopeptidase activity	Apr-29	234/18614	4.52E-04	0.005981729	0.003179449	1457/2534/4088/6714	4	CSNK2A1/FYN/SMAD3/SRC
CSNK2A1	BP	GO:0052547	regulation of peptidase activity	May-29	425/18614	4.58E-04	0.006014484	0.00319686	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
CSNK2A1	BP	GO:0016049	cell growth	May-29	495/18614	9.13E-04	0.00907924	0.00482586	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
CSNK2A1	BP	GO:0030177	positive regulation of Wnt signaling pathway	Mar-29	146/18614	0.001487403	0.012389914	0.006585572	1457/4088/6714	3	CSNK2A1/SMAD3/SRC
CSNK2A1	BP	GO:0009895	negative regulation of catabolic process	Apr-29	337/18614	0.001752946	0.013818341	0.007344819	1457/2534/4088/7157	4	CSNK2A1/FYN/SMAD3/TP53
CSNK2A1	BP	GO:0030111	regulation of Wnt signaling pathway	Apr-29	338/18614	0.001772034	0.013901007	0.007388758	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
CSNK2A1	BP	GO:0043281	regulation of cysteine-type endopeptidase activity involved in apoptotic process	Mar-29	204/18614	0.003841933	0.023340465	0.012406084	1457/4088/6714	3	CSNK2A1/SMAD3/SRC
CSNK2A1	BP	GO:0016055	Wnt signaling pathway	Apr-29	461/18614	0.00539908	0.029083044	0.015458418	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
CSNK2A1	BP	GO:0198738	cell-cell signaling by wnt	Apr-29	463/18614	0.005481916	0.029431148	0.015643445	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
CSNK2A1	BP	GO:0043154	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Feb-29	78/18614	0.006540588	0.032839994	0.017455338	1457/6714	2	CSNK2A1/SRC
CSNK2A1	BP	GO:2000117	negative regulation of cysteine-type endopeptidase activity	Feb-29	91/18614	0.008808247	0.040437862	0.021493809	1457/6714	2	CSNK2A1/SRC
CSNK2A1	CC	GO:0016581	NuRD complex	Feb-30	17/19518	3.06E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
CSNK2A1	CC	GO:0090545	CHD-type complex	Feb-30	17/19518	3.06E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
CSNK2A1	CC	GO:0016580	Sin3 complex	Feb-30	22/19518	5.18E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
CSNK2A1	CC	GO:0070822	Sin3-type complex	Feb-30	22/19518	5.18E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
CSNK2A1	CC	GO:1902554	serine/threonine protein kinase complex	Mar-30	121/19518	8.35E-04	0.019706033	0.012656864	1026/1457/9821	3	CDKN1A/CSNK2A1/RB1CC1
CSNK2A1	CC	GO:1902911	protein kinase complex	Mar-30	142/19518	0.001325491	0.026067996	0.016743049	1026/1457/9821	3	CDKN1A/CSNK2A1/RB1CC1
CSNK2A1	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
CSNK2A1	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
CSNK2A1	NA	hsa04137	Mitophagy - animal	Mar-22	105/8848	0.002122452	0.006111198	0.00227268	1457/6714/7157	3	CSNK2A1/SRC/TP53
CSNK2A1	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
CSNK2A1	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
CSNK2A1	NA	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	1457/5594	2	CSNK2A1/MAPK1
CSNK2A1	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
CSNK2A1	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
CSNK2A1	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
CSNK2A1	NA	hsa04137	Mitophagy - animal	Mar-22	105/8848	0.002122452	0.006111198	0.00227268	1457/6714/7157	3	CSNK2A1/SRC/TP53
CSNK2A1	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
CSNK2A1	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
CSNK2A1	NA	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	1457/5594	2	CSNK2A1/MAPK1
CSNK2A1	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
EIF5A	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
EIF5A	BP	GO:0097193	intrinsic apoptotic signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1026/1984/2033/3065/6714/7157	6	CDKN1A/EIF5A/EP300/HDAC1/SRC/TP53
EIF5A	BP	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
EIF5A	BP	GO:0072331	signal transduction by p53 class mediator	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
EIF5A	BP	GO:2001242	regulation of intrinsic apoptotic signaling pathway	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1984/3065/6714/7157	4	EIF5A/HDAC1/SRC/TP53
EIF5A	BP	GO:1901796	regulation of signal transduction by p53 class mediator	Mar-29	106/18614	5.89E-04	0.007049017	0.003746742	1984/2033/7157	3	EIF5A/EP300/TP53
EIF5A	BP	GO:1902253	regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Feb-29	35/18614	0.001350728	0.011549078	0.006138645	1984/7157	2	EIF5A/TP53
EIF5A	BP	GO:2001244	positive regulation of intrinsic apoptotic signaling pathway	Feb-29	63/18614	0.004315506	0.0249306	0.013251283	1984/7157	2	EIF5A/TP53
EIF5A	BP	GO:0071356	cellular response to tumor necrosis factor	Mar-29	235/18614	0.00569757	0.029893744	0.015889327	1984/5594/7157	3	EIF5A/MAPK1/TP53
EIF5A	BP	GO:0034612	response to tumor necrosis factor	Mar-29	257/18614	0.007291568	0.035266347	0.01874501	1984/5594/7157	3	EIF5A/MAPK1/TP53
EIF5A	BP	GO:0098586	cellular response to virus	Feb-29	85/18614	0.007723378	0.036281916	0.019284812	1984/4088	2	EIF5A/SMAD3
EP300	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
EP300	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
EP300	BP	GO:0002223	stimulatory C-type lectin receptor signaling pathway	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
EP300	BP	GO:1990840	response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
EP300	BP	GO:1990858	cellular response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
EP300	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
EP300	BP	GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	Jun-29	148/18614	9.32E-08	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
EP300	BP	GO:1903844	regulation of cellular response to transforming growth factor beta stimulus	Jun-29	151/18614	1.05E-07	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
EP300	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
EP300	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
EP300	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
EP300	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
EP300	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
EP300	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
EP300	BP	GO:0030518	intracellular steroid hormone receptor signaling pathway	May-29	115/18614	8.70E-07	9.37E-05	4.98E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
EP300	BP	GO:0043401	steroid hormone mediated signaling pathway	May-29	135/18614	1.92E-06	1.81E-04	9.62E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
EP300	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
EP300	BP	GO:0033143	regulation of intracellular steroid hormone receptor signaling pathway	Apr-29	72/18614	4.54E-06	3.19E-04	1.70E-04	367/2033/3065/6714	4	AR/EP300/HDAC1/SRC
EP300	BP	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
EP300	BP	GO:0097193	intrinsic apoptotic signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1026/1984/2033/3065/6714/7157	6	CDKN1A/EIF5A/EP300/HDAC1/SRC/TP53
EP300	BP	GO:0002220	innate immune response activating cell surface receptor signaling pathway	Apr-29	78/18614	6.26E-06	3.74E-04	1.99E-04	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
EP300	BP	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
EP300	BP	GO:0031647	regulation of protein stability	Jun-29	322/18614	8.69E-06	4.25E-04	2.26E-04	1387/2033/5594/4088/6714/7157	6	CREBBP/EP300/MAPK1/SMAD3/SRC/TP53
EP300	BP	GO:0071478	cellular response to radiation	May-29	191/18614	1.05E-05	4.97E-04	2.64E-04	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
EP300	BP	GO:0009755	hormone-mediated signaling pathway	May-29	192/18614	1.08E-05	4.97E-04	2.64E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
EP300	BP	GO:0034644	cellular response to UV	Apr-29	93/18614	1.26E-05	5.62E-04	2.99E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
EP300	BP	GO:0090287	regulation of cellular response to growth factor stimulus	Jun-29	345/18614	1.29E-05	5.62E-04	2.99E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
EP300	BP	GO:0002758	innate immune response-activating signaling pathway	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:0071383	cellular response to steroid hormone stimulus	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
EP300	BP	GO:0002218	activation of innate immune response	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:0071482	cellular response to light stimulus	Apr-29	127/18614	4.30E-05	0.001422587	7.56E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
EP300	BP	GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Mar-29	44/18614	4.31E-05	0.001422587	7.56E-04	1026/2033/7157	3	CDKN1A/EP300/TP53
EP300	BP	GO:0030521	androgen receptor signaling pathway	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	367/2033/3065	3	AR/EP300/HDAC1
EP300	BP	GO:0031648	protein destabilization	Mar-29	48/18614	5.61E-05	0.001650943	8.78E-04	1387/2033/6714	3	CREBBP/EP300/SRC
EP300	BP	GO:0001666	response to hypoxia	May-29	293/18614	8.13E-05	0.00221531	0.001177497	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
EP300	BP	GO:0030522	intracellular receptor signaling pathway	May-29	299/18614	8.95E-05	0.002336435	0.001241878	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
EP300	BP	GO:0045089	positive regulation of innate immune response	May-29	300/18614	9.09E-05	0.002336435	0.001241878	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:0009411	response to UV	Apr-29	154/18614	9.11E-05	0.002336435	0.001241878	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
EP300	BP	GO:0036293	response to decreased oxygen levels	May-29	306/18614	9.98E-05	0.002481349	0.001318903	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
EP300	BP	GO:0002833	positive regulation of response to biotic stimulus	May-29	327/18614	1.36E-04	0.003058239	0.001625536	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:0072331	signal transduction by p53 class mediator	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
EP300	BP	GO:0001756	somitogenesis	Mar-29	66/18614	1.46E-04	0.003138186	0.00166803	2033/4088/7157	3	EP300/SMAD3/TP53
EP300	BP	GO:0070482	response to oxygen levels	May-29	333/18614	1.48E-04	0.003154276	0.001676583	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
EP300	BP	GO:0048545	response to steroid hormone	May-29	339/18614	1.61E-04	0.003257009	0.001731188	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
EP300	BP	GO:0071214	cellular response to abiotic stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
EP300	BP	GO:0104004	cellular response to environmental stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
EP300	BP	GO:0043627	response to estrogen	Mar-29	70/18614	1.74E-04	0.00341922	0.001817407	367/2033/2099	3	AR/EP300/ESR1
EP300	BP	GO:0051098	regulation of binding	May-29	369/18614	2.39E-04	0.004206819	0.002236037	1026/2033/4087/4088/6714	5	CDKN1A/EP300/SMAD2/SMAD3/SRC
EP300	BP	GO:0045088	regulation of innate immune response	May-29	373/18614	2.51E-04	0.004314593	0.002293322	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:0009952	anterior/posterior pattern specification	Apr-29	209/18614	2.94E-04	0.004803929	0.002553417	2033/4087/4088/7157	4	EP300/SMAD2/SMAD3/TP53
EP300	BP	GO:0006474	N-terminal protein amino acid acetylation	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	1387/2033	2	CREBBP/EP300
EP300	BP	GO:1900034	regulation of cellular response to heat	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	1387/2033	2	CREBBP/EP300
EP300	BP	GO:0061053	somite development	Mar-29	86/18614	3.19E-04	0.004863024	0.002584828	2033/4088/7157	3	EP300/SMAD3/TP53
EP300	BP	GO:0043254	regulation of protein-containing complex assembly	May-29	409/18614	3.84E-04	0.005539882	0.002944596	2033/2099/2885/6714/7157	5	EP300/ESR1/GRB2/SRC/TP53
EP300	BP	GO:0006140	regulation of nucleotide metabolic process	Mar-29	94/18614	4.14E-04	0.005722622	0.003041727	978/2033/7157	3	CDA/EP300/TP53
EP300	BP	GO:0003002	regionalization	May-29	422/18614	4.43E-04	0.005919313	0.003146274	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
EP300	BP	GO:0035282	segmentation	Mar-29	100/18614	4.97E-04	0.006370133	0.003385897	2033/4088/7157	3	EP300/SMAD3/TP53
EP300	BP	GO:0008630	intrinsic apoptotic signaling pathway in response to DNA damage	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	1026/2033/7157	3	CDKN1A/EP300/TP53
EP300	BP	GO:0010906	regulation of glucose metabolic process	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0031349	positive regulation of defense response	May-29	441/18614	5.42E-04	0.006631889	0.003525027	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:1901796	regulation of signal transduction by p53 class mediator	Mar-29	106/18614	5.89E-04	0.007049017	0.003746742	1984/2033/7157	3	EIF5A/EP300/TP53
EP300	BP	GO:0062014	negative regulation of small molecule metabolic process	Mar-29	107/18614	6.05E-04	0.007094243	0.003770781	978/2033/7157	3	CDA/EP300/TP53
EP300	BP	GO:0009314	response to radiation	May-29	452/18614	6.06E-04	0.007094243	0.003770781	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
EP300	BP	GO:0002831	regulation of response to biotic stimulus	May-29	463/18614	6.75E-04	0.00779709	0.004144362	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
EP300	BP	GO:0007389	pattern specification process	May-29	467/18614	7.02E-04	0.007936074	0.004218236	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
EP300	BP	GO:0006476	protein deacetylation	Mar-29	116/18614	7.66E-04	0.008303657	0.004413616	2033/3065/7157	3	EP300/HDAC1/TP53
EP300	BP	GO:0051091	positive regulation of DNA-binding transcription factor activity	Apr-29	271/18614	7.83E-04	0.008440626	0.004486419	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
EP300	BP	GO:0045815	transcription initiation-coupled chromatin remodeling	Feb-29	27/18614	8.03E-04	0.008537085	0.00453769	2033/7157	2	EP300/TP53
EP300	BP	GO:0007611	learning or memory	Apr-29	276/18614	8.39E-04	0.00885882	0.004708701	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
EP300	BP	GO:0060765	regulation of androgen receptor signaling pathway	Feb-29	28/18614	8.64E-04	0.0089494	0.004756846	2033/3065	2	EP300/HDAC1
EP300	BP	GO:0090100	positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Mar-29	122/18614	8.86E-04	0.009064455	0.004818001	1387/2033/4087	3	CREBBP/EP300/SMAD2
EP300	BP	GO:0031365	N-terminal protein amino acid modification	Feb-29	30/18614	9.92E-04	0.009519221	0.005059721	1387/2033	2	CREBBP/EP300
EP300	BP	GO:0035601	protein deacylation	Mar-29	127/18614	9.96E-04	0.009519221	0.005059721	2033/3065/7157	3	EP300/HDAC1/TP53
EP300	BP	GO:0044262	cellular carbohydrate metabolic process	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2033/9821/6714/7157	4	EP300/RB1CC1/SRC/TP53
EP300	BP	GO:0098732	macromolecule deacylation	Mar-29	131/18614	0.00108881	0.01011217	0.00537489	2033/3065/7157	3	EP300/HDAC1/TP53
EP300	BP	GO:0030511	positive regulation of transforming growth factor beta receptor signaling pathway	Feb-29	34/18614	0.001274773	0.011135312	0.005918717	1387/2033	2	CREBBP/EP300
EP300	BP	GO:1903846	positive regulation of cellular response to transforming growth factor beta stimulus	Feb-29	34/18614	0.001274773	0.011135312	0.005918717	1387/2033	2	CREBBP/EP300
EP300	BP	GO:0050890	cognition	Apr-29	317/18614	0.001400637	0.011856515	0.006302056	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
EP300	BP	GO:0035264	multicellular organism growth	Mar-29	145/18614	0.001458362	0.012274545	0.00652425	367/2033/7157	3	AR/EP300/TP53
EP300	BP	GO:0009416	response to light stimulus	Apr-29	323/18614	0.001500559	0.0124354	0.006609749	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
EP300	BP	GO:0062012	regulation of small molecule metabolic process	Apr-29	331/18614	0.001641417	0.013354479	0.007098264	978/2033/6714/7157	4	CDA/EP300/SRC/TP53
EP300	BP	GO:0051604	protein maturation	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	552900/1387/2033/6714	4	BOLA2/CREBBP/EP300/SRC
EP300	BP	GO:0010675	regulation of cellular carbohydrate metabolic process	Mar-29	152/18614	0.00166931	0.013354479	0.007098264	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0098751	bone cell development	Feb-29	41/18614	0.001850762	0.0143102	0.007606255	2033/6714	2	EP300/SRC
EP300	BP	GO:0016052	carbohydrate catabolic process	Mar-29	162/18614	0.002002413	0.015263674	0.008113053	2033/9821/7157	3	EP300/RB1CC1/TP53
EP300	BP	GO:0006109	regulation of carbohydrate metabolic process	Mar-29	183/18614	0.00282996	0.019270953	0.010243029	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0019083	viral transcription	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	2033/3065	2	EP300/HDAC1
EP300	BP	GO:0045912	negative regulation of carbohydrate metabolic process	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	2033/7157	2	EP300/TP53
EP300	BP	GO:0060324	face development	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	2033/5594	2	EP300/MAPK1
EP300	BP	GO:0030324	lung development	Mar-29	186/18614	0.002962942	0.019543326	0.010387802	2033/5594/4087	3	EP300/MAPK1/SMAD2
EP300	BP	GO:0006006	glucose metabolic process	Mar-29	187/18614	0.003008113	0.019680611	0.010460773	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0040029	epigenetic regulation of gene expression	Mar-29	188/18614	0.003053708	0.019872984	0.010563024	2033/3065/7157	3	EP300/HDAC1/TP53
EP300	BP	GO:0030323	respiratory tube development	Mar-29	190/18614	0.003146174	0.020255847	0.010766526	2033/5594/4087	3	EP300/MAPK1/SMAD2
EP300	BP	GO:0006338	chromatin remodeling	Apr-29	402/18614	0.003319658	0.021203821	0.0112704	2033/2099/3065/7157	4	EP300/ESR1/HDAC1/TP53
EP300	BP	GO:0043470	regulation of carbohydrate catabolic process	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	2033/7157	2	EP300/TP53
EP300	BP	GO:0090311	regulation of protein deacetylation	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	2033/7157	2	EP300/TP53
EP300	BP	GO:0043393	regulation of protein binding	Mar-29	201/18614	0.003685608	0.022489469	0.011953756	1026/2033/6714	3	CDKN1A/EP300/SRC
EP300	BP	GO:0007623	circadian rhythm	Mar-29	207/18614	0.004002267	0.024012739	0.012763415	2033/3065/7157	3	EP300/HDAC1/TP53
EP300	BP	GO:0060541	respiratory system development	Mar-29	211/18614	0.004222335	0.024632828	0.013093009	2033/5594/4087	3	EP300/MAPK1/SMAD2
EP300	BP	GO:0050821	protein stabilization	Mar-29	213/18614	0.004335086	0.0249306	0.013251283	2033/4088/7157	3	EP300/SMAD3/TP53
EP300	BP	GO:0034605	cellular response to heat	Feb-29	67/18614	0.004866828	0.027213818	0.014464874	1387/2033	2	CREBBP/EP300
EP300	BP	GO:0019318	hexose metabolic process	Mar-29	228/18614	0.005239432	0.028508155	0.015152849	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0051090	regulation of DNA-binding transcription factor activity	Apr-29	465/18614	0.005565604	0.029569806	0.015717146	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
EP300	BP	GO:0060348	bone development	Mar-29	235/18614	0.00569757	0.029893744	0.015889327	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0016570	histone modification	Apr-29	475/18614	0.005996982	0.031161166	0.016562996	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
EP300	BP	GO:0005996	monosaccharide metabolic process	Mar-29	256/18614	0.007213953	0.035008252	0.018607825	2033/6714/7157	3	EP300/SRC/TP53
EP300	BP	GO:0051851	modulation by host of symbiont process	Feb-29	83/18614	0.007376253	0.035266347	0.01874501	2033/3065	2	EP300/HDAC1
EP300	BP	GO:0061515	myeloid cell development	Feb-29	84/18614	0.007548903	0.035879491	0.019070913	2033/6714	2	EP300/SRC
EP300	BP	GO:0042113	B cell activation	Mar-29	276/18614	0.00886175	0.040568238	0.021563107	1026/2033/7157	3	CDKN1A/EP300/TP53
EP300	BP	GO:1900542	regulation of purine nucleotide metabolic process	Feb-29	93/18614	0.009184217	0.041341769	0.02197426	2033/7157	2	EP300/TP53
EP300	BP	GO:0019080	viral gene expression	Feb-29	100/18614	0.010555722	0.045246808	0.024049893	2033/3065	2	EP300/HDAC1
EP300	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
EP300	MF	GO:0001223	transcription coactivator binding	May-32	43/18369	1.06E-08	9.45E-07	4.03E-07	367/1387/2033/2099/4088	5	AR/CREBBP/EP300/ESR1/SMAD3
EP300	MF	GO:0001221	transcription coregulator binding	Jun-32	111/18369	3.39E-08	2.01E-06	8.56E-07	367/1387/2033/2099/3065/4088	6	AR/CREBBP/EP300/ESR1/HDAC1/SMAD3
EP300	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
EP300	MF	GO:0002039	p53 binding	Apr-32	67/18369	5.38E-06	1.92E-04	8.16E-05	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
EP300	MF	GO:0008013	beta-catenin binding	Apr-32	88/18369	1.60E-05	3.37E-04	1.43E-04	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
EP300	MF	GO:0031490	chromatin DNA binding	Apr-32	118/18369	5.06E-05	8.19E-04	3.49E-04	1387/2033/3065/4088	4	CREBBP/EP300/HDAC1/SMAD3
EP300	MF	GO:0048156	tau protein binding	Mar-32	43/18369	5.65E-05	8.38E-04	3.57E-04	2033/2534/4087	3	EP300/FYN/SMAD2
EP300	MF	GO:0016922	nuclear receptor binding	Apr-32	138/18369	9.31E-05	0.001275187	5.43E-04	2033/2099/4088/6714	4	EP300/ESR1/SMAD3/SRC
EP300	MF	GO:0016410	N-acyltransferase activity	Mar-32	93/18369	5.60E-04	0.004335707	0.001846073	79603/1387/2033	3	CERS4/CREBBP/EP300
EP300	MF	GO:0051059	NF-kappaB binding	Feb-32	31/18369	0.001324689	0.007145292	0.003042348	2033/3065	2	EP300/HDAC1
EP300	MF	GO:0004402	histone acetyltransferase activity	Feb-32	43/18369	0.002539157	0.010272045	0.004373668	1387/2033	2	CREBBP/EP300
EP300	MF	GO:0061733	peptide-lysine-N-acetyltransferase activity	Feb-32	46/18369	0.002900871	0.010757398	0.004580323	1387/2033	2	CREBBP/EP300
EP300	MF	GO:0034212	peptide N-acetyltransferase activity	Feb-32	51/18369	0.003554209	0.012404887	0.005281797	1387/2033	2	CREBBP/EP300
EP300	MF	GO:0008080	N-acetyltransferase activity	Feb-32	67/18369	0.006057486	0.019967267	0.008501734	1387/2033	2	CREBBP/EP300
EP300	MF	GO:0003684	damaged DNA binding	Feb-32	71/18369	0.00677875	0.0219385	0.009341053	1387/2033	2	CREBBP/EP300
EP300	MF	GO:0016747	acyltransferase activity, transferring groups other than amino-acyl groups	Mar-32	226/18369	0.007007449	0.022273676	0.009483765	79603/1387/2033	3	CERS4/CREBBP/EP300
EP300	MF	GO:0016746	acyltransferase activity	Mar-32	253/18369	0.009537861	0.029271365	0.012463266	79603/1387/2033	3	CERS4/CREBBP/EP300
EP300	MF	GO:0016407	acetyltransferase activity	Feb-32	94/18369	0.011630709	0.034504438	0.014691422	1387/2033	2	CREBBP/EP300
EP300	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
EP300	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
EP300	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
EP300	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
EP300	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
EP300	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
EP300	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
EP300	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
EP300	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
EP300	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
EP300	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
EP300	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
EP300	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
EP300	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
EP300	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
EP300	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
EP300	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
EP300	NA	hsa04330	Notch signaling pathway	Mar-22	62/8848	4.59E-04	0.001824653	6.79E-04	1387/2033/3065	3	CREBBP/EP300/HDAC1
EP300	NA	hsa04720	Long-term potentiation	Mar-22	67/8848	5.77E-04	0.002239357	8.33E-04	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
EP300	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
EP300	NA	hsa03083	Polycomb repressive complex	Mar-22	83/8848	0.001077785	0.0035998	0.001338722	1387/2033/3065	3	CREBBP/EP300/HDAC1
EP300	NA	hsa04916	Melanogenesis	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa05164	Influenza A	Mar-22	172/8848	0.008471789	0.020211268	0.007516324	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa03250	Viral life cycle - HIV-1	Feb-22	64/8848	0.010839453	0.024135849	0.008975828	1387/2033	2	CREBBP/EP300
EP300	NA	hsa04024	cAMP signaling pathway	Mar-22	226/8848	0.017697314	0.033584675	0.012489731	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa04922	Glucagon signaling pathway	Feb-22	107/8848	0.028593175	0.048725104	0.018120272	1387/2033	2	CREBBP/EP300
EP300	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
EP300	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
EP300	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
EP300	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
EP300	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
EP300	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
EP300	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
EP300	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
EP300	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
EP300	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
EP300	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
EP300	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
EP300	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
EP300	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
EP300	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
EP300	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
EP300	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
EP300	NA	hsa04330	Notch signaling pathway	Mar-22	62/8848	4.59E-04	0.001824653	6.79E-04	1387/2033/3065	3	CREBBP/EP300/HDAC1
EP300	NA	hsa04720	Long-term potentiation	Mar-22	67/8848	5.77E-04	0.002239357	8.33E-04	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
EP300	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
EP300	NA	hsa03083	Polycomb repressive complex	Mar-22	83/8848	0.001077785	0.0035998	0.001338722	1387/2033/3065	3	CREBBP/EP300/HDAC1
EP300	NA	hsa04916	Melanogenesis	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa05164	Influenza A	Mar-22	172/8848	0.008471789	0.020211268	0.007516324	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa03250	Viral life cycle - HIV-1	Feb-22	64/8848	0.010839453	0.024135849	0.008975828	1387/2033	2	CREBBP/EP300
EP300	NA	hsa04024	cAMP signaling pathway	Mar-22	226/8848	0.017697314	0.033584675	0.012489731	1387/2033/5594	3	CREBBP/EP300/MAPK1
EP300	NA	hsa04922	Glucagon signaling pathway	Feb-22	107/8848	0.028593175	0.048725104	0.018120272	1387/2033	2	CREBBP/EP300
ESR1	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
ESR1	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
ESR1	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
ESR1	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
ESR1	BP	GO:0030518	intracellular steroid hormone receptor signaling pathway	May-29	115/18614	8.70E-07	9.37E-05	4.98E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
ESR1	BP	GO:0043401	steroid hormone mediated signaling pathway	May-29	135/18614	1.92E-06	1.81E-04	9.62E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
ESR1	BP	GO:0061180	mammary gland epithelium development	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
ESR1	BP	GO:1902893	regulation of miRNA transcription	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
ESR1	BP	GO:0061614	miRNA transcription	Apr-29	69/18614	3.83E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
ESR1	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
ESR1	BP	GO:0060444	branching involved in mammary gland duct morphogenesis	Mar-29	22/18614	5.13E-06	3.46E-04	1.84E-04	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:2000628	regulation of miRNA metabolic process	Apr-29	81/18614	7.27E-06	4.05E-04	2.15E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
ESR1	BP	GO:0009755	hormone-mediated signaling pathway	May-29	192/18614	1.08E-05	4.97E-04	2.64E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
ESR1	BP	GO:0060603	mammary gland duct morphogenesis	Mar-29	30/18614	1.34E-05	5.71E-04	3.03E-04	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0010586	miRNA metabolic process	Apr-29	97/18614	1.49E-05	6.17E-04	3.28E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
ESR1	BP	GO:0002758	innate immune response-activating signaling pathway	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0071383	cellular response to steroid hormone stimulus	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
ESR1	BP	GO:0002218	activation of innate immune response	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0060443	mammary gland morphogenesis	Mar-29	45/18614	4.62E-05	0.001492153	7.93E-04	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0030879	mammary gland development	Apr-29	136/18614	5.62E-05	0.001650943	8.78E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
ESR1	BP	GO:0030520	intracellular estrogen receptor signaling pathway	Mar-29	54/18614	7.99E-05	0.00221531	0.001177497	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0030522	intracellular receptor signaling pathway	May-29	299/18614	8.95E-05	0.002336435	0.001241878	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
ESR1	BP	GO:0045089	positive regulation of innate immune response	May-29	300/18614	9.09E-05	0.002336435	0.001241878	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0060736	prostate gland growth	Feb-29	11/18614	1.28E-04	0.002908472	0.001545931	367/2099	2	AR/ESR1
ESR1	BP	GO:0002833	positive regulation of response to biotic stimulus	May-29	327/18614	1.36E-04	0.003058239	0.001625536	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0048545	response to steroid hormone	May-29	339/18614	1.61E-04	0.003257009	0.001731188	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
ESR1	BP	GO:0043627	response to estrogen	Mar-29	70/18614	1.74E-04	0.00341922	0.001817407	367/2033/2099	3	AR/EP300/ESR1
ESR1	BP	GO:0061138	morphogenesis of a branching epithelium	Apr-29	188/18614	1.96E-04	0.003691252	0.001961999	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
ESR1	BP	GO:0031334	positive regulation of protein-containing complex assembly	Apr-29	195/18614	2.26E-04	0.004102277	0.00218047	2099/2885/6714/7157	4	ESR1/GRB2/SRC/TP53
ESR1	BP	GO:0045088	regulation of innate immune response	May-29	373/18614	2.51E-04	0.004314593	0.002293322	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0001763	morphogenesis of a branching structure	Apr-29	203/18614	2.63E-04	0.004433918	0.002356747	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
ESR1	BP	GO:2000241	regulation of reproductive process	Apr-29	206/18614	2.79E-04	0.004593103	0.002441358	367/246184/2099/6714	4	AR/CDC26/ESR1/SRC
ESR1	BP	GO:0048145	regulation of fibroblast proliferation	Mar-29	87/18614	3.30E-04	0.004984416	0.002649351	1026/2099/7157	3	CDKN1A/ESR1/TP53
ESR1	BP	GO:0071391	cellular response to estrogen stimulus	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	367/2099	2	AR/ESR1
ESR1	BP	GO:0043254	regulation of protein-containing complex assembly	May-29	409/18614	3.84E-04	0.005539882	0.002944596	2033/2099/2885/6714/7157	5	EP300/ESR1/GRB2/SRC/TP53
ESR1	BP	GO:0060749	mammary gland alveolus development	Feb-29	20/18614	4.38E-04	0.005893251	0.003132421	367/2099	2	AR/ESR1
ESR1	BP	GO:0061377	mammary gland lobule development	Feb-29	20/18614	4.38E-04	0.005893251	0.003132421	367/2099	2	AR/ESR1
ESR1	BP	GO:0048144	fibroblast proliferation	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	1026/2099/7157	3	CDKN1A/ESR1/TP53
ESR1	BP	GO:0031349	positive regulation of defense response	May-29	441/18614	5.42E-04	0.006631889	0.003525027	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0048863	stem cell differentiation	Apr-29	247/18614	5.54E-04	0.00672641	0.003575267	2099/3065/5594/7157	4	ESR1/HDAC1/MAPK1/TP53
ESR1	BP	GO:0060065	uterus development	Feb-29	23/18614	5.81E-04	0.007007121	0.003724473	2099/6714	2	ESR1/SRC
ESR1	BP	GO:0002831	regulation of response to biotic stimulus	May-29	463/18614	6.75E-04	0.00779709	0.004144362	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
ESR1	BP	GO:0033598	mammary gland epithelial cell proliferation	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	2099/5594	2	ESR1/MAPK1
ESR1	BP	GO:0060740	prostate gland epithelium morphogenesis	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	367/2099	2	AR/ESR1
ESR1	BP	GO:0051091	positive regulation of DNA-binding transcription factor activity	Apr-29	271/18614	7.83E-04	0.008440626	0.004486419	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
ESR1	BP	GO:0060512	prostate gland morphogenesis	Feb-29	28/18614	8.64E-04	0.0089494	0.004756846	367/2099	2	AR/ESR1
ESR1	BP	GO:0022612	gland morphogenesis	Mar-29	123/18614	9.07E-04	0.00907924	0.00482586	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0060562	epithelial tube morphogenesis	Apr-29	334/18614	0.001696541	0.013439265	0.00714333	367/2099/4088/6714	4	AR/ESR1/SMAD3/SRC
ESR1	BP	GO:0048754	branching morphogenesis of an epithelial tube	Mar-29	157/18614	0.001831111	0.014226325	0.007561674	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0048806	genitalia development	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	367/2099	2	AR/ESR1
ESR1	BP	GO:0030850	prostate gland development	Feb-29	48/18614	0.0025288	0.017962061	0.009547318	367/2099	2	AR/ESR1
ESR1	BP	GO:0035265	organ growth	Mar-29	180/18614	0.002700744	0.018893519	0.010042412	367/2099/4087	3	AR/ESR1/SMAD2
ESR1	BP	GO:0043124	negative regulation of I-kappaB kinase/NF-kappaB signaling	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	2099/3065	2	ESR1/HDAC1
ESR1	BP	GO:0060688	regulation of morphogenesis of a branching structure	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	367/2099	2	AR/ESR1
ESR1	BP	GO:0022602	ovulation cycle process	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	2099/6714	2	ESR1/SRC
ESR1	BP	GO:0048146	positive regulation of fibroblast proliferation	Feb-29	53/18614	0.00307441	0.019872984	0.010563024	1026/2099	2	CDKN1A/ESR1
ESR1	BP	GO:0006338	chromatin remodeling	Apr-29	402/18614	0.003319658	0.021203821	0.0112704	2033/2099/3065/7157	4	EP300/ESR1/HDAC1/TP53
ESR1	BP	GO:0001541	ovarian follicle development	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	2099/6714	2	ESR1/SRC
ESR1	BP	GO:0050727	regulation of inflammatory response	Apr-29	414/18614	0.003687939	0.022489469	0.011953756	2099/2534/4088/6714	4	ESR1/FYN/SMAD3/SRC
ESR1	BP	GO:0060135	maternal process involved in female pregnancy	Feb-29	61/18614	0.00405151	0.024012739	0.012763415	367/2099	2	AR/ESR1
ESR1	BP	GO:0002064	epithelial cell development	Mar-29	210/18614	0.004166641	0.024484695	0.013014272	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0060261	positive regulation of transcription initiation by RNA polymerase II	Feb-29	62/18614	0.004182531	0.02448902	0.013016571	2099/7157	2	ESR1/TP53
ESR1	BP	GO:1905330	regulation of morphogenesis of an epithelium	Feb-29	65/18614	0.004587294	0.025829504	0.013729074	367/2099	2	AR/ESR1
ESR1	BP	GO:0001655	urogenital system development	Feb-29	66/18614	0.004726096	0.026518648	0.014095373	367/2099	2	AR/ESR1
ESR1	BP	GO:0051123	RNA polymerase II preinitiation complex assembly	Feb-29	68/18614	0.005009484	0.027723717	0.0147359	2099/7157	2	ESR1/TP53
ESR1	BP	GO:2000144	positive regulation of DNA-templated transcription initiation	Feb-29	68/18614	0.005009484	0.027723717	0.0147359	2099/7157	2	ESR1/TP53
ESR1	BP	GO:0008406	gonad development	Mar-29	228/18614	0.005239432	0.028508155	0.015152849	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0045137	development of primary sexual characteristics	Mar-29	233/18614	0.005564295	0.029569806	0.015717146	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0051090	regulation of DNA-binding transcription factor activity	Apr-29	465/18614	0.005565604	0.029569806	0.015717146	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
ESR1	BP	GO:0060260	regulation of transcription initiation by RNA polymerase II	Feb-29	72/18614	0.005599233	0.029569806	0.015717146	2099/7157	2	ESR1/TP53
ESR1	BP	GO:0042698	ovulation cycle	Feb-29	75/18614	0.006061462	0.031195296	0.016581137	2099/6714	2	ESR1/SRC
ESR1	BP	GO:0050673	epithelial cell proliferation	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	367/2099/5594/4088	4	AR/ESR1/MAPK1/SMAD3
ESR1	BP	GO:2000142	regulation of DNA-templated transcription initiation	Feb-29	80/18614	0.006869314	0.033947437	0.018043974	2099/7157	2	ESR1/TP53
ESR1	BP	GO:0043122	regulation of I-kappaB kinase/NF-kappaB signaling	Mar-29	258/18614	0.007369682	0.035266347	0.01874501	2099/2534/3065	3	ESR1/FYN/HDAC1
ESR1	BP	GO:0070897	transcription preinitiation complex assembly	Feb-29	83/18614	0.007376253	0.035266347	0.01874501	2099/7157	2	ESR1/TP53
ESR1	BP	GO:0007548	sex differentiation	Mar-29	283/18614	0.00948657	0.042466197	0.022571923	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0007249	I-kappaB kinase/NF-kappaB signaling	Mar-29	293/18614	0.01042313	0.04503684	0.023938289	2099/2534/3065	3	ESR1/FYN/HDAC1
ESR1	BP	GO:0008585	female gonad development	Feb-29	102/18614	0.010963285	0.046745829	0.024846663	2099/6714	2	ESR1/SRC
ESR1	BP	GO:0048608	reproductive structure development	Mar-29	301/18614	0.011209976	0.047546773	0.025272386	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0061458	reproductive system development	Mar-29	305/18614	0.011616029	0.049011756	0.026051064	367/2099/6714	3	AR/ESR1/SRC
ESR1	BP	GO:0046545	development of primary female sexual characteristics	Feb-29	106/18614	0.011799066	0.049654401	0.026392647	2099/6714	2	ESR1/SRC
ESR1	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
ESR1	MF	GO:0001223	transcription coactivator binding	May-32	43/18369	1.06E-08	9.45E-07	4.03E-07	367/1387/2033/2099/4088	5	AR/CREBBP/EP300/ESR1/SMAD3
ESR1	MF	GO:0001221	transcription coregulator binding	Jun-32	111/18369	3.39E-08	2.01E-06	8.56E-07	367/1387/2033/2099/3065/4088	6	AR/CREBBP/EP300/ESR1/HDAC1/SMAD3
ESR1	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
ESR1	MF	GO:0001091	RNA polymerase II general transcription initiation factor binding	Mar-32	26/18369	1.22E-05	3.37E-04	1.43E-04	367/2099/7157	3	AR/ESR1/TP53
ESR1	MF	GO:0008013	beta-catenin binding	Apr-32	88/18369	1.60E-05	3.37E-04	1.43E-04	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
ESR1	MF	GO:0016922	nuclear receptor binding	Apr-32	138/18369	9.31E-05	0.001275187	5.43E-04	2033/2099/4088/6714	4	EP300/ESR1/SMAD3/SRC
ESR1	MF	GO:0140296	general transcription initiation factor binding	Mar-32	53/18369	1.06E-04	0.001348122	5.74E-04	367/2099/7157	3	AR/ESR1/TP53
ESR1	MF	GO:0001098	basal transcription machinery binding	Mar-32	61/18369	1.61E-04	0.001689597	7.19E-04	367/2099/7157	3	AR/ESR1/TP53
ESR1	MF	GO:0001099	basal RNA polymerase II transcription machinery binding	Mar-32	61/18369	1.61E-04	0.001689597	7.19E-04	367/2099/7157	3	AR/ESR1/TP53
ESR1	MF	GO:0051117	ATPase binding	Mar-32	86/18369	4.45E-04	0.003776103	0.001607803	367/2099/6714	3	AR/ESR1/SRC
ESR1	MF	GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	May-32	468/18369	0.001198605	0.007136975	0.003038807	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
ESR1	MF	GO:0001216	DNA-binding transcription activator activity	May-32	472/18369	0.001244795	0.007145292	0.003042348	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
ESR1	MF	GO:0030331	nuclear estrogen receptor binding	Feb-32	39/18369	0.002092694	0.009312487	0.003965104	2099/6714	2	ESR1/SRC
ESR1	MF	GO:0001222	transcription corepressor binding	Feb-32	45/18369	0.002777759	0.010757398	0.004580323	2099/3065	2	ESR1/HDAC1
ESR1	MF	GO:0004879	nuclear receptor activity	Feb-32	46/18369	0.002900871	0.010757398	0.004580323	367/2099	2	AR/ESR1
ESR1	MF	GO:0098531	ligand-activated transcription factor activity	Feb-32	46/18369	0.002900871	0.010757398	0.004580323	367/2099	2	AR/ESR1
ESR1	MF	GO:0005496	steroid binding	Feb-32	99/18369	0.012838451	0.037463021	0.015951139	367/2099	2	AR/ESR1
ESR1	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
ESR1	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
ESR1	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
ESR1	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
ESR1	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
ESR1	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
ESR1	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
ESR1	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
ESR1	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
ESR1	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
ESR1	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
ESR1	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
ESR1	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
ESR1	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
FYN	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
FYN	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
FYN	BP	GO:0002223	stimulatory C-type lectin receptor signaling pathway	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
FYN	BP	GO:1990840	response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
FYN	BP	GO:1990858	cellular response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
FYN	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
FYN	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
FYN	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
FYN	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
FYN	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
FYN	BP	GO:0002220	innate immune response activating cell surface receptor signaling pathway	Apr-29	78/18614	6.26E-06	3.74E-04	1.99E-04	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
FYN	BP	GO:0036120	cellular response to platelet-derived growth factor stimulus	Mar-29	24/18614	6.73E-06	3.89E-04	2.07E-04	2534/3065/6714	3	FYN/HDAC1/SRC
FYN	BP	GO:0036119	response to platelet-derived growth factor	Mar-29	26/18614	8.63E-06	4.25E-04	2.26E-04	2534/3065/6714	3	FYN/HDAC1/SRC
FYN	BP	GO:0002758	innate immune response-activating signaling pathway	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:1901653	cellular response to peptide	Jun-29	375/18614	2.06E-05	7.93E-04	4.22E-04	2534/2885/5594/6714/7157/7532	6	FYN/GRB2/MAPK1/SRC/TP53/YWHAG
FYN	BP	GO:0002218	activation of innate immune response	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:2000377	regulation of reactive oxygen species metabolic process	Apr-29	150/18614	8.23E-05	0.00221531	0.001177497	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
FYN	BP	GO:0045089	positive regulation of innate immune response	May-29	300/18614	9.09E-05	0.002336435	0.001241878	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:0034504	protein localization to nucleus	May-29	304/18614	9.68E-05	0.002443574	0.001298825	1026/2534/4088/6714/7157	5	CDKN1A/FYN/SMAD3/SRC/TP53
FYN	BP	GO:0002833	positive regulation of response to biotic stimulus	May-29	327/18614	1.36E-04	0.003058239	0.001625536	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:0052548	regulation of endopeptidase activity	May-29	336/18614	1.55E-04	0.003246445	0.001725573	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
FYN	BP	GO:0070661	leukocyte proliferation	May-29	348/18614	1.82E-04	0.003463376	0.001840877	11119/1026/2534/5594/7157	5	BTN3A1/CDKN1A/FYN/MAPK1/TP53
FYN	BP	GO:0045088	regulation of innate immune response	May-29	373/18614	2.51E-04	0.004314593	0.002293322	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:0050851	antigen receptor-mediated signaling pathway	Apr-29	201/18614	2.54E-04	0.004314593	0.002293322	11119/2534/2885/5594	4	BTN3A1/FYN/GRB2/MAPK1
FYN	BP	GO:1900182	positive regulation of protein localization to nucleus	Mar-29	86/18614	3.19E-04	0.004863024	0.002584828	2534/4088/6714	3	FYN/SMAD3/SRC
FYN	BP	GO:2000116	regulation of cysteine-type endopeptidase activity	Apr-29	234/18614	4.52E-04	0.005981729	0.003179449	1457/2534/4088/6714	4	CSNK2A1/FYN/SMAD3/SRC
FYN	BP	GO:0052547	regulation of peptidase activity	May-29	425/18614	4.58E-04	0.006014484	0.00319686	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
FYN	BP	GO:0072593	reactive oxygen species metabolic process	Apr-29	237/18614	4.74E-04	0.006174999	0.003282178	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
FYN	BP	GO:0006979	response to oxidative stress	May-29	434/18614	5.04E-04	0.006409007	0.003406559	2534/5594/4700/6714/7157	5	FYN/MAPK1/NDUFA6/SRC/TP53
FYN	BP	GO:0031349	positive regulation of defense response	May-29	441/18614	5.42E-04	0.006631889	0.003525027	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:0002831	regulation of response to biotic stimulus	May-29	463/18614	6.75E-04	0.00779709	0.004144362	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
FYN	BP	GO:0002433	immune response-regulating cell surface receptor signaling pathway involved in phagocytosis	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	2534/6714	2	FYN/SRC
FYN	BP	GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	2534/6714	2	FYN/SRC
FYN	BP	GO:0007611	learning or memory	Apr-29	276/18614	8.39E-04	0.00885882	0.004708701	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
FYN	BP	GO:0034599	cellular response to oxidative stress	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
FYN	BP	GO:0002431	Fc receptor mediated stimulatory signaling pathway	Feb-29	32/18614	0.00112925	0.010368564	0.00551117	2534/6714	2	FYN/SRC
FYN	BP	GO:0002862	negative regulation of inflammatory response to antigenic stimulus	Feb-29	32/18614	0.00112925	0.010368564	0.00551117	2534/6714	2	FYN/SRC
FYN	BP	GO:1900180	regulation of protein localization to nucleus	Mar-29	134/18614	0.001162298	0.010552099	0.005608724	2534/4088/6714	3	FYN/SMAD3/SRC
FYN	BP	GO:0038094	Fc-gamma receptor signaling pathway	Feb-29	33/18614	0.001200945	0.010842048	0.005762839	2534/6714	2	FYN/SRC
FYN	BP	GO:0046651	lymphocyte proliferation	Apr-29	306/18614	0.001229728	0.011040225	0.005868176	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
FYN	BP	GO:0050852	T cell receptor signaling pathway	Mar-29	140/18614	0.001318524	0.01145556	0.006088937	11119/2534/5594	3	BTN3A1/FYN/MAPK1
FYN	BP	GO:0032943	mononuclear cell proliferation	Apr-29	313/18614	0.001336677	0.011549078	0.006138645	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
FYN	BP	GO:0050890	cognition	Apr-29	317/18614	0.001400637	0.011856515	0.006302056	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
FYN	BP	GO:0032386	regulation of intracellular transport	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	2534/5594/4088/6714	4	FYN/MAPK1/SMAD3/SRC
FYN	BP	GO:0034614	cellular response to reactive oxygen species	Mar-29	152/18614	0.00166931	0.013354479	0.007098264	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	BP	GO:0009895	negative regulation of catabolic process	Apr-29	337/18614	0.001752946	0.013818341	0.007344819	1457/2534/4088/7157	4	CSNK2A1/FYN/SMAD3/TP53
FYN	BP	GO:0062197	cellular response to chemical stress	Apr-29	349/18614	0.001991682	0.015253833	0.008107822	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
FYN	BP	GO:0031295	T cell costimulation	Feb-29	45/18614	0.002225854	0.016424566	0.008730098	2534/6714	2	FYN/SRC
FYN	BP	GO:0002861	regulation of inflammatory response to antigenic stimulus	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	2534/6714	2	FYN/SRC
FYN	BP	GO:0031294	lymphocyte costimulation	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	2534/6714	2	FYN/SRC
FYN	BP	GO:0050798	activated T cell proliferation	Feb-29	48/18614	0.0025288	0.017962061	0.009547318	11119/2534	2	BTN3A1/FYN
FYN	BP	GO:2000378	negative regulation of reactive oxygen species metabolic process	Feb-29	50/18614	0.002740969	0.018945874	0.01007024	2534/7157	2	FYN/TP53
FYN	BP	GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	Mar-29	181/18614	0.0027434	0.018945874	0.01007024	2534/6714/7157	3	FYN/SRC/TP53
FYN	BP	GO:0048013	ephrin receptor signaling pathway	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	2534/6714	2	FYN/SRC
FYN	BP	GO:0050728	negative regulation of inflammatory response	Mar-29	187/18614	0.003008113	0.019680611	0.010460773	2534/4088/6714	3	FYN/SMAD3/SRC
FYN	BP	GO:0038093	Fc receptor signaling pathway	Feb-29	54/18614	0.003189581	0.020453823	0.010871756	2534/6714	2	FYN/SRC
FYN	BP	GO:0048010	vascular endothelial growth factor receptor signaling pathway	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	2534/6714	2	FYN/SRC
FYN	BP	GO:0050727	regulation of inflammatory response	Apr-29	414/18614	0.003687939	0.022489469	0.011953756	2099/2534/4088/6714	4	ESR1/FYN/SMAD3/SRC
FYN	BP	GO:0000302	response to reactive oxygen species	Mar-29	205/18614	0.003894931	0.023573812	0.012530114	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	BP	GO:0042098	T cell proliferation	Mar-29	213/18614	0.004335086	0.0249306	0.013251283	11119/2534/7157	3	BTN3A1/FYN/TP53
FYN	BP	GO:0046777	protein autophosphorylation	Mar-29	227/18614	0.005175879	0.028353288	0.015070533	2534/9821/6714	3	FYN/RB1CC1/SRC
FYN	BP	GO:0002437	inflammatory response to antigenic stimulus	Feb-29	78/18614	0.006540588	0.032839994	0.017455338	2534/6714	2	FYN/SRC
FYN	BP	GO:0050804	modulation of chemical synaptic transmission	Apr-29	487/18614	0.006543613	0.032839994	0.017455338	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
FYN	BP	GO:0099177	regulation of trans-synaptic signaling	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
FYN	BP	GO:0097305	response to alcohol	Mar-29	252/18614	0.006908455	0.034036777	0.01809146	978/2534/4087	3	CDA/FYN/SMAD2
FYN	BP	GO:0050730	regulation of peptidyl-tyrosine phosphorylation	Mar-29	255/18614	0.007136835	0.034738328	0.018464353	2534/6714/7157	3	FYN/SRC/TP53
FYN	BP	GO:0043122	regulation of I-kappaB kinase/NF-kappaB signaling	Mar-29	258/18614	0.007369682	0.035266347	0.01874501	2099/2534/3065	3	ESR1/FYN/HDAC1
FYN	BP	GO:1901216	positive regulation of neuron death	Feb-29	92/18614	0.008995342	0.040832789	0.021703723	2534/7157	2	FYN/TP53
FYN	BP	GO:0070301	cellular response to hydrogen peroxide	Feb-29	93/18614	0.009184217	0.041341769	0.02197426	2534/6714	2	FYN/SRC
FYN	BP	GO:0031348	negative regulation of defense response	Mar-29	284/18614	0.009577891	0.042521627	0.022601386	2534/4088/6714	3	FYN/SMAD3/SRC
FYN	BP	GO:0007249	I-kappaB kinase/NF-kappaB signaling	Mar-29	293/18614	0.01042313	0.04503684	0.023938289	2099/2534/3065	3	ESR1/FYN/HDAC1
FYN	MF	GO:0046875	ephrin receptor binding	Mar-32	29/18369	1.70E-05	3.37E-04	1.43E-04	2534/2885/6714	3	FYN/GRB2/SRC
FYN	MF	GO:0097718	disordered domain specific binding	Mar-32	36/18369	3.30E-05	5.87E-04	2.50E-04	2534/4087/7157	3	FYN/SMAD2/TP53
FYN	MF	GO:0048156	tau protein binding	Mar-32	43/18369	5.65E-05	8.38E-04	3.57E-04	2033/2534/4087	3	EP300/FYN/SMAD2
FYN	MF	GO:0016004	phospholipase activator activity	Feb-32	22/18369	6.65E-04	0.004928677	0.00209855	2534/6714	2	FYN/SRC
FYN	MF	GO:0043274	phospholipase binding	Feb-32	23/18369	7.27E-04	0.004977423	0.002119305	2534/6714	2	FYN/SRC
FYN	MF	GO:0060229	lipase activator activity	Feb-32	25/18369	8.60E-04	0.0054686	0.00232844	2534/6714	2	FYN/SRC
FYN	MF	GO:0070851	growth factor receptor binding	Mar-32	137/18369	0.001718305	0.008147008	0.003468862	2534/2885/6714	3	FYN/GRB2/SRC
FYN	MF	GO:0004715	non-membrane spanning protein tyrosine kinase activity	Feb-32	43/18369	0.002539157	0.010272045	0.004373668	2534/6714	2	FYN/SRC
FYN	MF	GO:0097110	scaffold protein binding	Feb-32	66/18369	0.005883031	0.019758105	0.008412676	2534/6714	2	FYN/SRC
FYN	MF	GO:0035256	G protein-coupled glutamate receptor binding	Jan-32	11/18369	0.019001803	0.049740015	0.021178481	2534	1	FYN
FYN	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
FYN	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
FYN	NA	hsa04664	Fc epsilon RI signaling pathway	Mar-22	69/8848	6.29E-04	0.002385838	8.87E-04	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
FYN	NA	hsa04660	T cell receptor signaling pathway	Mar-22	122/8848	0.003252579	0.008904602	0.003311513	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04611	Platelet activation	Mar-22	126/8848	0.003562952	0.009596983	0.003569001	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	NA	hsa04650	Natural killer cell mediated cytotoxicity	Mar-22	135/8848	0.004326265	0.011468035	0.004264822	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
FYN	NA	hsa04380	Osteoclast differentiation	Mar-22	142/8848	0.004983922	0.012610832	0.004689815	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04072	Phospholipase D signaling pathway	Mar-22	149/8848	0.005699212	0.014205499	0.005282852	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04360	Axon guidance	Mar-22	184/8848	0.010185291	0.023624218	0.008785558	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	NA	hsa05130	Pathogenic Escherichia coli infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
FYN	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
FYN	NA	hsa04664	Fc epsilon RI signaling pathway	Mar-22	69/8848	6.29E-04	0.002385838	8.87E-04	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
FYN	NA	hsa04660	T cell receptor signaling pathway	Mar-22	122/8848	0.003252579	0.008904602	0.003311513	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04611	Platelet activation	Mar-22	126/8848	0.003562952	0.009596983	0.003569001	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	NA	hsa04650	Natural killer cell mediated cytotoxicity	Mar-22	135/8848	0.004326265	0.011468035	0.004264822	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
FYN	NA	hsa04380	Osteoclast differentiation	Mar-22	142/8848	0.004983922	0.012610832	0.004689815	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04072	Phospholipase D signaling pathway	Mar-22	149/8848	0.005699212	0.014205499	0.005282852	2534/2885/5594	3	FYN/GRB2/MAPK1
FYN	NA	hsa04360	Axon guidance	Mar-22	184/8848	0.010185291	0.023624218	0.008785558	2534/5594/6714	3	FYN/MAPK1/SRC
FYN	NA	hsa05130	Pathogenic Escherichia coli infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	2534/5594/6714	3	FYN/MAPK1/SRC
GRB2	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
GRB2	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
GRB2	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
GRB2	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
GRB2	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
GRB2	BP	GO:0007492	endoderm development	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	2885/3065/4087/4088	4	GRB2/HDAC1/SMAD2/SMAD3
GRB2	BP	GO:0071478	cellular response to radiation	May-29	191/18614	1.05E-05	4.97E-04	2.64E-04	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
GRB2	BP	GO:1901653	cellular response to peptide	Jun-29	375/18614	2.06E-05	7.93E-04	4.22E-04	2534/2885/5594/6714/7157/7532	6	FYN/GRB2/MAPK1/SRC/TP53/YWHAG
GRB2	BP	GO:0001701	in utero embryonic development	Jun-29	398/18614	2.88E-05	0.001012157	5.38E-04	367/2885/5594/4087/4088/7157	6	AR/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	BP	GO:0048009	insulin-like growth factor receptor signaling pathway	Mar-29	50/18614	6.34E-05	0.001830608	9.73E-04	367/2885/5594	3	AR/GRB2/MAPK1
GRB2	BP	GO:2000377	regulation of reactive oxygen species metabolic process	Apr-29	150/18614	8.23E-05	0.00221531	0.001177497	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
GRB2	BP	GO:0071214	cellular response to abiotic stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
GRB2	BP	GO:0104004	cellular response to environmental stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
GRB2	BP	GO:2000379	positive regulation of reactive oxygen species metabolic process	Mar-29	70/18614	1.74E-04	0.00341922	0.001817407	1026/2885/7157	3	CDKN1A/GRB2/TP53
GRB2	BP	GO:0061138	morphogenesis of a branching epithelium	Apr-29	188/18614	1.96E-04	0.003691252	0.001961999	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
GRB2	BP	GO:0071479	cellular response to ionizing radiation	Mar-29	75/18614	2.13E-04	0.003909723	0.002078123	1026/2885/7157	3	CDKN1A/GRB2/TP53
GRB2	BP	GO:0031334	positive regulation of protein-containing complex assembly	Apr-29	195/18614	2.26E-04	0.004102277	0.00218047	2099/2885/6714/7157	4	ESR1/GRB2/SRC/TP53
GRB2	BP	GO:0007369	gastrulation	Apr-29	196/18614	2.30E-04	0.004136761	0.0021988	2885/4087/4088/7157	4	GRB2/SMAD2/SMAD3/TP53
GRB2	BP	GO:0050851	antigen receptor-mediated signaling pathway	Apr-29	201/18614	2.54E-04	0.004314593	0.002293322	11119/2534/2885/5594	4	BTN3A1/FYN/GRB2/MAPK1
GRB2	BP	GO:0001763	morphogenesis of a branching structure	Apr-29	203/18614	2.63E-04	0.004433918	0.002356747	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
GRB2	BP	GO:0032869	cellular response to insulin stimulus	Apr-29	211/18614	3.05E-04	0.004863024	0.002584828	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
GRB2	BP	GO:0043254	regulation of protein-containing complex assembly	May-29	409/18614	3.84E-04	0.005539882	0.002944596	2033/2099/2885/6714/7157	5	EP300/ESR1/GRB2/SRC/TP53
GRB2	BP	GO:0072593	reactive oxygen species metabolic process	Apr-29	237/18614	4.74E-04	0.006174999	0.003282178	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
GRB2	BP	GO:0009314	response to radiation	May-29	452/18614	6.06E-04	0.007094243	0.003770781	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
GRB2	BP	GO:0048568	embryonic organ development	May-29	453/18614	6.12E-04	0.007114114	0.003781342	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	BP	GO:0032868	response to insulin	Apr-29	272/18614	7.94E-04	0.008500733	0.004518368	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
GRB2	BP	GO:0001704	formation of primary germ layer	Mar-29	127/18614	9.96E-04	0.009519221	0.005059721	2885/4087/4088	3	GRB2/SMAD2/SMAD3
GRB2	BP	GO:0008286	insulin receptor signaling pathway	Mar-29	128/18614	0.001018341	0.009567665	0.005085471	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	BP	GO:0038127	ERBB signaling pathway	Mar-29	131/18614	0.00108881	0.01011217	0.00537489	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	BP	GO:0071375	cellular response to peptide hormone stimulus	Apr-29	308/18614	0.001259647	0.011135312	0.005918717	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
GRB2	BP	GO:0010212	response to ionizing radiation	Mar-29	143/18614	0.001401358	0.011856515	0.006302056	1026/2885/7157	3	CDKN1A/GRB2/TP53
GRB2	BP	GO:0007265	Ras protein signal transduction	Apr-29	333/18614	0.001678025	0.013358069	0.007100172	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
GRB2	BP	GO:0060711	labyrinthine layer development	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	2885/5594	2	GRB2/MAPK1
GRB2	BP	GO:0042770	signal transduction in response to DNA damage	Mar-29	184/18614	0.002873867	0.019350706	0.010285419	1026/2885/7157	3	CDKN1A/GRB2/TP53
GRB2	BP	GO:0001706	endoderm formation	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	2885/4087	2	GRB2/SMAD2
GRB2	BP	GO:0043434	response to peptide hormone	Apr-29	427/18614	0.00411742	0.024283759	0.01290747	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
GRB2	BP	GO:0007264	small GTPase mediated signal transduction	Apr-29	483/18614	0.006357843	0.032384911	0.017213449	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
GRB2	BP	GO:0050853	B cell receptor signaling pathway	Feb-29	77/18614	0.006379011	0.032384911	0.017213449	2885/5594	2	GRB2/MAPK1
GRB2	BP	GO:0001892	embryonic placenta development	Feb-29	89/18614	0.00843942	0.03896601	0.02071148	2885/5594	2	GRB2/MAPK1
GRB2	MF	GO:0019902	phosphatase binding	May-32	187/18369	1.67E-05	3.37E-04	1.43E-04	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	MF	GO:0046875	ephrin receptor binding	Mar-32	29/18369	1.70E-05	3.37E-04	1.43E-04	2534/2885/6714	3	FYN/GRB2/SRC
GRB2	MF	GO:0030971	receptor tyrosine kinase binding	Mar-32	76/18369	3.10E-04	0.00275597	0.001173447	2885/7157/7532	3	GRB2/TP53/YWHAG
GRB2	MF	GO:0051219	phosphoprotein binding	Mar-32	92/18369	5.43E-04	0.004335707	0.001846073	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	MF	GO:1990782	protein tyrosine kinase binding	Mar-32	121/18369	0.001202861	0.007136975	0.003038807	2885/7157/7532	3	GRB2/TP53/YWHAG
GRB2	MF	GO:0070851	growth factor receptor binding	Mar-32	137/18369	0.001718305	0.008147008	0.003468862	2534/2885/6714	3	FYN/GRB2/SRC
GRB2	MF	GO:0001784	phosphotyrosine residue binding	Feb-32	47/18369	0.003026514	0.010994274	0.004681181	2885/5594	2	GRB2/MAPK1
GRB2	MF	GO:0045309	protein phosphorylated amino acid binding	Feb-32	58/18369	0.004573095	0.015654054	0.006665239	2885/5594	2	GRB2/MAPK1
GRB2	MF	GO:0005126	cytokine receptor binding	Mar-32	270/18369	0.011372314	0.034309692	0.014608503	2885/4087/4088	3	GRB2/SMAD2/SMAD3
GRB2	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
GRB2	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
GRB2	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
GRB2	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
GRB2	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
GRB2	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
GRB2	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
GRB2	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
GRB2	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
GRB2	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
GRB2	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
GRB2	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
GRB2	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
GRB2	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
GRB2	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
GRB2	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
GRB2	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
GRB2	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
GRB2	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
GRB2	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
GRB2	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
GRB2	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
GRB2	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
GRB2	NA	hsa04664	Fc epsilon RI signaling pathway	Mar-22	69/8848	6.29E-04	0.002385838	8.87E-04	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
GRB2	NA	hsa01521	EGFR tyrosine kinase inhibitor resistance	Mar-22	80/8848	9.68E-04	0.003300536	0.001227429	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
GRB2	NA	hsa04540	Gap junction	Mar-22	92/8848	0.001451895	0.004662816	0.001734044	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa04912	GnRH signaling pathway	Mar-22	93/8848	0.001497879	0.004719731	0.00175521	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
GRB2	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
GRB2	NA	hsa04722	Neurotrophin signaling pathway	Mar-22	120/8848	0.003103907	0.008639206	0.003212816	2885/5594/7157	3	GRB2/MAPK1/TP53
GRB2	NA	hsa04660	T cell receptor signaling pathway	Mar-22	122/8848	0.003252579	0.008904602	0.003311513	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04650	Natural killer cell mediated cytotoxicity	Mar-22	135/8848	0.004326265	0.011468035	0.004264822	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04380	Osteoclast differentiation	Mar-22	142/8848	0.004983922	0.012610832	0.004689815	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04072	Phospholipase D signaling pathway	Mar-22	149/8848	0.005699212	0.014205499	0.005282852	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa05034	Alcoholism	Mar-22	188/8848	0.010798334	0.024135849	0.008975828	2885/3065/5594	3	GRB2/HDAC1/MAPK1
GRB2	NA	hsa04062	Chemokine signaling pathway	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa05221	Acute myeloid leukemia	Feb-22	68/8848	0.012174976	0.025415262	0.009451626	2885/5594	2	GRB2/MAPK1
GRB2	NA	hsa04662	B cell receptor signaling pathway	Feb-22	91/8848	0.021145947	0.038806298	0.014431589	2885/5594	2	GRB2/MAPK1
GRB2	NA	hsa05231	Choline metabolism in cancer	Feb-22	99/8848	0.024752372	0.043512065	0.016181606	2885/5594	2	GRB2/MAPK1
GRB2	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
GRB2	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
GRB2	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
GRB2	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
GRB2	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
GRB2	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
GRB2	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
GRB2	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
GRB2	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
GRB2	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
GRB2	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
GRB2	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
GRB2	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
GRB2	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
GRB2	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
GRB2	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
GRB2	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
GRB2	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
GRB2	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
GRB2	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
GRB2	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
GRB2	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
GRB2	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
GRB2	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
GRB2	NA	hsa04664	Fc epsilon RI signaling pathway	Mar-22	69/8848	6.29E-04	0.002385838	8.87E-04	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04630	JAK-STAT signaling pathway	Apr-22	168/8848	7.02E-04	0.002605905	9.69E-04	1026/1387/2033/2885	4	CDKN1A/CREBBP/EP300/GRB2
GRB2	NA	hsa01521	EGFR tyrosine kinase inhibitor resistance	Mar-22	80/8848	9.68E-04	0.003300536	0.001227429	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
GRB2	NA	hsa04540	Gap junction	Mar-22	92/8848	0.001451895	0.004662816	0.001734044	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa04912	GnRH signaling pathway	Mar-22	93/8848	0.001497879	0.004719731	0.00175521	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
GRB2	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
GRB2	NA	hsa04722	Neurotrophin signaling pathway	Mar-22	120/8848	0.003103907	0.008639206	0.003212816	2885/5594/7157	3	GRB2/MAPK1/TP53
GRB2	NA	hsa04660	T cell receptor signaling pathway	Mar-22	122/8848	0.003252579	0.008904602	0.003311513	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04650	Natural killer cell mediated cytotoxicity	Mar-22	135/8848	0.004326265	0.011468035	0.004264822	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04380	Osteoclast differentiation	Mar-22	142/8848	0.004983922	0.012610832	0.004689815	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa04072	Phospholipase D signaling pathway	Mar-22	149/8848	0.005699212	0.014205499	0.005282852	2534/2885/5594	3	FYN/GRB2/MAPK1
GRB2	NA	hsa05034	Alcoholism	Mar-22	188/8848	0.010798334	0.024135849	0.008975828	2885/3065/5594	3	GRB2/HDAC1/MAPK1
GRB2	NA	hsa04062	Chemokine signaling pathway	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	2885/5594/6714	3	GRB2/MAPK1/SRC
GRB2	NA	hsa05221	Acute myeloid leukemia	Feb-22	68/8848	0.012174976	0.025415262	0.009451626	2885/5594	2	GRB2/MAPK1
GRB2	NA	hsa04662	B cell receptor signaling pathway	Feb-22	91/8848	0.021145947	0.038806298	0.014431589	2885/5594	2	GRB2/MAPK1
GRB2	NA	hsa05231	Choline metabolism in cancer	Feb-22	99/8848	0.024752372	0.043512065	0.016181606	2885/5594	2	GRB2/MAPK1
HDAC1	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
HDAC1	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
HDAC1	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
HDAC1	BP	GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	Jun-29	148/18614	9.32E-08	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
HDAC1	BP	GO:1903844	regulation of cellular response to transforming growth factor beta stimulus	Jun-29	151/18614	1.05E-07	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
HDAC1	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
HDAC1	BP	GO:0030518	intracellular steroid hormone receptor signaling pathway	May-29	115/18614	8.70E-07	9.37E-05	4.98E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
HDAC1	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
HDAC1	BP	GO:0043401	steroid hormone mediated signaling pathway	May-29	135/18614	1.92E-06	1.81E-04	9.62E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
HDAC1	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
HDAC1	BP	GO:0033143	regulation of intracellular steroid hormone receptor signaling pathway	Apr-29	72/18614	4.54E-06	3.19E-04	1.70E-04	367/2033/3065/6714	4	AR/EP300/HDAC1/SRC
HDAC1	BP	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
HDAC1	BP	GO:0097193	intrinsic apoptotic signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1026/1984/2033/3065/6714/7157	6	CDKN1A/EIF5A/EP300/HDAC1/SRC/TP53
HDAC1	BP	GO:0036120	cellular response to platelet-derived growth factor stimulus	Mar-29	24/18614	6.73E-06	3.89E-04	2.07E-04	2534/3065/6714	3	FYN/HDAC1/SRC
HDAC1	BP	GO:0007492	endoderm development	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	2885/3065/4087/4088	4	GRB2/HDAC1/SMAD2/SMAD3
HDAC1	BP	GO:0036119	response to platelet-derived growth factor	Mar-29	26/18614	8.63E-06	4.25E-04	2.26E-04	2534/3065/6714	3	FYN/HDAC1/SRC
HDAC1	BP	GO:0009755	hormone-mediated signaling pathway	May-29	192/18614	1.08E-05	4.97E-04	2.64E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
HDAC1	BP	GO:0090287	regulation of cellular response to growth factor stimulus	Jun-29	345/18614	1.29E-05	5.62E-04	2.99E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
HDAC1	BP	GO:0071383	cellular response to steroid hormone stimulus	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
HDAC1	BP	GO:2001234	negative regulation of apoptotic signaling pathway	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	367/1457/3065/9821/6714	5	AR/CSNK2A1/HDAC1/RB1CC1/SRC
HDAC1	BP	GO:0030521	androgen receptor signaling pathway	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	367/2033/3065	3	AR/EP300/HDAC1
HDAC1	BP	GO:0030522	intracellular receptor signaling pathway	May-29	299/18614	8.95E-05	0.002336435	0.001241878	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
HDAC1	BP	GO:2001242	regulation of intrinsic apoptotic signaling pathway	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1984/3065/6714/7157	4	EIF5A/HDAC1/SRC/TP53
HDAC1	BP	GO:0052548	regulation of endopeptidase activity	May-29	336/18614	1.55E-04	0.003246445	0.001725573	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
HDAC1	BP	GO:0048545	response to steroid hormone	May-29	339/18614	1.61E-04	0.003257009	0.001731188	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
HDAC1	BP	GO:0052547	regulation of peptidase activity	May-29	425/18614	4.58E-04	0.006014484	0.00319686	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
HDAC1	BP	GO:0048863	stem cell differentiation	Apr-29	247/18614	5.54E-04	0.00672641	0.003575267	2099/3065/5594/7157	4	ESR1/HDAC1/MAPK1/TP53
HDAC1	BP	GO:0042659	regulation of cell fate specification	Feb-29	25/18614	6.88E-04	0.007825603	0.004159518	367/3065	2	AR/HDAC1
HDAC1	BP	GO:0006476	protein deacetylation	Mar-29	116/18614	7.66E-04	0.008303657	0.004413616	2033/3065/7157	3	EP300/HDAC1/TP53
HDAC1	BP	GO:0060765	regulation of androgen receptor signaling pathway	Feb-29	28/18614	8.64E-04	0.0089494	0.004756846	2033/3065	2	EP300/HDAC1
HDAC1	BP	GO:0045165	cell fate commitment	Apr-29	281/18614	8.97E-04	0.00907924	0.00482586	367/3065/4087/7157	4	AR/HDAC1/SMAD2/TP53
HDAC1	BP	GO:0035601	protein deacylation	Mar-29	127/18614	9.96E-04	0.009519221	0.005059721	2033/3065/7157	3	EP300/HDAC1/TP53
HDAC1	BP	GO:0098732	macromolecule deacylation	Mar-29	131/18614	0.00108881	0.01011217	0.00537489	2033/3065/7157	3	EP300/HDAC1/TP53
HDAC1	BP	GO:0030111	regulation of Wnt signaling pathway	Apr-29	338/18614	0.001772034	0.013901007	0.007388758	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
HDAC1	BP	GO:0010453	regulation of cell fate commitment	Feb-29	42/18614	0.001941427	0.014939743	0.007940874	367/3065	2	AR/HDAC1
HDAC1	BP	GO:0048660	regulation of smooth muscle cell proliferation	Mar-29	176/18614	0.002534251	0.017962061	0.009547318	1026/3065/6714	3	CDKN1A/HDAC1/SRC
HDAC1	BP	GO:0048659	smooth muscle cell proliferation	Mar-29	180/18614	0.002700744	0.018893519	0.010042412	1026/3065/6714	3	CDKN1A/HDAC1/SRC
HDAC1	BP	GO:0019083	viral transcription	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	2033/3065	2	EP300/HDAC1
HDAC1	BP	GO:0043124	negative regulation of I-kappaB kinase/NF-kappaB signaling	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	2099/3065	2	ESR1/HDAC1
HDAC1	BP	GO:0040029	epigenetic regulation of gene expression	Mar-29	188/18614	0.003053708	0.019872984	0.010563024	2033/3065/7157	3	EP300/HDAC1/TP53
HDAC1	BP	GO:0006338	chromatin remodeling	Apr-29	402/18614	0.003319658	0.021203821	0.0112704	2033/2099/3065/7157	4	EP300/ESR1/HDAC1/TP53
HDAC1	BP	GO:0042733	embryonic digit morphogenesis	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	1387/3065	2	CREBBP/HDAC1
HDAC1	BP	GO:0007623	circadian rhythm	Mar-29	207/18614	0.004002267	0.024012739	0.012763415	2033/3065/7157	3	EP300/HDAC1/TP53
HDAC1	BP	GO:0016055	Wnt signaling pathway	Apr-29	461/18614	0.00539908	0.029083044	0.015458418	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
HDAC1	BP	GO:0198738	cell-cell signaling by wnt	Apr-29	463/18614	0.005481916	0.029431148	0.015643445	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
HDAC1	BP	GO:0016570	histone modification	Apr-29	475/18614	0.005996982	0.031161166	0.016562996	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
HDAC1	BP	GO:0033002	muscle cell proliferation	Mar-29	249/18614	0.006684519	0.033237488	0.017666617	1026/3065/6714	3	CDKN1A/HDAC1/SRC
HDAC1	BP	GO:0043122	regulation of I-kappaB kinase/NF-kappaB signaling	Mar-29	258/18614	0.007369682	0.035266347	0.01874501	2099/2534/3065	3	ESR1/FYN/HDAC1
HDAC1	BP	GO:0051851	modulation by host of symbiont process	Feb-29	83/18614	0.007376253	0.035266347	0.01874501	2033/3065	2	EP300/HDAC1
HDAC1	BP	GO:0060828	regulation of canonical Wnt signaling pathway	Mar-29	260/18614	0.007527405	0.035879491	0.019070913	3065/4088/6714	3	HDAC1/SMAD3/SRC
HDAC1	BP	GO:0016575	histone deacetylation	Feb-29	94/18614	0.009374867	0.042082737	0.022368104	3065/7157	2	HDAC1/TP53
HDAC1	BP	GO:0048661	positive regulation of smooth muscle cell proliferation	Feb-29	99/18614	0.010354541	0.044860425	0.02384452	3065/6714	2	HDAC1/SRC
HDAC1	BP	GO:2001243	negative regulation of intrinsic apoptotic signaling pathway	Feb-29	99/18614	0.010354541	0.044860425	0.02384452	3065/6714	2	HDAC1/SRC
HDAC1	BP	GO:0007249	I-kappaB kinase/NF-kappaB signaling	Mar-29	293/18614	0.01042313	0.04503684	0.023938289	2099/2534/3065	3	ESR1/FYN/HDAC1
HDAC1	BP	GO:0019080	viral gene expression	Feb-29	100/18614	0.010555722	0.045246808	0.024049893	2033/3065	2	EP300/HDAC1
HDAC1	BP	GO:0030512	negative regulation of transforming growth factor beta receptor signaling pathway	Feb-29	100/18614	0.010555722	0.045246808	0.024049893	3065/7157	2	HDAC1/TP53
HDAC1	CC	GO:0016581	NuRD complex	Feb-30	17/19518	3.06E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
HDAC1	CC	GO:0090545	CHD-type complex	Feb-30	17/19518	3.06E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
HDAC1	CC	GO:0016580	Sin3 complex	Feb-30	22/19518	5.18E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
HDAC1	CC	GO:0070822	Sin3-type complex	Feb-30	22/19518	5.18E-04	0.015268608	0.009806778	1457/3065	2	CSNK2A1/HDAC1
HDAC1	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
HDAC1	MF	GO:0001221	transcription coregulator binding	Jun-32	111/18369	3.39E-08	2.01E-06	8.56E-07	367/1387/2033/2099/3065/4088	6	AR/CREBBP/EP300/ESR1/HDAC1/SMAD3
HDAC1	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
HDAC1	MF	GO:0002039	p53 binding	Apr-32	67/18369	5.38E-06	1.92E-04	8.16E-05	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
HDAC1	MF	GO:0031490	chromatin DNA binding	Apr-32	118/18369	5.06E-05	8.19E-04	3.49E-04	1387/2033/3065/4088	4	CREBBP/EP300/HDAC1/SMAD3
HDAC1	MF	GO:1990841	promoter-specific chromatin binding	Mar-32	63/18369	1.78E-04	0.001756554	7.48E-04	3065/4088/7157	3	HDAC1/SMAD3/TP53
HDAC1	MF	GO:0051059	NF-kappaB binding	Feb-32	31/18369	0.001324689	0.007145292	0.003042348	2033/3065	2	EP300/HDAC1
HDAC1	MF	GO:0016810	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	Mar-32	131/18369	0.001511415	0.007686625	0.003272839	23536/978/3065	3	ADAT1/CDA/HDAC1
HDAC1	MF	GO:0001046	core promoter sequence-specific DNA binding	Feb-32	43/18369	0.002539157	0.010272045	0.004373668	3065/7157	2	HDAC1/TP53
HDAC1	MF	GO:0001222	transcription corepressor binding	Feb-32	45/18369	0.002777759	0.010757398	0.004580323	2099/3065	2	ESR1/HDAC1
HDAC1	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
HDAC1	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
HDAC1	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
HDAC1	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
HDAC1	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
HDAC1	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
HDAC1	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
HDAC1	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
HDAC1	NA	hsa04330	Notch signaling pathway	Mar-22	62/8848	4.59E-04	0.001824653	6.79E-04	1387/2033/3065	3	CREBBP/EP300/HDAC1
HDAC1	NA	hsa03083	Polycomb repressive complex	Mar-22	83/8848	0.001077785	0.0035998	0.001338722	1387/2033/3065	3	CREBBP/EP300/HDAC1
HDAC1	NA	hsa05034	Alcoholism	Mar-22	188/8848	0.010798334	0.024135849	0.008975828	2885/3065/5594	3	GRB2/HDAC1/MAPK1
HDAC1	NA	hsa04613	Neutrophil extracellular trap formation	Mar-22	192/8848	0.011432575	0.024509819	0.009114903	3065/5594/6714	3	HDAC1/MAPK1/SRC
HDAC1	NA	hsa05202	Transcriptional misregulation in cancer	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	1026/3065/7157	3	CDKN1A/HDAC1/TP53
HDAC1	NA	hsa05169	Epstein-Barr virus infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	1026/3065/7157	3	CDKN1A/HDAC1/TP53
HDAC1	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
HDAC1	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
HDAC1	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
HDAC1	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
HDAC1	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
HDAC1	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
HDAC1	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
HDAC1	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
HDAC1	NA	hsa04330	Notch signaling pathway	Mar-22	62/8848	4.59E-04	0.001824653	6.79E-04	1387/2033/3065	3	CREBBP/EP300/HDAC1
HDAC1	NA	hsa03083	Polycomb repressive complex	Mar-22	83/8848	0.001077785	0.0035998	0.001338722	1387/2033/3065	3	CREBBP/EP300/HDAC1
HDAC1	NA	hsa05034	Alcoholism	Mar-22	188/8848	0.010798334	0.024135849	0.008975828	2885/3065/5594	3	GRB2/HDAC1/MAPK1
HDAC1	NA	hsa04613	Neutrophil extracellular trap formation	Mar-22	192/8848	0.011432575	0.024509819	0.009114903	3065/5594/6714	3	HDAC1/MAPK1/SRC
HDAC1	NA	hsa05202	Transcriptional misregulation in cancer	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	1026/3065/7157	3	CDKN1A/HDAC1/TP53
HDAC1	NA	hsa05169	Epstein-Barr virus infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	1026/3065/7157	3	CDKN1A/HDAC1/TP53
MAPK1	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
MAPK1	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
MAPK1	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
MAPK1	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
MAPK1	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
MAPK1	BP	GO:0061180	mammary gland epithelium development	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
MAPK1	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
MAPK1	BP	GO:0031647	regulation of protein stability	Jun-29	322/18614	8.69E-06	4.25E-04	2.26E-04	1387/2033/5594/4088/6714/7157	6	CREBBP/EP300/MAPK1/SMAD3/SRC/TP53
MAPK1	BP	GO:1901653	cellular response to peptide	Jun-29	375/18614	2.06E-05	7.93E-04	4.22E-04	2534/2885/5594/6714/7157/7532	6	FYN/GRB2/MAPK1/SRC/TP53/YWHAG
MAPK1	BP	GO:0001701	in utero embryonic development	Jun-29	398/18614	2.88E-05	0.001012157	5.38E-04	367/2885/5594/4087/4088/7157	6	AR/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	BP	GO:2000278	regulation of DNA biosynthetic process	Apr-29	121/18614	3.56E-05	0.001223397	6.50E-04	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
MAPK1	BP	GO:0051972	regulation of telomerase activity	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	5594/6714/7157	3	MAPK1/SRC/TP53
MAPK1	BP	GO:0030879	mammary gland development	Apr-29	136/18614	5.62E-05	0.001650943	8.78E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
MAPK1	BP	GO:0048009	insulin-like growth factor receptor signaling pathway	Mar-29	50/18614	6.34E-05	0.001830608	9.73E-04	367/2885/5594	3	AR/GRB2/MAPK1
MAPK1	BP	GO:0072584	caveolin-mediated endocytosis	Feb-29	11/18614	1.28E-04	0.002908472	0.001545931	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0070661	leukocyte proliferation	May-29	348/18614	1.82E-04	0.003463376	0.001840877	11119/1026/2534/5594/7157	5	BTN3A1/CDKN1A/FYN/MAPK1/TP53
MAPK1	BP	GO:0071897	DNA biosynthetic process	Apr-29	198/18614	2.39E-04	0.004206819	0.002236037	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
MAPK1	BP	GO:0006206	pyrimidine nucleobase metabolic process	Feb-29	15/18614	2.43E-04	0.004222673	0.002244464	978/5594	2	CDA/MAPK1
MAPK1	BP	GO:0050851	antigen receptor-mediated signaling pathway	Apr-29	201/18614	2.54E-04	0.004314593	0.002293322	11119/2534/2885/5594	4	BTN3A1/FYN/GRB2/MAPK1
MAPK1	BP	GO:0032869	cellular response to insulin stimulus	Apr-29	211/18614	3.05E-04	0.004863024	0.002584828	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
MAPK1	BP	GO:2000641	regulation of early endosome to late endosome transport	Feb-29	19/18614	3.94E-04	0.005539882	0.002944596	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0006979	response to oxidative stress	May-29	434/18614	5.04E-04	0.006409007	0.003406559	2534/5594/4700/6714/7157	5	FYN/MAPK1/NDUFA6/SRC/TP53
MAPK1	BP	GO:0048863	stem cell differentiation	Apr-29	247/18614	5.54E-04	0.00672641	0.003575267	2099/3065/5594/7157	4	ESR1/HDAC1/MAPK1/TP53
MAPK1	BP	GO:0048568	embryonic organ development	May-29	453/18614	6.12E-04	0.007114114	0.003781342	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	BP	GO:0071216	cellular response to biotic stimulus	Apr-29	264/18614	7.11E-04	0.007973549	0.004238155	978/5594/6714/7157	4	CDA/MAPK1/SRC/TP53
MAPK1	BP	GO:0033598	mammary gland epithelial cell proliferation	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	2099/5594	2	ESR1/MAPK1
MAPK1	BP	GO:0032868	response to insulin	Apr-29	272/18614	7.94E-04	0.008500733	0.004518368	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
MAPK1	BP	GO:0007611	learning or memory	Apr-29	276/18614	8.39E-04	0.00885882	0.004708701	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
MAPK1	BP	GO:0030878	thyroid gland development	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	5594/4088	2	MAPK1/SMAD3
MAPK1	BP	GO:1903649	regulation of cytoplasmic transport	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0034599	cellular response to oxidative stress	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
MAPK1	BP	GO:0008286	insulin receptor signaling pathway	Mar-29	128/18614	0.001018341	0.009567665	0.005085471	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	BP	GO:0038127	ERBB signaling pathway	Mar-29	131/18614	0.00108881	0.01011217	0.00537489	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	BP	GO:0035270	endocrine system development	Mar-29	137/18614	0.001238853	0.011060698	0.005879058	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	BP	GO:0071375	cellular response to peptide hormone stimulus	Apr-29	308/18614	0.001259647	0.011135312	0.005918717	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
MAPK1	BP	GO:0009112	nucleobase metabolic process	Feb-29	34/18614	0.001274773	0.011135312	0.005918717	978/5594	2	CDA/MAPK1
MAPK1	BP	GO:0050852	T cell receptor signaling pathway	Mar-29	140/18614	0.001318524	0.01145556	0.006088937	11119/2534/5594	3	BTN3A1/FYN/MAPK1
MAPK1	BP	GO:0050890	cognition	Apr-29	317/18614	0.001400637	0.011856515	0.006302056	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
MAPK1	BP	GO:0071496	cellular response to external stimulus	Apr-29	327/18614	0.001569882	0.012877816	0.006844905	978/1026/5594/7157	4	CDA/CDKN1A/MAPK1/TP53
MAPK1	BP	GO:0032386	regulation of intracellular transport	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	2534/5594/4088/6714	4	FYN/MAPK1/SMAD3/SRC
MAPK1	BP	GO:0034614	cellular response to reactive oxygen species	Mar-29	152/18614	0.00166931	0.013354479	0.007098264	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	BP	GO:0062197	cellular response to chemical stress	Apr-29	349/18614	0.001991682	0.015253833	0.008107822	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
MAPK1	BP	GO:0045022	early endosome to late endosome transport	Feb-29	44/18614	0.002128979	0.015927917	0.008466115	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0009267	cellular response to starvation	Mar-29	170/18614	0.002296745	0.016870633	0.008967194	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	BP	GO:0060711	labyrinthine layer development	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	2885/5594	2	GRB2/MAPK1
MAPK1	BP	GO:0098927	vesicle-mediated transport between endosomal compartments	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0034198	cellular response to amino acid starvation	Feb-29	49/18614	0.002633868	0.018586598	0.009879276	1026/5594	2	CDKN1A/MAPK1
MAPK1	BP	GO:0060324	face development	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	2033/5594	2	EP300/MAPK1
MAPK1	BP	GO:1990928	response to amino acid starvation	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	1026/5594	2	CDKN1A/MAPK1
MAPK1	BP	GO:0030324	lung development	Mar-29	186/18614	0.002962942	0.019543326	0.010387802	2033/5594/4087	3	EP300/MAPK1/SMAD2
MAPK1	BP	GO:0032210	regulation of telomere maintenance via telomerase	Feb-29	53/18614	0.00307441	0.019872984	0.010563024	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0030323	respiratory tube development	Mar-29	190/18614	0.003146174	0.020255847	0.010766526	2033/5594/4087	3	EP300/MAPK1/SMAD2
MAPK1	BP	GO:0002520	immune system development	Mar-29	197/18614	0.003483352	0.022131628	0.011763554	5594/4088/7157	3	MAPK1/SMAD3/TP53
MAPK1	BP	GO:0000302	response to reactive oxygen species	Mar-29	205/18614	0.003894931	0.023573812	0.012530114	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	BP	GO:0042594	response to starvation	Mar-29	207/18614	0.004002267	0.024012739	0.012763415	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	BP	GO:1904356	regulation of telomere maintenance via telomere lengthening	Feb-29	61/18614	0.00405151	0.024012739	0.012763415	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0043434	response to peptide hormone	Apr-29	427/18614	0.00411742	0.024283759	0.01290747	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
MAPK1	BP	GO:0060541	respiratory system development	Mar-29	211/18614	0.004222335	0.024632828	0.013093009	2033/5594/4087	3	EP300/MAPK1/SMAD2
MAPK1	BP	GO:0048645	animal organ formation	Feb-29	68/18614	0.005009484	0.027723717	0.0147359	367/5594	2	AR/MAPK1
MAPK1	BP	GO:0007004	telomere maintenance via telomerase	Feb-29	69/18614	0.005154058	0.028329789	0.015058043	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0031669	cellular response to nutrient levels	Mar-29	230/18614	0.005367955	0.02901209	0.015420705	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	BP	GO:0071356	cellular response to tumor necrosis factor	Mar-29	235/18614	0.00569757	0.029893744	0.015889327	1984/5594/7157	3	EIF5A/MAPK1/TP53
MAPK1	BP	GO:0051403	stress-activated MAPK cascade	Mar-29	237/18614	0.00583276	0.030504012	0.016213701	5594/9821/4088	3	MAPK1/RB1CC1/SMAD3
MAPK1	BP	GO:2000573	positive regulation of DNA biosynthetic process	Feb-29	74/18614	0.005905501	0.030784803	0.016362949	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0006278	RNA-templated DNA biosynthetic process	Feb-29	75/18614	0.006061462	0.031195296	0.016581137	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0031667	response to nutrient levels	Apr-29	477/18614	0.006085872	0.03122149	0.01659506	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
MAPK1	BP	GO:0050853	B cell receptor signaling pathway	Feb-29	77/18614	0.006379011	0.032384911	0.017213449	2885/5594	2	GRB2/MAPK1
MAPK1	BP	GO:0031098	stress-activated protein kinase signaling cascade	Mar-29	245/18614	0.006392814	0.032384911	0.017213449	5594/9821/4088	3	MAPK1/RB1CC1/SMAD3
MAPK1	BP	GO:0050804	modulation of chemical synaptic transmission	Apr-29	487/18614	0.006543613	0.032839994	0.017455338	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
MAPK1	BP	GO:0050673	epithelial cell proliferation	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	367/2099/5594/4088	4	AR/ESR1/MAPK1/SMAD3
MAPK1	BP	GO:0099177	regulation of trans-synaptic signaling	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
MAPK1	BP	GO:0033044	regulation of chromosome organization	Mar-29	250/18614	0.006758672	0.033503111	0.017807803	246184/5594/6714	3	CDC26/MAPK1/SRC
MAPK1	BP	GO:0010833	telomere maintenance via telomere lengthening	Feb-29	81/18614	0.007036453	0.034457298	0.018314979	5594/6714	2	MAPK1/SRC
MAPK1	BP	GO:0048762	mesenchymal cell differentiation	Mar-29	255/18614	0.007136835	0.034738328	0.018464353	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	BP	GO:0034612	response to tumor necrosis factor	Mar-29	257/18614	0.007291568	0.035266347	0.01874501	1984/5594/7157	3	EIF5A/MAPK1/TP53
MAPK1	BP	GO:0072527	pyrimidine-containing compound metabolic process	Feb-29	83/18614	0.007376253	0.035266347	0.01874501	978/5594	2	CDA/MAPK1
MAPK1	BP	GO:0031668	cellular response to extracellular stimulus	Mar-29	261/18614	0.007607017	0.036049677	0.019161371	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	BP	GO:0001892	embryonic placenta development	Feb-29	89/18614	0.00843942	0.03896601	0.02071148	2885/5594	2	GRB2/MAPK1
MAPK1	BP	GO:0048534	hematopoietic or lymphoid organ development	Feb-29	96/18614	0.009761469	0.043099817	0.02290871	5594/7157	2	MAPK1/TP53
MAPK1	BP	GO:0048562	embryonic organ morphogenesis	Mar-29	294/18614	0.010519651	0.045246808	0.024049893	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	BP	GO:0032204	regulation of telomere maintenance	Feb-29	104/18614	0.011377748	0.048132043	0.025583473	5594/6714	2	MAPK1/SRC
MAPK1	MF	GO:0019902	phosphatase binding	May-32	187/18369	1.67E-05	3.37E-04	1.43E-04	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	MF	GO:0051219	phosphoprotein binding	Mar-32	92/18369	5.43E-04	0.004335707	0.001846073	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	MF	GO:0001784	phosphotyrosine residue binding	Feb-32	47/18369	0.003026514	0.010994274	0.004681181	2885/5594	2	GRB2/MAPK1
MAPK1	MF	GO:0045309	protein phosphorylated amino acid binding	Feb-32	58/18369	0.004573095	0.015654054	0.006665239	2885/5594	2	GRB2/MAPK1
MAPK1	MF	GO:0008353	RNA polymerase II CTD heptapeptide repeat kinase activity	Jan-32	10/18369	0.017288924	0.04808482	0.020473726	5594	1	MAPK1
MAPK1	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
MAPK1	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
MAPK1	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
MAPK1	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
MAPK1	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
MAPK1	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
MAPK1	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
MAPK1	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
MAPK1	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
MAPK1	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
MAPK1	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
MAPK1	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
MAPK1	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
MAPK1	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
MAPK1	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
MAPK1	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
MAPK1	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
MAPK1	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
MAPK1	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
MAPK1	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
MAPK1	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
MAPK1	NA	hsa05216	Thyroid cancer	Mar-22	37/8848	9.82E-05	5.12E-04	1.90E-04	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
MAPK1	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
MAPK1	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
MAPK1	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
MAPK1	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
MAPK1	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
MAPK1	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
MAPK1	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
MAPK1	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa04720	Long-term potentiation	Mar-22	67/8848	5.77E-04	0.002239357	8.33E-04	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa04664	Fc epsilon RI signaling pathway	Mar-22	69/8848	6.29E-04	0.002385838	8.87E-04	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa05218	Melanoma	Mar-22	73/8848	7.41E-04	0.002691655	0.001000994	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	NA	hsa01524	Platinum drug resistance	Mar-22	75/8848	8.02E-04	0.002850907	0.001060217	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
MAPK1	NA	hsa01521	EGFR tyrosine kinase inhibitor resistance	Mar-22	80/8848	9.68E-04	0.003300536	0.001227429	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
MAPK1	NA	hsa04540	Gap junction	Mar-22	92/8848	0.001451895	0.004662816	0.001734044	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa04912	GnRH signaling pathway	Mar-22	93/8848	0.001497879	0.004719731	0.00175521	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
MAPK1	NA	hsa04916	Melanogenesis	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa04933	AGE-RAGE signaling pathway in diabetic complications	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
MAPK1	NA	hsa04659	Th17 cell differentiation	Mar-22	108/8848	0.002300357	0.006511179	0.002421428	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa04722	Neurotrophin signaling pathway	Mar-22	120/8848	0.003103907	0.008639206	0.003212816	2885/5594/7157	3	GRB2/MAPK1/TP53
MAPK1	NA	hsa04660	T cell receptor signaling pathway	Mar-22	122/8848	0.003252579	0.008904602	0.003311513	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa04611	Platelet activation	Mar-22	126/8848	0.003562952	0.009596983	0.003569001	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	NA	hsa04650	Natural killer cell mediated cytotoxicity	Mar-22	135/8848	0.004326265	0.011468035	0.004264822	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
MAPK1	NA	hsa04371	Apelin signaling pathway	Mar-22	140/8848	0.004790203	0.012307136	0.004576874	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa04380	Osteoclast differentiation	Mar-22	142/8848	0.004983922	0.012610832	0.004689815	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa04072	Phospholipase D signaling pathway	Mar-22	149/8848	0.005699212	0.014205499	0.005282852	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa04921	Oxytocin signaling pathway	Mar-22	154/8848	0.006246197	0.015339925	0.005704731	1026/5594/6714	3	CDKN1A/MAPK1/SRC
MAPK1	NA	hsa05164	Influenza A	Mar-22	172/8848	0.008471789	0.020211268	0.007516324	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa04370	VEGF signaling pathway	Feb-22	60/8848	0.009574006	0.022519142	0.008374594	5594/6714	2	MAPK1/SRC
MAPK1	NA	hsa04360	Axon guidance	Mar-22	184/8848	0.010185291	0.023624218	0.008785558	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	NA	hsa05034	Alcoholism	Mar-22	188/8848	0.010798334	0.024135849	0.008975828	2885/3065/5594	3	GRB2/HDAC1/MAPK1
MAPK1	NA	hsa04613	Neutrophil extracellular trap formation	Mar-22	192/8848	0.011432575	0.024509819	0.009114903	3065/5594/6714	3	HDAC1/MAPK1/SRC
MAPK1	NA	hsa04062	Chemokine signaling pathway	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa05221	Acute myeloid leukemia	Feb-22	68/8848	0.012174976	0.025415262	0.009451626	2885/5594	2	GRB2/MAPK1
MAPK1	NA	hsa05230	Central carbon metabolism in cancer	Feb-22	71/8848	0.013221774	0.02673445	0.009942216	5594/7157	2	MAPK1/TP53
MAPK1	NA	hsa05130	Pathogenic Escherichia coli infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
MAPK1	NA	hsa05417	Lipid and atherosclerosis	Mar-22	216/8848	0.015690563	0.030118667	0.011200765	5594/6714/7157	3	MAPK1/SRC/TP53
MAPK1	NA	hsa04024	cAMP signaling pathway	Mar-22	226/8848	0.017697314	0.033584675	0.012489731	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	1457/5594	2	CSNK2A1/MAPK1
MAPK1	NA	hsa04662	B cell receptor signaling pathway	Feb-22	91/8848	0.021145947	0.038806298	0.014431589	2885/5594	2	GRB2/MAPK1
MAPK1	NA	hsa05131	Shigellosis	Mar-22	249/8848	0.022840621	0.041014879	0.015252933	5594/6714/7157	3	MAPK1/SRC/TP53
MAPK1	NA	hsa05231	Choline metabolism in cancer	Feb-22	99/8848	0.024752372	0.043512065	0.016181606	2885/5594	2	GRB2/MAPK1
MAPK1	NA	hsa05142	Chagas disease	Feb-22	103/8848	0.026644093	0.046349619	0.017236858	5594/4087	2	MAPK1/SMAD2
MAPK1	NA	hsa04625	C-type lectin receptor signaling pathway	Feb-22	105/8848	0.027611539	0.047537393	0.017678577	5594/6714	2	MAPK1/SRC
MAPK1	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
MAPK1	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
MAPK1	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
MAPK1	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
MAPK1	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
MAPK1	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
MAPK1	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
MAPK1	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
MAPK1	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
MAPK1	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
MAPK1	NA	hsa05211	Renal cell carcinoma	May-22	70/8848	6.36E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594	5	CDKN1A/CREBBP/EP300/GRB2/MAPK1
MAPK1	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
MAPK1	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
MAPK1	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
MAPK1	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
MAPK1	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
MAPK1	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
MAPK1	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
MAPK1	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
MAPK1	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
MAPK1	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
MAPK1	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
MAPK1	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
MAPK1	NA	hsa05216	Thyroid cancer	Mar-22	37/8848	9.82E-05	5.12E-04	1.90E-04	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	NA	hsa04066	HIF-1 signaling pathway	Apr-22	109/8848	1.34E-04	6.80E-04	2.53E-04	1026/1387/2033/5594	4	CDKN1A/CREBBP/EP300/MAPK1
MAPK1	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
MAPK1	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
MAPK1	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
MAPK1	NA	hsa04935	Growth hormone synthesis, secretion and action	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	1387/2033/2885/5594	4	CREBBP/EP300/GRB2/MAPK1
MAPK1	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
MAPK1	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
MAPK1	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
MAPK1	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa04720	Long-term potentiation	Mar-22	67/8848	5.77E-04	0.002239357	8.33E-04	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa04664	Fc epsilon RI signaling pathway	Mar-22	69/8848	6.29E-04	0.002385838	8.87E-04	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa05218	Melanoma	Mar-22	73/8848	7.41E-04	0.002691655	0.001000994	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	NA	hsa01524	Platinum drug resistance	Mar-22	75/8848	8.02E-04	0.002850907	0.001060217	1026/5594/7157	3	CDKN1A/MAPK1/TP53
MAPK1	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
MAPK1	NA	hsa01521	EGFR tyrosine kinase inhibitor resistance	Mar-22	80/8848	9.68E-04	0.003300536	0.001227429	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
MAPK1	NA	hsa04540	Gap junction	Mar-22	92/8848	0.001451895	0.004662816	0.001734044	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa04912	GnRH signaling pathway	Mar-22	93/8848	0.001497879	0.004719731	0.00175521	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
MAPK1	NA	hsa04916	Melanogenesis	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa04933	AGE-RAGE signaling pathway in diabetic complications	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
MAPK1	NA	hsa04659	Th17 cell differentiation	Mar-22	108/8848	0.002300357	0.006511179	0.002421428	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa04722	Neurotrophin signaling pathway	Mar-22	120/8848	0.003103907	0.008639206	0.003212816	2885/5594/7157	3	GRB2/MAPK1/TP53
MAPK1	NA	hsa04660	T cell receptor signaling pathway	Mar-22	122/8848	0.003252579	0.008904602	0.003311513	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa04611	Platelet activation	Mar-22	126/8848	0.003562952	0.009596983	0.003569001	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	NA	hsa04650	Natural killer cell mediated cytotoxicity	Mar-22	135/8848	0.004326265	0.011468035	0.004264822	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
MAPK1	NA	hsa04371	Apelin signaling pathway	Mar-22	140/8848	0.004790203	0.012307136	0.004576874	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
MAPK1	NA	hsa04380	Osteoclast differentiation	Mar-22	142/8848	0.004983922	0.012610832	0.004689815	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa04072	Phospholipase D signaling pathway	Mar-22	149/8848	0.005699212	0.014205499	0.005282852	2534/2885/5594	3	FYN/GRB2/MAPK1
MAPK1	NA	hsa04921	Oxytocin signaling pathway	Mar-22	154/8848	0.006246197	0.015339925	0.005704731	1026/5594/6714	3	CDKN1A/MAPK1/SRC
MAPK1	NA	hsa05164	Influenza A	Mar-22	172/8848	0.008471789	0.020211268	0.007516324	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa04370	VEGF signaling pathway	Feb-22	60/8848	0.009574006	0.022519142	0.008374594	5594/6714	2	MAPK1/SRC
MAPK1	NA	hsa04360	Axon guidance	Mar-22	184/8848	0.010185291	0.023624218	0.008785558	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	NA	hsa05034	Alcoholism	Mar-22	188/8848	0.010798334	0.024135849	0.008975828	2885/3065/5594	3	GRB2/HDAC1/MAPK1
MAPK1	NA	hsa04613	Neutrophil extracellular trap formation	Mar-22	192/8848	0.011432575	0.024509819	0.009114903	3065/5594/6714	3	HDAC1/MAPK1/SRC
MAPK1	NA	hsa04062	Chemokine signaling pathway	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	2885/5594/6714	3	GRB2/MAPK1/SRC
MAPK1	NA	hsa05221	Acute myeloid leukemia	Feb-22	68/8848	0.012174976	0.025415262	0.009451626	2885/5594	2	GRB2/MAPK1
MAPK1	NA	hsa05230	Central carbon metabolism in cancer	Feb-22	71/8848	0.013221774	0.02673445	0.009942216	5594/7157	2	MAPK1/TP53
MAPK1	NA	hsa05130	Pathogenic Escherichia coli infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	2534/5594/6714	3	FYN/MAPK1/SRC
MAPK1	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
MAPK1	NA	hsa05417	Lipid and atherosclerosis	Mar-22	216/8848	0.015690563	0.030118667	0.011200765	5594/6714/7157	3	MAPK1/SRC/TP53
MAPK1	NA	hsa04024	cAMP signaling pathway	Mar-22	226/8848	0.017697314	0.033584675	0.012489731	1387/2033/5594	3	CREBBP/EP300/MAPK1
MAPK1	NA	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	1457/5594	2	CSNK2A1/MAPK1
MAPK1	NA	hsa04662	B cell receptor signaling pathway	Feb-22	91/8848	0.021145947	0.038806298	0.014431589	2885/5594	2	GRB2/MAPK1
MAPK1	NA	hsa05131	Shigellosis	Mar-22	249/8848	0.022840621	0.041014879	0.015252933	5594/6714/7157	3	MAPK1/SRC/TP53
MAPK1	NA	hsa05231	Choline metabolism in cancer	Feb-22	99/8848	0.024752372	0.043512065	0.016181606	2885/5594	2	GRB2/MAPK1
MAPK1	NA	hsa05142	Chagas disease	Feb-22	103/8848	0.026644093	0.046349619	0.017236858	5594/4087	2	MAPK1/SMAD2
MAPK1	NA	hsa04625	C-type lectin receptor signaling pathway	Feb-22	105/8848	0.027611539	0.047537393	0.017678577	5594/6714	2	MAPK1/SRC
MAPK1	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
NDUFA6	BP	GO:0006979	response to oxidative stress	May-29	434/18614	5.04E-04	0.006409007	0.003406559	2534/5594/4700/6714/7157	5	FYN/MAPK1/NDUFA6/SRC/TP53
NDUFA6	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
NDUFA6	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
NDUFA6	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
NDUFA6	NA	hsa05415	Diabetic cardiomyopathy	Mar-22	205/8848	0.013641931	0.027121459	0.01008614	4700/4087/4088	3	NDUFA6/SMAD2/SMAD3
NDUFA6	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
NDUFA6	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
NDUFA6	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
NDUFA6	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
NDUFA6	NA	hsa05020	Prion disease	Apr-22	278/8848	0.004460533	0.011639204	0.004328478	1457/2534/5594/4700	4	CSNK2A1/FYN/MAPK1/NDUFA6
NDUFA6	NA	hsa05415	Diabetic cardiomyopathy	Mar-22	205/8848	0.013641931	0.027121459	0.01008614	4700/4087/4088	3	NDUFA6/SMAD2/SMAD3
NDUFA6	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
NDUFA6	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
RB1	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
RB1	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
RB1	BP	GO:2001234	negative regulation of apoptotic signaling pathway	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	367/1457/3065/9821/6714	5	AR/CSNK2A1/HDAC1/RB1CC1/SRC
RB1	BP	GO:0097191	extrinsic apoptotic signaling pathway	Apr-29	227/18614	4.03E-04	0.005609047	0.002981359	367/9821/4088/6714	4	AR/RB1CC1/SMAD3/SRC
RB1	BP	GO:2001237	negative regulation of extrinsic apoptotic signaling pathway	Mar-29	99/18614	4.82E-04	0.006234977	0.003314057	367/9821/6714	3	AR/RB1CC1/SRC
RB1	BP	GO:0044262	cellular carbohydrate metabolic process	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2033/9821/6714/7157	4	EP300/RB1CC1/SRC/TP53
RB1	BP	GO:2001236	regulation of extrinsic apoptotic signaling pathway	Mar-29	156/18614	0.001797997	0.014036539	0.007460797	367/9821/6714	3	AR/RB1CC1/SRC
RB1	BP	GO:0016052	carbohydrate catabolic process	Mar-29	162/18614	0.002002413	0.015263674	0.008113053	2033/9821/7157	3	EP300/RB1CC1/TP53
RB1	BP	GO:0044275	cellular carbohydrate catabolic process	Feb-29	44/18614	0.002128979	0.015927917	0.008466115	9821/7157	2	RB1CC1/TP53
RB1	BP	GO:0046777	protein autophosphorylation	Mar-29	227/18614	0.005175879	0.028353288	0.015070533	2534/9821/6714	3	FYN/RB1CC1/SRC
RB1	BP	GO:0051403	stress-activated MAPK cascade	Mar-29	237/18614	0.00583276	0.030504012	0.016213701	5594/9821/4088	3	MAPK1/RB1CC1/SMAD3
RB1	BP	GO:0031098	stress-activated protein kinase signaling cascade	Mar-29	245/18614	0.006392814	0.032384911	0.017213449	5594/9821/4088	3	MAPK1/RB1CC1/SMAD3
RB1	BP	GO:0000422	autophagy of mitochondrion	Feb-29	92/18614	0.008995342	0.040832789	0.021703723	9821/7157	2	RB1CC1/TP53
RB1	BP	GO:0061726	mitochondrion disassembly	Feb-29	92/18614	0.008995342	0.040832789	0.021703723	9821/7157	2	RB1CC1/TP53
RB1	BP	GO:0061912	selective autophagy	Feb-29	93/18614	0.009184217	0.041341769	0.02197426	9821/7157	2	RB1CC1/TP53
RB1	CC	GO:1902554	serine/threonine protein kinase complex	Mar-30	121/19518	8.35E-04	0.019706033	0.012656864	1026/1457/9821	3	CDKN1A/CSNK2A1/RB1CC1
RB1	CC	GO:1902911	protein kinase complex	Mar-30	142/19518	0.001325491	0.026067996	0.016743049	1026/1457/9821	3	CDKN1A/CSNK2A1/RB1CC1
RB1	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
RB1	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
RB1	NA	hsa04211	Longevity regulating pathway	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	9821/7157	2	RB1CC1/TP53
RB1	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
RB1	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
RB1	NA	hsa05010	Alzheimer disease	Apr-22	391/8848	0.014593725	0.02849994	0.01059878	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
RB1	NA	hsa04211	Longevity regulating pathway	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	9821/7157	2	RB1CC1/TP53
RB1	NA	hsa05022	Pathways of neurodegeneration - multiple diseases	Apr-22	483/8848	0.0293051	0.049433855	0.018383848	1457/5594/4700/9821	4	CSNK2A1/MAPK1/NDUFA6/RB1CC1
SMAD2	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD2	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD2	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD2	BP	GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	Jun-29	148/18614	9.32E-08	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:1903844	regulation of cellular response to transforming growth factor beta stimulus	Jun-29	151/18614	1.05E-07	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD2	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
SMAD2	BP	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0007492	endoderm development	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	2885/3065/4087/4088	4	GRB2/HDAC1/SMAD2/SMAD3
SMAD2	BP	GO:0090287	regulation of cellular response to growth factor stimulus	Jun-29	345/18614	1.29E-05	5.62E-04	2.99E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0001701	in utero embryonic development	Jun-29	398/18614	2.88E-05	0.001012157	5.38E-04	367/2885/5594/4087/4088/7157	6	AR/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0035196	miRNA processing	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	4087/4088/7157	3	SMAD2/SMAD3/TP53
SMAD2	BP	GO:0007440	foregut morphogenesis	Feb-29	10/18614	1.05E-04	0.002487048	0.001321933	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048340	paraxial mesoderm morphogenesis	Feb-29	10/18614	1.05E-04	0.002487048	0.001321933	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0007183	SMAD protein complex assembly	Feb-29	13/18614	1.81E-04	0.003463376	0.001840877	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0070918	regulatory ncRNA processing	Mar-29	71/18614	1.81E-04	0.003463376	0.001840877	4087/4088/7157	3	SMAD2/SMAD3/TP53
SMAD2	BP	GO:0007369	gastrulation	Apr-29	196/18614	2.30E-04	0.004136761	0.0021988	2885/4087/4088/7157	4	GRB2/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0051098	regulation of binding	May-29	369/18614	2.39E-04	0.004206819	0.002236037	1026/2033/4087/4088/6714	5	CDKN1A/EP300/SMAD2/SMAD3/SRC
SMAD2	BP	GO:0038092	nodal signaling pathway	Feb-29	16/18614	2.77E-04	0.004593103	0.002441358	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0009952	anterior/posterior pattern specification	Apr-29	209/18614	2.94E-04	0.004803929	0.002553417	2033/4087/4088/7157	4	EP300/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0031053	primary miRNA processing	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048339	paraxial mesoderm development	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0060039	pericardium development	Feb-29	19/18614	3.94E-04	0.005539882	0.002944596	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0003002	regionalization	May-29	422/18614	4.43E-04	0.005919313	0.003146274	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0023019	signal transduction involved in regulation of gene expression	Feb-29	22/18614	5.31E-04	0.006631889	0.003525027	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048568	embryonic organ development	May-29	453/18614	6.12E-04	0.007114114	0.003781342	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0007389	pattern specification process	May-29	467/18614	7.02E-04	0.007936074	0.004218236	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0030325	adrenal gland development	Feb-29	28/18614	8.64E-04	0.0089494	0.004756846	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0090100	positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Mar-29	122/18614	8.86E-04	0.009064455	0.004818001	1387/2033/4087	3	CREBBP/EP300/SMAD2
SMAD2	BP	GO:0045165	cell fate commitment	Apr-29	281/18614	8.97E-04	0.00907924	0.00482586	367/3065/4087/7157	4	AR/HDAC1/SMAD2/TP53
SMAD2	BP	GO:0001704	formation of primary germ layer	Mar-29	127/18614	9.96E-04	0.009519221	0.005059721	2885/4087/4088	3	GRB2/SMAD2/SMAD3
SMAD2	BP	GO:0048565	digestive tract development	Mar-29	134/18614	0.001162298	0.010552099	0.005608724	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD2	BP	GO:0035270	endocrine system development	Mar-29	137/18614	0.001238853	0.011060698	0.005879058	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	BP	GO:0055123	digestive system development	Mar-29	146/18614	0.001487403	0.012389914	0.006585572	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD2	BP	GO:0032924	activin receptor signaling pathway	Feb-29	44/18614	0.002128979	0.015927917	0.008466115	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048701	embryonic cranial skeleton morphogenesis	Feb-29	45/18614	0.002225854	0.016424566	0.008730098	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0035265	organ growth	Mar-29	180/18614	0.002700744	0.018893519	0.010042412	367/2099/4087	3	AR/ESR1/SMAD2
SMAD2	BP	GO:0048546	digestive tract morphogenesis	Feb-29	50/18614	0.002740969	0.018945874	0.01007024	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0030324	lung development	Mar-29	186/18614	0.002962942	0.019543326	0.010387802	2033/5594/4087	3	EP300/MAPK1/SMAD2
SMAD2	BP	GO:0030323	respiratory tube development	Mar-29	190/18614	0.003146174	0.020255847	0.010766526	2033/5594/4087	3	EP300/MAPK1/SMAD2
SMAD2	BP	GO:0001706	endoderm formation	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	2885/4087	2	GRB2/SMAD2
SMAD2	BP	GO:0072132	mesenchyme morphogenesis	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0010718	positive regulation of epithelial to mesenchymal transition	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0060541	respiratory system development	Mar-29	211/18614	0.004222335	0.024632828	0.013093009	2033/5594/4087	3	EP300/MAPK1/SMAD2
SMAD2	BP	GO:0034470	ncRNA processing	Apr-29	432/18614	0.004291296	0.0249306	0.013251283	23536/4087/4088/7157	4	ADAT1/SMAD2/SMAD3/TP53
SMAD2	BP	GO:0042060	wound healing	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	1026/4087/4088/6714	4	CDKN1A/SMAD2/SMAD3/SRC
SMAD2	BP	GO:0009880	embryonic pattern specification	Feb-29	70/18614	0.005300545	0.028743896	0.015278152	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:1904888	cranial skeletal system development	Feb-29	72/18614	0.005599233	0.029569806	0.015717146	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0001707	mesoderm formation	Feb-29	75/18614	0.006061462	0.031195296	0.016581137	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048332	mesoderm morphogenesis	Feb-29	77/18614	0.006379011	0.032384911	0.017213449	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0097305	response to alcohol	Mar-29	252/18614	0.006908455	0.034036777	0.01809146	978/2534/4087	3	CDA/FYN/SMAD2
SMAD2	BP	GO:0048762	mesenchymal cell differentiation	Mar-29	255/18614	0.007136835	0.034738328	0.018464353	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	BP	GO:0003007	heart morphogenesis	Mar-29	262/18614	0.00768713	0.036281916	0.019284812	4087/4088/7157	3	SMAD2/SMAD3/TP53
SMAD2	BP	GO:0060395	SMAD protein signal transduction	Feb-29	90/18614	0.008622938	0.039699909	0.021101567	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048704	embryonic skeletal system morphogenesis	Feb-29	95/18614	0.009567286	0.042521627	0.022601386	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0001657	ureteric bud development	Feb-29	97/18614	0.009957409	0.043607514	0.023178564	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0072163	mesonephric epithelium development	Feb-29	98/18614	0.010155102	0.044233542	0.023511315	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0072164	mesonephric tubule development	Feb-29	98/18614	0.010155102	0.044233542	0.023511315	4087/4088	2	SMAD2/SMAD3
SMAD2	BP	GO:0048562	embryonic organ morphogenesis	Mar-29	294/18614	0.010519651	0.045246808	0.024049893	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	BP	GO:0001823	mesonephros development	Feb-29	102/18614	0.010963285	0.046745829	0.024846663	4087/4088	2	SMAD2/SMAD3
SMAD2	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD2	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD2	MF	GO:0019902	phosphatase binding	May-32	187/18369	1.67E-05	3.37E-04	1.43E-04	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	MF	GO:0097718	disordered domain specific binding	Mar-32	36/18369	3.30E-05	5.87E-04	2.50E-04	2534/4087/7157	3	FYN/SMAD2/TP53
SMAD2	MF	GO:0048156	tau protein binding	Mar-32	43/18369	5.65E-05	8.38E-04	3.57E-04	2033/2534/4087	3	EP300/FYN/SMAD2
SMAD2	MF	GO:0070410	co-SMAD binding	Feb-32	11/18369	1.60E-04	0.001689597	7.19E-04	4087/4088	2	SMAD2/SMAD3
SMAD2	MF	GO:0070411	I-SMAD binding	Feb-32	14/18369	2.64E-04	0.002473985	0.001053382	4087/4088	2	SMAD2/SMAD3
SMAD2	MF	GO:0005160	transforming growth factor beta receptor binding	Feb-32	23/18369	7.27E-04	0.004977423	0.002119305	4087/4088	2	SMAD2/SMAD3
SMAD2	MF	GO:0070412	R-SMAD binding	Feb-32	24/18369	7.92E-04	0.005223125	0.002223921	4087/4088	2	SMAD2/SMAD3
SMAD2	MF	GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	May-32	468/18369	0.001198605	0.007136975	0.003038807	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
SMAD2	MF	GO:0001216	DNA-binding transcription activator activity	May-32	472/18369	0.001244795	0.007145292	0.003042348	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
SMAD2	MF	GO:0031625	ubiquitin protein ligase binding	Apr-32	301/18369	0.001769913	0.008147008	0.003468862	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
SMAD2	MF	GO:0044389	ubiquitin-like protein ligase binding	Apr-32	320/18369	0.002211874	0.009602771	0.004088702	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
SMAD2	MF	GO:0046332	SMAD binding	Feb-32	77/18369	0.007930094	0.024764152	0.010544169	4087/4088	2	SMAD2/SMAD3
SMAD2	MF	GO:0005126	cytokine receptor binding	Mar-32	270/18369	0.011372314	0.034309692	0.014608503	2885/4087/4088	3	GRB2/SMAD2/SMAD3
SMAD2	MF	GO:0034713	type I transforming growth factor beta receptor binding	Jan-32	11/18369	0.019001803	0.049740015	0.021178481	4087	1	SMAD2
SMAD2	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
SMAD2	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
SMAD2	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
SMAD2	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04933	AGE-RAGE signaling pathway in diabetic complications	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04659	Th17 cell differentiation	Mar-22	108/8848	0.002300357	0.006511179	0.002421428	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04371	Apelin signaling pathway	Mar-22	140/8848	0.004790203	0.012307136	0.004576874	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04390	Hippo signaling pathway	Mar-22	157/8848	0.006589044	0.015947396	0.005930642	4087/4088/7532	3	SMAD2/SMAD3/YWHAG
SMAD2	NA	hsa05321	Inflammatory bowel disease	Feb-22	65/8848	0.011166818	0.024509819	0.009114903	4087/4088	2	SMAD2/SMAD3
SMAD2	NA	hsa05415	Diabetic cardiomyopathy	Mar-22	205/8848	0.013641931	0.027121459	0.01008614	4700/4087/4088	3	NDUFA6/SMAD2/SMAD3
SMAD2	NA	hsa04144	Endocytosis	Mar-22	252/8848	0.023566067	0.041867374	0.015569966	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD2	NA	hsa05142	Chagas disease	Feb-22	103/8848	0.026644093	0.046349619	0.017236858	5594/4087	2	MAPK1/SMAD2
SMAD2	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
SMAD2	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
SMAD2	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD2	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
SMAD2	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04933	AGE-RAGE signaling pathway in diabetic complications	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04659	Th17 cell differentiation	Mar-22	108/8848	0.002300357	0.006511179	0.002421428	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04371	Apelin signaling pathway	Mar-22	140/8848	0.004790203	0.012307136	0.004576874	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD2	NA	hsa04390	Hippo signaling pathway	Mar-22	157/8848	0.006589044	0.015947396	0.005930642	4087/4088/7532	3	SMAD2/SMAD3/YWHAG
SMAD2	NA	hsa05321	Inflammatory bowel disease	Feb-22	65/8848	0.011166818	0.024509819	0.009114903	4087/4088	2	SMAD2/SMAD3
SMAD2	NA	hsa05415	Diabetic cardiomyopathy	Mar-22	205/8848	0.013641931	0.027121459	0.01008614	4700/4087/4088	3	NDUFA6/SMAD2/SMAD3
SMAD2	NA	hsa04144	Endocytosis	Mar-22	252/8848	0.023566067	0.041867374	0.015569966	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD2	NA	hsa05142	Chagas disease	Feb-22	103/8848	0.026644093	0.046349619	0.017236858	5594/4087	2	MAPK1/SMAD2
SMAD3	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD3	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD3	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD3	BP	GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	Jun-29	148/18614	9.32E-08	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:1903844	regulation of cellular response to transforming growth factor beta stimulus	Jun-29	151/18614	1.05E-07	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD3	BP	GO:1902893	regulation of miRNA transcription	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
SMAD3	BP	GO:0061614	miRNA transcription	Apr-29	69/18614	3.83E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
SMAD3	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
SMAD3	BP	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:2000628	regulation of miRNA metabolic process	Apr-29	81/18614	7.27E-06	4.05E-04	2.15E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
SMAD3	BP	GO:0007492	endoderm development	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	2885/3065/4087/4088	4	GRB2/HDAC1/SMAD2/SMAD3
SMAD3	BP	GO:0031647	regulation of protein stability	Jun-29	322/18614	8.69E-06	4.25E-04	2.26E-04	1387/2033/5594/4088/6714/7157	6	CREBBP/EP300/MAPK1/SMAD3/SRC/TP53
SMAD3	BP	GO:0090287	regulation of cellular response to growth factor stimulus	Jun-29	345/18614	1.29E-05	5.62E-04	2.99E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0010586	miRNA metabolic process	Apr-29	97/18614	1.49E-05	6.17E-04	3.28E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
SMAD3	BP	GO:0001701	in utero embryonic development	Jun-29	398/18614	2.88E-05	0.001012157	5.38E-04	367/2885/5594/4087/4088/7157	6	AR/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0035196	miRNA processing	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	4087/4088/7157	3	SMAD2/SMAD3/TP53
SMAD3	BP	GO:1902895	positive regulation of miRNA transcription	Mar-29	51/18614	6.73E-05	0.001908899	0.001014631	367/4088/7157	3	AR/SMAD3/TP53
SMAD3	BP	GO:0001666	response to hypoxia	May-29	293/18614	8.13E-05	0.00221531	0.001177497	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
SMAD3	BP	GO:0034504	protein localization to nucleus	May-29	304/18614	9.68E-05	0.002443574	0.001298825	1026/2534/4088/6714/7157	5	CDKN1A/FYN/SMAD3/SRC/TP53
SMAD3	BP	GO:0036293	response to decreased oxygen levels	May-29	306/18614	9.98E-05	0.002481349	0.001318903	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
SMAD3	BP	GO:0007440	foregut morphogenesis	Feb-29	10/18614	1.05E-04	0.002487048	0.001321933	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0048340	paraxial mesoderm morphogenesis	Feb-29	10/18614	1.05E-04	0.002487048	0.001321933	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:2000630	positive regulation of miRNA metabolic process	Mar-29	60/18614	1.10E-04	0.002566918	0.001364386	367/4088/7157	3	AR/SMAD3/TP53
SMAD3	BP	GO:0001756	somitogenesis	Mar-29	66/18614	1.46E-04	0.003138186	0.00166803	2033/4088/7157	3	EP300/SMAD3/TP53
SMAD3	BP	GO:0070482	response to oxygen levels	May-29	333/18614	1.48E-04	0.003154276	0.001676583	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
SMAD3	BP	GO:0052548	regulation of endopeptidase activity	May-29	336/18614	1.55E-04	0.003246445	0.001725573	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
SMAD3	BP	GO:0007183	SMAD protein complex assembly	Feb-29	13/18614	1.81E-04	0.003463376	0.001840877	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0070918	regulatory ncRNA processing	Mar-29	71/18614	1.81E-04	0.003463376	0.001840877	4087/4088/7157	3	SMAD2/SMAD3/TP53
SMAD3	BP	GO:0030308	negative regulation of cell growth	Apr-29	191/18614	2.09E-04	0.003876813	0.00206063	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
SMAD3	BP	GO:0007369	gastrulation	Apr-29	196/18614	2.30E-04	0.004136761	0.0021988	2885/4087/4088/7157	4	GRB2/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0051098	regulation of binding	May-29	369/18614	2.39E-04	0.004206819	0.002236037	1026/2033/4087/4088/6714	5	CDKN1A/EP300/SMAD2/SMAD3/SRC
SMAD3	BP	GO:0038092	nodal signaling pathway	Feb-29	16/18614	2.77E-04	0.004593103	0.002441358	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0009952	anterior/posterior pattern specification	Apr-29	209/18614	2.94E-04	0.004803929	0.002553417	2033/4087/4088/7157	4	EP300/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0031053	primary miRNA processing	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0061053	somite development	Mar-29	86/18614	3.19E-04	0.004863024	0.002584828	2033/4088/7157	3	EP300/SMAD3/TP53
SMAD3	BP	GO:1900182	positive regulation of protein localization to nucleus	Mar-29	86/18614	3.19E-04	0.004863024	0.002584828	2534/4088/6714	3	FYN/SMAD3/SRC
SMAD3	BP	GO:0048339	paraxial mesoderm development	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0060039	pericardium development	Feb-29	19/18614	3.94E-04	0.005539882	0.002944596	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0097191	extrinsic apoptotic signaling pathway	Apr-29	227/18614	4.03E-04	0.005609047	0.002981359	367/9821/4088/6714	4	AR/RB1CC1/SMAD3/SRC
SMAD3	BP	GO:0001558	regulation of cell growth	May-29	420/18614	4.34E-04	0.005893251	0.003132421	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
SMAD3	BP	GO:0003002	regionalization	May-29	422/18614	4.43E-04	0.005919313	0.003146274	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
SMAD3	BP	GO:2000116	regulation of cysteine-type endopeptidase activity	Apr-29	234/18614	4.52E-04	0.005981729	0.003179449	1457/2534/4088/6714	4	CSNK2A1/FYN/SMAD3/SRC
SMAD3	BP	GO:0052547	regulation of peptidase activity	May-29	425/18614	4.58E-04	0.006014484	0.00319686	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
SMAD3	BP	GO:0035282	segmentation	Mar-29	100/18614	4.97E-04	0.006370133	0.003385897	2033/4088/7157	3	EP300/SMAD3/TP53
SMAD3	BP	GO:0023019	signal transduction involved in regulation of gene expression	Feb-29	22/18614	5.31E-04	0.006631889	0.003525027	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0045926	negative regulation of growth	Apr-29	252/18614	5.97E-04	0.007092315	0.003769756	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
SMAD3	BP	GO:0048568	embryonic organ development	May-29	453/18614	6.12E-04	0.007114114	0.003781342	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0007389	pattern specification process	May-29	467/18614	7.02E-04	0.007936074	0.004218236	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0051091	positive regulation of DNA-binding transcription factor activity	Apr-29	271/18614	7.83E-04	0.008440626	0.004486419	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
SMAD3	BP	GO:0030325	adrenal gland development	Feb-29	28/18614	8.64E-04	0.0089494	0.004756846	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0016049	cell growth	May-29	495/18614	9.13E-04	0.00907924	0.00482586	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
SMAD3	BP	GO:0030878	thyroid gland development	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	5594/4088	2	MAPK1/SMAD3
SMAD3	BP	GO:0001704	formation of primary germ layer	Mar-29	127/18614	9.96E-04	0.009519221	0.005059721	2885/4087/4088	3	GRB2/SMAD2/SMAD3
SMAD3	BP	GO:0048565	digestive tract development	Mar-29	134/18614	0.001162298	0.010552099	0.005608724	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD3	BP	GO:1900180	regulation of protein localization to nucleus	Mar-29	134/18614	0.001162298	0.010552099	0.005608724	2534/4088/6714	3	FYN/SMAD3/SRC
SMAD3	BP	GO:0035270	endocrine system development	Mar-29	137/18614	0.001238853	0.011060698	0.005879058	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	BP	GO:0030177	positive regulation of Wnt signaling pathway	Mar-29	146/18614	0.001487403	0.012389914	0.006585572	1457/4088/6714	3	CSNK2A1/SMAD3/SRC
SMAD3	BP	GO:0055123	digestive system development	Mar-29	146/18614	0.001487403	0.012389914	0.006585572	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD3	BP	GO:0032386	regulation of intracellular transport	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	2534/5594/4088/6714	4	FYN/MAPK1/SMAD3/SRC
SMAD3	BP	GO:0060562	epithelial tube morphogenesis	Apr-29	334/18614	0.001696541	0.013439265	0.00714333	367/2099/4088/6714	4	AR/ESR1/SMAD3/SRC
SMAD3	BP	GO:0009895	negative regulation of catabolic process	Apr-29	337/18614	0.001752946	0.013818341	0.007344819	1457/2534/4088/7157	4	CSNK2A1/FYN/SMAD3/TP53
SMAD3	BP	GO:0030111	regulation of Wnt signaling pathway	Apr-29	338/18614	0.001772034	0.013901007	0.007388758	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
SMAD3	BP	GO:0006606	protein import into nucleus	Mar-29	163/18614	0.00203783	0.015460723	0.008217789	1026/4088/7157	3	CDKN1A/SMAD3/TP53
SMAD3	BP	GO:0032924	activin receptor signaling pathway	Feb-29	44/18614	0.002128979	0.015927917	0.008466115	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0051170	import into nucleus	Mar-29	168/18614	0.002220791	0.016424566	0.008730098	1026/4088/7157	3	CDKN1A/SMAD3/TP53
SMAD3	BP	GO:0048701	embryonic cranial skeleton morphogenesis	Feb-29	45/18614	0.002225854	0.016424566	0.008730098	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0048546	digestive tract morphogenesis	Feb-29	50/18614	0.002740969	0.018945874	0.01007024	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0050728	negative regulation of inflammatory response	Mar-29	187/18614	0.003008113	0.019680611	0.010460773	2534/4088/6714	3	FYN/SMAD3/SRC
SMAD3	BP	GO:0002520	immune system development	Mar-29	197/18614	0.003483352	0.022131628	0.011763554	5594/4088/7157	3	MAPK1/SMAD3/TP53
SMAD3	BP	GO:0072132	mesenchyme morphogenesis	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0010718	positive regulation of epithelial to mesenchymal transition	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0050727	regulation of inflammatory response	Apr-29	414/18614	0.003687939	0.022489469	0.011953756	2099/2534/4088/6714	4	ESR1/FYN/SMAD3/SRC
SMAD3	BP	GO:0043281	regulation of cysteine-type endopeptidase activity involved in apoptotic process	Mar-29	204/18614	0.003841933	0.023340465	0.012406084	1457/4088/6714	3	CSNK2A1/SMAD3/SRC
SMAD3	BP	GO:0035306	positive regulation of dephosphorylation	Feb-29	61/18614	0.00405151	0.024012739	0.012763415	4088/6714	2	SMAD3/SRC
SMAD3	BP	GO:0034470	ncRNA processing	Apr-29	432/18614	0.004291296	0.0249306	0.013251283	23536/4087/4088/7157	4	ADAT1/SMAD2/SMAD3/TP53
SMAD3	BP	GO:0050821	protein stabilization	Mar-29	213/18614	0.004335086	0.0249306	0.013251283	2033/4088/7157	3	EP300/SMAD3/TP53
SMAD3	BP	GO:0051893	regulation of focal adhesion assembly	Feb-29	64/18614	0.004450429	0.02541305	0.013507718	4088/6714	2	SMAD3/SRC
SMAD3	BP	GO:0090109	regulation of cell-substrate junction assembly	Feb-29	64/18614	0.004450429	0.02541305	0.013507718	4088/6714	2	SMAD3/SRC
SMAD3	BP	GO:0042060	wound healing	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	1026/4087/4088/6714	4	CDKN1A/SMAD2/SMAD3/SRC
SMAD3	BP	GO:0150116	regulation of cell-substrate junction organization	Feb-29	69/18614	0.005154058	0.028329789	0.015058043	4088/6714	2	SMAD3/SRC
SMAD3	BP	GO:0009880	embryonic pattern specification	Feb-29	70/18614	0.005300545	0.028743896	0.015278152	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0016055	Wnt signaling pathway	Apr-29	461/18614	0.00539908	0.029083044	0.015458418	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
SMAD3	BP	GO:0198738	cell-cell signaling by wnt	Apr-29	463/18614	0.005481916	0.029431148	0.015643445	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
SMAD3	BP	GO:0051090	regulation of DNA-binding transcription factor activity	Apr-29	465/18614	0.005565604	0.029569806	0.015717146	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
SMAD3	BP	GO:1904888	cranial skeletal system development	Feb-29	72/18614	0.005599233	0.029569806	0.015717146	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0051403	stress-activated MAPK cascade	Mar-29	237/18614	0.00583276	0.030504012	0.016213701	5594/9821/4088	3	MAPK1/RB1CC1/SMAD3
SMAD3	BP	GO:0001707	mesoderm formation	Feb-29	75/18614	0.006061462	0.031195296	0.016581137	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0048332	mesoderm morphogenesis	Feb-29	77/18614	0.006379011	0.032384911	0.017213449	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0031098	stress-activated protein kinase signaling cascade	Mar-29	245/18614	0.006392814	0.032384911	0.017213449	5594/9821/4088	3	MAPK1/RB1CC1/SMAD3
SMAD3	BP	GO:0050673	epithelial cell proliferation	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	367/2099/5594/4088	4	AR/ESR1/MAPK1/SMAD3
SMAD3	BP	GO:0048762	mesenchymal cell differentiation	Mar-29	255/18614	0.007136835	0.034738328	0.018464353	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	BP	GO:0060828	regulation of canonical Wnt signaling pathway	Mar-29	260/18614	0.007527405	0.035879491	0.019070913	3065/4088/6714	3	HDAC1/SMAD3/SRC
SMAD3	BP	GO:0003007	heart morphogenesis	Mar-29	262/18614	0.00768713	0.036281916	0.019284812	4087/4088/7157	3	SMAD2/SMAD3/TP53
SMAD3	BP	GO:0098586	cellular response to virus	Feb-29	85/18614	0.007723378	0.036281916	0.019284812	1984/4088	2	EIF5A/SMAD3
SMAD3	BP	GO:0048041	focal adhesion assembly	Feb-29	86/18614	0.007899673	0.036789256	0.019554477	4088/6714	2	SMAD3/SRC
SMAD3	BP	GO:0060395	SMAD protein signal transduction	Feb-29	90/18614	0.008622938	0.039699909	0.021101567	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0048704	embryonic skeletal system morphogenesis	Feb-29	95/18614	0.009567286	0.042521627	0.022601386	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0031348	negative regulation of defense response	Mar-29	284/18614	0.009577891	0.042521627	0.022601386	2534/4088/6714	3	FYN/SMAD3/SRC
SMAD3	BP	GO:0007044	cell-substrate junction assembly	Feb-29	96/18614	0.009761469	0.043099817	0.02290871	4088/6714	2	SMAD3/SRC
SMAD3	BP	GO:0001657	ureteric bud development	Feb-29	97/18614	0.009957409	0.043607514	0.023178564	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0072163	mesonephric epithelium development	Feb-29	98/18614	0.010155102	0.044233542	0.023511315	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0072164	mesonephric tubule development	Feb-29	98/18614	0.010155102	0.044233542	0.023511315	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0048562	embryonic organ morphogenesis	Mar-29	294/18614	0.010519651	0.045246808	0.024049893	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	BP	GO:0001823	mesonephros development	Feb-29	102/18614	0.010963285	0.046745829	0.024846663	4087/4088	2	SMAD2/SMAD3
SMAD3	BP	GO:0150115	cell-substrate junction organization	Feb-29	103/18614	0.011169657	0.047500436	0.025247756	4088/6714	2	SMAD3/SRC
SMAD3	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD3	MF	GO:0001223	transcription coactivator binding	May-32	43/18369	1.06E-08	9.45E-07	4.03E-07	367/1387/2033/2099/4088	5	AR/CREBBP/EP300/ESR1/SMAD3
SMAD3	MF	GO:0001221	transcription coregulator binding	Jun-32	111/18369	3.39E-08	2.01E-06	8.56E-07	367/1387/2033/2099/3065/4088	6	AR/CREBBP/EP300/ESR1/HDAC1/SMAD3
SMAD3	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
SMAD3	MF	GO:0008013	beta-catenin binding	Apr-32	88/18369	1.60E-05	3.37E-04	1.43E-04	367/2033/2099/4088	4	AR/EP300/ESR1/SMAD3
SMAD3	MF	GO:0019902	phosphatase binding	May-32	187/18369	1.67E-05	3.37E-04	1.43E-04	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	MF	GO:0031490	chromatin DNA binding	Apr-32	118/18369	5.06E-05	8.19E-04	3.49E-04	1387/2033/3065/4088	4	CREBBP/EP300/HDAC1/SMAD3
SMAD3	MF	GO:0016922	nuclear receptor binding	Apr-32	138/18369	9.31E-05	0.001275187	5.43E-04	2033/2099/4088/6714	4	EP300/ESR1/SMAD3/SRC
SMAD3	MF	GO:0070410	co-SMAD binding	Feb-32	11/18369	1.60E-04	0.001689597	7.19E-04	4087/4088	2	SMAD2/SMAD3
SMAD3	MF	GO:1990841	promoter-specific chromatin binding	Mar-32	63/18369	1.78E-04	0.001756554	7.48E-04	3065/4088/7157	3	HDAC1/SMAD3/TP53
SMAD3	MF	GO:0070411	I-SMAD binding	Feb-32	14/18369	2.64E-04	0.002473985	0.001053382	4087/4088	2	SMAD2/SMAD3
SMAD3	MF	GO:0005160	transforming growth factor beta receptor binding	Feb-32	23/18369	7.27E-04	0.004977423	0.002119305	4087/4088	2	SMAD2/SMAD3
SMAD3	MF	GO:0070412	R-SMAD binding	Feb-32	24/18369	7.92E-04	0.005223125	0.002223921	4087/4088	2	SMAD2/SMAD3
SMAD3	MF	GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	May-32	468/18369	0.001198605	0.007136975	0.003038807	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
SMAD3	MF	GO:0001216	DNA-binding transcription activator activity	May-32	472/18369	0.001244795	0.007145292	0.003042348	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
SMAD3	MF	GO:0043425	bHLH transcription factor binding	Feb-32	31/18369	0.001324689	0.007145292	0.003042348	1387/4088	2	CREBBP/SMAD3
SMAD3	MF	GO:0031625	ubiquitin protein ligase binding	Apr-32	301/18369	0.001769913	0.008147008	0.003468862	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
SMAD3	MF	GO:0044389	ubiquitin-like protein ligase binding	Apr-32	320/18369	0.002211874	0.009602771	0.004088702	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
SMAD3	MF	GO:0046332	SMAD binding	Feb-32	77/18369	0.007930094	0.024764152	0.010544169	4087/4088	2	SMAD2/SMAD3
SMAD3	MF	GO:0005126	cytokine receptor binding	Mar-32	270/18369	0.011372314	0.034309692	0.014608503	2885/4087/4088	3	GRB2/SMAD2/SMAD3
SMAD3	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
SMAD3	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
SMAD3	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
SMAD3	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
SMAD3	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
SMAD3	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
SMAD3	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04933	AGE-RAGE signaling pathway in diabetic complications	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04659	Th17 cell differentiation	Mar-22	108/8848	0.002300357	0.006511179	0.002421428	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04371	Apelin signaling pathway	Mar-22	140/8848	0.004790203	0.012307136	0.004576874	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04390	Hippo signaling pathway	Mar-22	157/8848	0.006589044	0.015947396	0.005930642	4087/4088/7532	3	SMAD2/SMAD3/YWHAG
SMAD3	NA	hsa05321	Inflammatory bowel disease	Feb-22	65/8848	0.011166818	0.024509819	0.009114903	4087/4088	2	SMAD2/SMAD3
SMAD3	NA	hsa05415	Diabetic cardiomyopathy	Mar-22	205/8848	0.013641931	0.027121459	0.01008614	4700/4087/4088	3	NDUFA6/SMAD2/SMAD3
SMAD3	NA	hsa04144	Endocytosis	Mar-22	252/8848	0.023566067	0.041867374	0.015569966	4087/4088/6714	3	SMAD2/SMAD3/SRC
SMAD3	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
SMAD3	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
SMAD3	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
SMAD3	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
SMAD3	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa04350	TGF-beta signaling pathway	Jun-22	108/8848	1.83E-07	2.78E-06	1.03E-06	1387/2033/3065/5594/4087/4088	6	CREBBP/EP300/HDAC1/MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04068	FoxO signaling pathway	Jun-22	133/8848	6.31E-07	7.59E-06	2.82E-06	1026/1387/2033/2885/5594/4088	6	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3
SMAD3	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
SMAD3	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
SMAD3	NA	hsa04550	Signaling pathways regulating pluripotency of stem cells	Apr-22	144/8848	3.92E-04	0.001595953	5.94E-04	2885/5594/4087/4088	4	GRB2/MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04933	AGE-RAGE signaling pathway in diabetic complications	Mar-22	101/8848	0.001899021	0.005663152	0.002106057	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04659	Th17 cell differentiation	Mar-22	108/8848	0.002300357	0.006511179	0.002421428	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04371	Apelin signaling pathway	Mar-22	140/8848	0.004790203	0.012307136	0.004576874	5594/4087/4088	3	MAPK1/SMAD2/SMAD3
SMAD3	NA	hsa04390	Hippo signaling pathway	Mar-22	157/8848	0.006589044	0.015947396	0.005930642	4087/4088/7532	3	SMAD2/SMAD3/YWHAG
SMAD3	NA	hsa05321	Inflammatory bowel disease	Feb-22	65/8848	0.011166818	0.024509819	0.009114903	4087/4088	2	SMAD2/SMAD3
SMAD3	NA	hsa05415	Diabetic cardiomyopathy	Mar-22	205/8848	0.013641931	0.027121459	0.01008614	4700/4087/4088	3	NDUFA6/SMAD2/SMAD3
SMAD3	NA	hsa04144	Endocytosis	Mar-22	252/8848	0.023566067	0.041867374	0.015569966	4087/4088/6714	3	SMAD2/SMAD3/SRC
SRC	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
SRC	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
SRC	BP	GO:0002223	stimulatory C-type lectin receptor signaling pathway	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
SRC	BP	GO:1990840	response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
SRC	BP	GO:1990858	cellular response to lectin	Apr-29	22/18614	3.41E-08	9.27E-06	4.93E-06	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
SRC	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
SRC	BP	GO:0002757	immune response-activating signaling pathway	Aug-29	423/18614	1.88E-07	3.38E-05	1.79E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
SRC	BP	GO:0002764	immune response-regulating signaling pathway	Aug-29	450/18614	3.01E-07	4.37E-05	2.32E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
SRC	BP	GO:0002429	immune response-activating cell surface receptor signaling pathway	Jul-29	302/18614	3.17E-07	4.37E-05	2.32E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
SRC	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
SRC	BP	GO:0002768	immune response-regulating cell surface receptor signaling pathway	Jul-29	329/18614	5.65E-07	7.02E-05	3.73E-05	11119/1387/2033/2534/2885/5594/6714	7	BTN3A1/CREBBP/EP300/FYN/GRB2/MAPK1/SRC
SRC	BP	GO:0002253	activation of immune response	Aug-29	495/18614	6.20E-07	7.16E-05	3.81E-05	11119/1387/2033/2099/2534/2885/5594/6714	8	BTN3A1/CREBBP/EP300/ESR1/FYN/GRB2/MAPK1/SRC
SRC	BP	GO:0030518	intracellular steroid hormone receptor signaling pathway	May-29	115/18614	8.70E-07	9.37E-05	4.98E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
SRC	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
SRC	BP	GO:0043401	steroid hormone mediated signaling pathway	May-29	135/18614	1.92E-06	1.81E-04	9.62E-05	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
SRC	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
SRC	BP	GO:0061180	mammary gland epithelium development	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
SRC	BP	GO:0048732	gland development	Jul-29	441/18614	3.97E-06	2.92E-04	1.55E-04	367/2099/5594/9821/4087/4088/6714	7	AR/ESR1/MAPK1/RB1CC1/SMAD2/SMAD3/SRC
SRC	BP	GO:0033143	regulation of intracellular steroid hormone receptor signaling pathway	Apr-29	72/18614	4.54E-06	3.19E-04	1.70E-04	367/2033/3065/6714	4	AR/EP300/HDAC1/SRC
SRC	BP	GO:0060444	branching involved in mammary gland duct morphogenesis	Mar-29	22/18614	5.13E-06	3.46E-04	1.84E-04	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0097193	intrinsic apoptotic signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1026/1984/2033/3065/6714/7157	6	CDKN1A/EIF5A/EP300/HDAC1/SRC/TP53
SRC	BP	GO:0002220	innate immune response activating cell surface receptor signaling pathway	Apr-29	78/18614	6.26E-06	3.74E-04	1.99E-04	1387/2033/2534/6714	4	CREBBP/EP300/FYN/SRC
SRC	BP	GO:0036120	cellular response to platelet-derived growth factor stimulus	Mar-29	24/18614	6.73E-06	3.89E-04	2.07E-04	2534/3065/6714	3	FYN/HDAC1/SRC
SRC	BP	GO:0036119	response to platelet-derived growth factor	Mar-29	26/18614	8.63E-06	4.25E-04	2.26E-04	2534/3065/6714	3	FYN/HDAC1/SRC
SRC	BP	GO:0031647	regulation of protein stability	Jun-29	322/18614	8.69E-06	4.25E-04	2.26E-04	1387/2033/5594/4088/6714/7157	6	CREBBP/EP300/MAPK1/SMAD3/SRC/TP53
SRC	BP	GO:0009755	hormone-mediated signaling pathway	May-29	192/18614	1.08E-05	4.97E-04	2.64E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
SRC	BP	GO:0060603	mammary gland duct morphogenesis	Mar-29	30/18614	1.34E-05	5.71E-04	3.03E-04	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0002758	innate immune response-activating signaling pathway	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:0071383	cellular response to steroid hormone stimulus	May-29	209/18614	1.62E-05	6.39E-04	3.40E-04	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
SRC	BP	GO:1901653	cellular response to peptide	Jun-29	375/18614	2.06E-05	7.93E-04	4.22E-04	2534/2885/5594/6714/7157/7532	6	FYN/GRB2/MAPK1/SRC/TP53/YWHAG
SRC	BP	GO:2000279	negative regulation of DNA biosynthetic process	Mar-29	37/18614	2.55E-05	9.58E-04	5.09E-04	1026/6714/7157	3	CDKN1A/SRC/TP53
SRC	BP	GO:0002218	activation of innate immune response	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:2001234	negative regulation of apoptotic signaling pathway	May-29	233/18614	2.74E-05	9.82E-04	5.22E-04	367/1457/3065/9821/6714	5	AR/CSNK2A1/HDAC1/RB1CC1/SRC
SRC	BP	GO:2000278	regulation of DNA biosynthetic process	Apr-29	121/18614	3.56E-05	0.001223397	6.50E-04	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
SRC	BP	GO:0060443	mammary gland morphogenesis	Mar-29	45/18614	4.62E-05	0.001492153	7.93E-04	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0051972	regulation of telomerase activity	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	5594/6714/7157	3	MAPK1/SRC/TP53
SRC	BP	GO:0031648	protein destabilization	Mar-29	48/18614	5.61E-05	0.001650943	8.78E-04	1387/2033/6714	3	CREBBP/EP300/SRC
SRC	BP	GO:0030879	mammary gland development	Apr-29	136/18614	5.62E-05	0.001650943	8.78E-04	367/2099/5594/6714	4	AR/ESR1/MAPK1/SRC
SRC	BP	GO:0030520	intracellular estrogen receptor signaling pathway	Mar-29	54/18614	7.99E-05	0.00221531	0.001177497	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0001666	response to hypoxia	May-29	293/18614	8.13E-05	0.00221531	0.001177497	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
SRC	BP	GO:0030522	intracellular receptor signaling pathway	May-29	299/18614	8.95E-05	0.002336435	0.001241878	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
SRC	BP	GO:0045089	positive regulation of innate immune response	May-29	300/18614	9.09E-05	0.002336435	0.001241878	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:0034504	protein localization to nucleus	May-29	304/18614	9.68E-05	0.002443574	0.001298825	1026/2534/4088/6714/7157	5	CDKN1A/FYN/SMAD3/SRC/TP53
SRC	BP	GO:0036293	response to decreased oxygen levels	May-29	306/18614	9.98E-05	0.002481349	0.001318903	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
SRC	BP	GO:0051974	negative regulation of telomerase activity	Feb-29	10/18614	1.05E-04	0.002487048	0.001321933	6714/7157	2	SRC/TP53
SRC	BP	GO:0072584	caveolin-mediated endocytosis	Feb-29	11/18614	1.28E-04	0.002908472	0.001545931	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0002833	positive regulation of response to biotic stimulus	May-29	327/18614	1.36E-04	0.003058239	0.001625536	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:2001242	regulation of intrinsic apoptotic signaling pathway	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1984/3065/6714/7157	4	EIF5A/HDAC1/SRC/TP53
SRC	BP	GO:0070482	response to oxygen levels	May-29	333/18614	1.48E-04	0.003154276	0.001676583	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
SRC	BP	GO:0052548	regulation of endopeptidase activity	May-29	336/18614	1.55E-04	0.003246445	0.001725573	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
SRC	BP	GO:0048545	response to steroid hormone	May-29	339/18614	1.61E-04	0.003257009	0.001731188	367/2033/2099/3065/6714	5	AR/EP300/ESR1/HDAC1/SRC
SRC	BP	GO:0061138	morphogenesis of a branching epithelium	Apr-29	188/18614	1.96E-04	0.003691252	0.001961999	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
SRC	BP	GO:0031334	positive regulation of protein-containing complex assembly	Apr-29	195/18614	2.26E-04	0.004102277	0.00218047	2099/2885/6714/7157	4	ESR1/GRB2/SRC/TP53
SRC	BP	GO:0051098	regulation of binding	May-29	369/18614	2.39E-04	0.004206819	0.002236037	1026/2033/4087/4088/6714	5	CDKN1A/EP300/SMAD2/SMAD3/SRC
SRC	BP	GO:0071897	DNA biosynthetic process	Apr-29	198/18614	2.39E-04	0.004206819	0.002236037	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
SRC	BP	GO:0045088	regulation of innate immune response	May-29	373/18614	2.51E-04	0.004314593	0.002293322	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:0001763	morphogenesis of a branching structure	Apr-29	203/18614	2.63E-04	0.004433918	0.002356747	367/2099/2885/6714	4	AR/ESR1/GRB2/SRC
SRC	BP	GO:2000241	regulation of reproductive process	Apr-29	206/18614	2.79E-04	0.004593103	0.002441358	367/246184/2099/6714	4	AR/CDC26/ESR1/SRC
SRC	BP	GO:0032869	cellular response to insulin stimulus	Apr-29	211/18614	3.05E-04	0.004863024	0.002584828	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
SRC	BP	GO:1900182	positive regulation of protein localization to nucleus	Mar-29	86/18614	3.19E-04	0.004863024	0.002584828	2534/4088/6714	3	FYN/SMAD3/SRC
SRC	BP	GO:0043254	regulation of protein-containing complex assembly	May-29	409/18614	3.84E-04	0.005539882	0.002944596	2033/2099/2885/6714/7157	5	EP300/ESR1/GRB2/SRC/TP53
SRC	BP	GO:2000641	regulation of early endosome to late endosome transport	Feb-29	19/18614	3.94E-04	0.005539882	0.002944596	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0097191	extrinsic apoptotic signaling pathway	Apr-29	227/18614	4.03E-04	0.005609047	0.002981359	367/9821/4088/6714	4	AR/RB1CC1/SMAD3/SRC
SRC	BP	GO:2000116	regulation of cysteine-type endopeptidase activity	Apr-29	234/18614	4.52E-04	0.005981729	0.003179449	1457/2534/4088/6714	4	CSNK2A1/FYN/SMAD3/SRC
SRC	BP	GO:0052547	regulation of peptidase activity	May-29	425/18614	4.58E-04	0.006014484	0.00319686	1457/2534/3065/4088/6714	5	CSNK2A1/FYN/HDAC1/SMAD3/SRC
SRC	BP	GO:2001237	negative regulation of extrinsic apoptotic signaling pathway	Mar-29	99/18614	4.82E-04	0.006234977	0.003314057	367/9821/6714	3	AR/RB1CC1/SRC
SRC	BP	GO:0006979	response to oxidative stress	May-29	434/18614	5.04E-04	0.006409007	0.003406559	2534/5594/4700/6714/7157	5	FYN/MAPK1/NDUFA6/SRC/TP53
SRC	BP	GO:0010906	regulation of glucose metabolic process	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:0031349	positive regulation of defense response	May-29	441/18614	5.42E-04	0.006631889	0.003525027	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:0060065	uterus development	Feb-29	23/18614	5.81E-04	0.007007121	0.003724473	2099/6714	2	ESR1/SRC
SRC	BP	GO:0002831	regulation of response to biotic stimulus	May-29	463/18614	6.75E-04	0.00779709	0.004144362	1387/2033/2099/2534/6714	5	CREBBP/EP300/ESR1/FYN/SRC
SRC	BP	GO:0071216	cellular response to biotic stimulus	Apr-29	264/18614	7.11E-04	0.007973549	0.004238155	978/5594/6714/7157	4	CDA/MAPK1/SRC/TP53
SRC	BP	GO:0002433	immune response-regulating cell surface receptor signaling pathway involved in phagocytosis	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	2534/6714	2	FYN/SRC
SRC	BP	GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	Feb-29	26/18614	7.44E-04	0.008126193	0.00431929	2534/6714	2	FYN/SRC
SRC	BP	GO:0032868	response to insulin	Apr-29	272/18614	7.94E-04	0.008500733	0.004518368	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
SRC	BP	GO:0007611	learning or memory	Apr-29	276/18614	8.39E-04	0.00885882	0.004708701	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
SRC	BP	GO:0051348	negative regulation of transferase activity	Apr-29	279/18614	8.73E-04	0.00898774	0.004777225	1026/6714/7157/7532	4	CDKN1A/SRC/TP53/YWHAG
SRC	BP	GO:0022612	gland morphogenesis	Mar-29	123/18614	9.07E-04	0.00907924	0.00482586	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:1903649	regulation of cytoplasmic transport	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0034599	cellular response to oxidative stress	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
SRC	BP	GO:0044262	cellular carbohydrate metabolic process	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2033/9821/6714/7157	4	EP300/RB1CC1/SRC/TP53
SRC	BP	GO:0008286	insulin receptor signaling pathway	Mar-29	128/18614	0.001018341	0.009567665	0.005085471	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	BP	GO:0038127	ERBB signaling pathway	Mar-29	131/18614	0.00108881	0.01011217	0.00537489	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	BP	GO:0002431	Fc receptor mediated stimulatory signaling pathway	Feb-29	32/18614	0.00112925	0.010368564	0.00551117	2534/6714	2	FYN/SRC
SRC	BP	GO:0002862	negative regulation of inflammatory response to antigenic stimulus	Feb-29	32/18614	0.00112925	0.010368564	0.00551117	2534/6714	2	FYN/SRC
SRC	BP	GO:0048565	digestive tract development	Mar-29	134/18614	0.001162298	0.010552099	0.005608724	4087/4088/6714	3	SMAD2/SMAD3/SRC
SRC	BP	GO:1900180	regulation of protein localization to nucleus	Mar-29	134/18614	0.001162298	0.010552099	0.005608724	2534/4088/6714	3	FYN/SMAD3/SRC
SRC	BP	GO:0038094	Fc-gamma receptor signaling pathway	Feb-29	33/18614	0.001200945	0.010842048	0.005762839	2534/6714	2	FYN/SRC
SRC	BP	GO:0071375	cellular response to peptide hormone stimulus	Apr-29	308/18614	0.001259647	0.011135312	0.005918717	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
SRC	BP	GO:0033146	regulation of intracellular estrogen receptor signaling pathway	Feb-29	35/18614	0.001350728	0.011549078	0.006138645	367/6714	2	AR/SRC
SRC	BP	GO:0050890	cognition	Apr-29	317/18614	0.001400637	0.011856515	0.006302056	2033/2534/5594/6714	4	EP300/FYN/MAPK1/SRC
SRC	BP	GO:0030177	positive regulation of Wnt signaling pathway	Mar-29	146/18614	0.001487403	0.012389914	0.006585572	1457/4088/6714	3	CSNK2A1/SMAD3/SRC
SRC	BP	GO:0055123	digestive system development	Mar-29	146/18614	0.001487403	0.012389914	0.006585572	4087/4088/6714	3	SMAD2/SMAD3/SRC
SRC	BP	GO:0051053	negative regulation of DNA metabolic process	Mar-29	148/18614	0.001546573	0.012751337	0.006777678	1026/6714/7157	3	CDKN1A/SRC/TP53
SRC	BP	GO:0062012	regulation of small molecule metabolic process	Apr-29	331/18614	0.001641417	0.013354479	0.007098264	978/2033/6714/7157	4	CDA/EP300/SRC/TP53
SRC	BP	GO:0032386	regulation of intracellular transport	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	2534/5594/4088/6714	4	FYN/MAPK1/SMAD3/SRC
SRC	BP	GO:0051604	protein maturation	Apr-29	332/18614	0.00165965	0.013354479	0.007098264	552900/1387/2033/6714	4	BOLA2/CREBBP/EP300/SRC
SRC	BP	GO:0010675	regulation of cellular carbohydrate metabolic process	Mar-29	152/18614	0.00166931	0.013354479	0.007098264	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:0034614	cellular response to reactive oxygen species	Mar-29	152/18614	0.00166931	0.013354479	0.007098264	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	BP	GO:0007265	Ras protein signal transduction	Apr-29	333/18614	0.001678025	0.013358069	0.007100172	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
SRC	BP	GO:0060562	epithelial tube morphogenesis	Apr-29	334/18614	0.001696541	0.013439265	0.00714333	367/2099/4088/6714	4	AR/ESR1/SMAD3/SRC
SRC	BP	GO:0030111	regulation of Wnt signaling pathway	Apr-29	338/18614	0.001772034	0.013901007	0.007388758	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
SRC	BP	GO:2001236	regulation of extrinsic apoptotic signaling pathway	Mar-29	156/18614	0.001797997	0.014036539	0.007460797	367/9821/6714	3	AR/RB1CC1/SRC
SRC	BP	GO:0048754	branching morphogenesis of an epithelial tube	Mar-29	157/18614	0.001831111	0.014226325	0.007561674	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0098751	bone cell development	Feb-29	41/18614	0.001850762	0.0143102	0.007606255	2033/6714	2	EP300/SRC
SRC	BP	GO:0062197	cellular response to chemical stress	Apr-29	349/18614	0.001991682	0.015253833	0.008107822	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
SRC	BP	GO:0045022	early endosome to late endosome transport	Feb-29	44/18614	0.002128979	0.015927917	0.008466115	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0031295	T cell costimulation	Feb-29	45/18614	0.002225854	0.016424566	0.008730098	2534/6714	2	FYN/SRC
SRC	BP	GO:0002861	regulation of inflammatory response to antigenic stimulus	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	2534/6714	2	FYN/SRC
SRC	BP	GO:0031294	lymphocyte costimulation	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	2534/6714	2	FYN/SRC
SRC	BP	GO:0098927	vesicle-mediated transport between endosomal compartments	Feb-29	47/18614	0.002425771	0.017422423	0.009260485	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0048660	regulation of smooth muscle cell proliferation	Mar-29	176/18614	0.002534251	0.017962061	0.009547318	1026/3065/6714	3	CDKN1A/HDAC1/SRC
SRC	BP	GO:0048659	smooth muscle cell proliferation	Mar-29	180/18614	0.002700744	0.018893519	0.010042412	1026/3065/6714	3	CDKN1A/HDAC1/SRC
SRC	BP	GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	Mar-29	181/18614	0.0027434	0.018945874	0.01007024	2534/6714/7157	3	FYN/SRC/TP53
SRC	BP	GO:0006109	regulation of carbohydrate metabolic process	Mar-29	183/18614	0.00282996	0.019270953	0.010243029	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:0022602	ovulation cycle process	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	2099/6714	2	ESR1/SRC
SRC	BP	GO:0048013	ephrin receptor signaling pathway	Feb-29	52/18614	0.002961246	0.019543326	0.010387802	2534/6714	2	FYN/SRC
SRC	BP	GO:0006006	glucose metabolic process	Mar-29	187/18614	0.003008113	0.019680611	0.010460773	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:0050728	negative regulation of inflammatory response	Mar-29	187/18614	0.003008113	0.019680611	0.010460773	2534/4088/6714	3	FYN/SMAD3/SRC
SRC	BP	GO:0032210	regulation of telomere maintenance via telomerase	Feb-29	53/18614	0.00307441	0.019872984	0.010563024	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0038093	Fc receptor signaling pathway	Feb-29	54/18614	0.003189581	0.020453823	0.010871756	2534/6714	2	FYN/SRC
SRC	BP	GO:0001541	ovarian follicle development	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	2099/6714	2	ESR1/SRC
SRC	BP	GO:0048010	vascular endothelial growth factor receptor signaling pathway	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	2534/6714	2	FYN/SRC
SRC	BP	GO:0043393	regulation of protein binding	Mar-29	201/18614	0.003685608	0.022489469	0.011953756	1026/2033/6714	3	CDKN1A/EP300/SRC
SRC	BP	GO:0050727	regulation of inflammatory response	Apr-29	414/18614	0.003687939	0.022489469	0.011953756	2099/2534/4088/6714	4	ESR1/FYN/SMAD3/SRC
SRC	BP	GO:0043281	regulation of cysteine-type endopeptidase activity involved in apoptotic process	Mar-29	204/18614	0.003841933	0.023340465	0.012406084	1457/4088/6714	3	CSNK2A1/SMAD3/SRC
SRC	BP	GO:0000302	response to reactive oxygen species	Mar-29	205/18614	0.003894931	0.023573812	0.012530114	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	BP	GO:0035306	positive regulation of dephosphorylation	Feb-29	61/18614	0.00405151	0.024012739	0.012763415	4088/6714	2	SMAD3/SRC
SRC	BP	GO:1904356	regulation of telomere maintenance via telomere lengthening	Feb-29	61/18614	0.00405151	0.024012739	0.012763415	5594/6714	2	MAPK1/SRC
SRC	BP	GO:1901654	response to ketone	Mar-29	208/18614	0.004056608	0.024012739	0.012763415	367/978/6714	3	AR/CDA/SRC
SRC	BP	GO:0043434	response to peptide hormone	Apr-29	427/18614	0.00411742	0.024283759	0.01290747	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
SRC	BP	GO:0002064	epithelial cell development	Mar-29	210/18614	0.004166641	0.024484695	0.013014272	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0051893	regulation of focal adhesion assembly	Feb-29	64/18614	0.004450429	0.02541305	0.013507718	4088/6714	2	SMAD3/SRC
SRC	BP	GO:0090109	regulation of cell-substrate junction assembly	Feb-29	64/18614	0.004450429	0.02541305	0.013507718	4088/6714	2	SMAD3/SRC
SRC	BP	GO:0042060	wound healing	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	1026/4087/4088/6714	4	CDKN1A/SMAD2/SMAD3/SRC
SRC	BP	GO:0007004	telomere maintenance via telomerase	Feb-29	69/18614	0.005154058	0.028329789	0.015058043	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0150116	regulation of cell-substrate junction organization	Feb-29	69/18614	0.005154058	0.028329789	0.015058043	4088/6714	2	SMAD3/SRC
SRC	BP	GO:0046777	protein autophosphorylation	Mar-29	227/18614	0.005175879	0.028353288	0.015070533	2534/9821/6714	3	FYN/RB1CC1/SRC
SRC	BP	GO:0008406	gonad development	Mar-29	228/18614	0.005239432	0.028508155	0.015152849	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0019318	hexose metabolic process	Mar-29	228/18614	0.005239432	0.028508155	0.015152849	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:0016055	Wnt signaling pathway	Apr-29	461/18614	0.00539908	0.029083044	0.015458418	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
SRC	BP	GO:0198738	cell-cell signaling by wnt	Apr-29	463/18614	0.005481916	0.029431148	0.015643445	1457/3065/4088/6714	4	CSNK2A1/HDAC1/SMAD3/SRC
SRC	BP	GO:0045137	development of primary sexual characteristics	Mar-29	233/18614	0.005564295	0.029569806	0.015717146	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0060348	bone development	Mar-29	235/18614	0.00569757	0.029893744	0.015889327	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:2000573	positive regulation of DNA biosynthetic process	Feb-29	74/18614	0.005905501	0.030784803	0.016362949	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0006278	RNA-templated DNA biosynthetic process	Feb-29	75/18614	0.006061462	0.031195296	0.016581137	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0042698	ovulation cycle	Feb-29	75/18614	0.006061462	0.031195296	0.016581137	2099/6714	2	ESR1/SRC
SRC	BP	GO:0031667	response to nutrient levels	Apr-29	477/18614	0.006085872	0.03122149	0.01659506	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
SRC	BP	GO:0007264	small GTPase mediated signal transduction	Apr-29	483/18614	0.006357843	0.032384911	0.017213449	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
SRC	BP	GO:0002437	inflammatory response to antigenic stimulus	Feb-29	78/18614	0.006540588	0.032839994	0.017455338	2534/6714	2	FYN/SRC
SRC	BP	GO:0043154	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Feb-29	78/18614	0.006540588	0.032839994	0.017455338	1457/6714	2	CSNK2A1/SRC
SRC	BP	GO:0050804	modulation of chemical synaptic transmission	Apr-29	487/18614	0.006543613	0.032839994	0.017455338	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
SRC	BP	GO:0099177	regulation of trans-synaptic signaling	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
SRC	BP	GO:0033002	muscle cell proliferation	Mar-29	249/18614	0.006684519	0.033237488	0.017666617	1026/3065/6714	3	CDKN1A/HDAC1/SRC
SRC	BP	GO:0033044	regulation of chromosome organization	Mar-29	250/18614	0.006758672	0.033503111	0.017807803	246184/5594/6714	3	CDC26/MAPK1/SRC
SRC	BP	GO:0010833	telomere maintenance via telomere lengthening	Feb-29	81/18614	0.007036453	0.034457298	0.018314979	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0050730	regulation of peptidyl-tyrosine phosphorylation	Mar-29	255/18614	0.007136835	0.034738328	0.018464353	2534/6714/7157	3	FYN/SRC/TP53
SRC	BP	GO:0005996	monosaccharide metabolic process	Mar-29	256/18614	0.007213953	0.035008252	0.018607825	2033/6714/7157	3	EP300/SRC/TP53
SRC	BP	GO:0060828	regulation of canonical Wnt signaling pathway	Mar-29	260/18614	0.007527405	0.035879491	0.019070913	3065/4088/6714	3	HDAC1/SMAD3/SRC
SRC	BP	GO:0061515	myeloid cell development	Feb-29	84/18614	0.007548903	0.035879491	0.019070913	2033/6714	2	EP300/SRC
SRC	BP	GO:0034103	regulation of tissue remodeling	Feb-29	86/18614	0.007899673	0.036789256	0.019554477	6714/7157	2	SRC/TP53
SRC	BP	GO:0048041	focal adhesion assembly	Feb-29	86/18614	0.007899673	0.036789256	0.019554477	4088/6714	2	SMAD3/SRC
SRC	BP	GO:2000243	positive regulation of reproductive process	Feb-29	87/18614	0.008077782	0.037403141	0.019880773	367/6714	2	AR/SRC
SRC	BP	GO:2000117	negative regulation of cysteine-type endopeptidase activity	Feb-29	91/18614	0.008808247	0.040437862	0.021493809	1457/6714	2	CSNK2A1/SRC
SRC	BP	GO:0070301	cellular response to hydrogen peroxide	Feb-29	93/18614	0.009184217	0.041341769	0.02197426	2534/6714	2	FYN/SRC
SRC	BP	GO:0007548	sex differentiation	Mar-29	283/18614	0.00948657	0.042466197	0.022571923	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:1904705	regulation of vascular associated smooth muscle cell proliferation	Feb-29	95/18614	0.009567286	0.042521627	0.022601386	1026/6714	2	CDKN1A/SRC
SRC	BP	GO:0031348	negative regulation of defense response	Mar-29	284/18614	0.009577891	0.042521627	0.022601386	2534/4088/6714	3	FYN/SMAD3/SRC
SRC	BP	GO:0007044	cell-substrate junction assembly	Feb-29	96/18614	0.009761469	0.043099817	0.02290871	4088/6714	2	SMAD3/SRC
SRC	BP	GO:1990874	vascular associated smooth muscle cell proliferation	Feb-29	97/18614	0.009957409	0.043607514	0.023178564	1026/6714	2	CDKN1A/SRC
SRC	BP	GO:0048661	positive regulation of smooth muscle cell proliferation	Feb-29	99/18614	0.010354541	0.044860425	0.02384452	3065/6714	2	HDAC1/SRC
SRC	BP	GO:2001243	negative regulation of intrinsic apoptotic signaling pathway	Feb-29	99/18614	0.010354541	0.044860425	0.02384452	3065/6714	2	HDAC1/SRC
SRC	BP	GO:0008585	female gonad development	Feb-29	102/18614	0.010963285	0.046745829	0.024846663	2099/6714	2	ESR1/SRC
SRC	BP	GO:0150115	cell-substrate junction organization	Feb-29	103/18614	0.011169657	0.047500436	0.025247756	4088/6714	2	SMAD3/SRC
SRC	BP	GO:0048608	reproductive structure development	Mar-29	301/18614	0.011209976	0.047546773	0.025272386	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0032204	regulation of telomere maintenance	Feb-29	104/18614	0.011377748	0.048132043	0.025583473	5594/6714	2	MAPK1/SRC
SRC	BP	GO:0061458	reproductive system development	Mar-29	305/18614	0.011616029	0.049011756	0.026051064	367/2099/6714	3	AR/ESR1/SRC
SRC	BP	GO:0046545	development of primary female sexual characteristics	Feb-29	106/18614	0.011799066	0.049654401	0.026392647	2099/6714	2	ESR1/SRC
SRC	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
SRC	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
SRC	MF	GO:0046875	ephrin receptor binding	Mar-32	29/18369	1.70E-05	3.37E-04	1.43E-04	2534/2885/6714	3	FYN/GRB2/SRC
SRC	MF	GO:0016922	nuclear receptor binding	Apr-32	138/18369	9.31E-05	0.001275187	5.43E-04	2033/2099/4088/6714	4	EP300/ESR1/SMAD3/SRC
SRC	MF	GO:0051117	ATPase binding	Mar-32	86/18369	4.45E-04	0.003776103	0.001607803	367/2099/6714	3	AR/ESR1/SRC
SRC	MF	GO:0051219	phosphoprotein binding	Mar-32	92/18369	5.43E-04	0.004335707	0.001846073	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	MF	GO:0016004	phospholipase activator activity	Feb-32	22/18369	6.65E-04	0.004928677	0.00209855	2534/6714	2	FYN/SRC
SRC	MF	GO:0043274	phospholipase binding	Feb-32	23/18369	7.27E-04	0.004977423	0.002119305	2534/6714	2	FYN/SRC
SRC	MF	GO:0060229	lipase activator activity	Feb-32	25/18369	8.60E-04	0.0054686	0.00232844	2534/6714	2	FYN/SRC
SRC	MF	GO:0070851	growth factor receptor binding	Mar-32	137/18369	0.001718305	0.008147008	0.003468862	2534/2885/6714	3	FYN/GRB2/SRC
SRC	MF	GO:0030331	nuclear estrogen receptor binding	Feb-32	39/18369	0.002092694	0.009312487	0.003965104	2099/6714	2	ESR1/SRC
SRC	MF	GO:0004715	non-membrane spanning protein tyrosine kinase activity	Feb-32	43/18369	0.002539157	0.010272045	0.004373668	2534/6714	2	FYN/SRC
SRC	MF	GO:0005080	protein kinase C binding	Feb-32	49/18369	0.003285353	0.011695858	0.004979904	6714/7532	2	SRC/YWHAG
SRC	MF	GO:0097110	scaffold protein binding	Feb-32	66/18369	0.005883031	0.019758105	0.008412676	2534/6714	2	FYN/SRC
SRC	MF	GO:0070700	BMP receptor binding	Jan-32	10/18369	0.017288924	0.04808482	0.020473726	6714	1	SRC
SRC	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
SRC	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
SRC	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
SRC	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
SRC	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
SRC	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
SRC	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
SRC	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
SRC	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
SRC	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
SRC	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
SRC	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
SRC	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
SRC	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
SRC	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
SRC	NA	hsa01521	EGFR tyrosine kinase inhibitor resistance	Mar-22	80/8848	9.68E-04	0.003300536	0.001227429	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
SRC	NA	hsa04540	Gap junction	Mar-22	92/8848	0.001451895	0.004662816	0.001734044	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa04912	GnRH signaling pathway	Mar-22	93/8848	0.001497879	0.004719731	0.00175521	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
SRC	NA	hsa04137	Mitophagy - animal	Mar-22	105/8848	0.002122452	0.006111198	0.00227268	1457/6714/7157	3	CSNK2A1/SRC/TP53
SRC	NA	hsa04611	Platelet activation	Mar-22	126/8848	0.003562952	0.009596983	0.003569001	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	NA	hsa04921	Oxytocin signaling pathway	Mar-22	154/8848	0.006246197	0.015339925	0.005704731	1026/5594/6714	3	CDKN1A/MAPK1/SRC
SRC	NA	hsa04370	VEGF signaling pathway	Feb-22	60/8848	0.009574006	0.022519142	0.008374594	5594/6714	2	MAPK1/SRC
SRC	NA	hsa04360	Axon guidance	Mar-22	184/8848	0.010185291	0.023624218	0.008785558	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	NA	hsa04613	Neutrophil extracellular trap formation	Mar-22	192/8848	0.011432575	0.024509819	0.009114903	3065/5594/6714	3	HDAC1/MAPK1/SRC
SRC	NA	hsa04062	Chemokine signaling pathway	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa05130	Pathogenic Escherichia coli infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	NA	hsa05417	Lipid and atherosclerosis	Mar-22	216/8848	0.015690563	0.030118667	0.011200765	5594/6714/7157	3	MAPK1/SRC/TP53
SRC	NA	hsa05131	Shigellosis	Mar-22	249/8848	0.022840621	0.041014879	0.015252933	5594/6714/7157	3	MAPK1/SRC/TP53
SRC	NA	hsa04144	Endocytosis	Mar-22	252/8848	0.023566067	0.041867374	0.015569966	4087/4088/6714	3	SMAD2/SMAD3/SRC
SRC	NA	hsa04625	C-type lectin receptor signaling pathway	Feb-22	105/8848	0.027611539	0.047537393	0.017678577	5594/6714	2	MAPK1/SRC
SRC	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
SRC	NA	hsa04520	Adherens junction	Jul-22	93/8848	1.69E-09	9.42E-08	3.50E-08	1387/1457/2033/2534/5594/4088/6714	7	CREBBP/CSNK2A1/EP300/FYN/MAPK1/SMAD3/SRC
SRC	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
SRC	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
SRC	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
SRC	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
SRC	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
SRC	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
SRC	NA	hsa04917	Prolactin signaling pathway	Apr-22	71/8848	2.50E-05	1.78E-04	6.63E-05	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
SRC	NA	hsa04012	ErbB signaling pathway	Apr-22	86/8848	5.32E-05	3.07E-04	1.14E-04	1026/2885/5594/6714	4	CDKN1A/GRB2/MAPK1/SRC
SRC	NA	hsa05207	Chemical carcinogenesis - receptor activation	May-22	215/8848	1.52E-04	7.46E-04	2.78E-04	367/2099/2885/5594/6714	5	AR/ESR1/GRB2/MAPK1/SRC
SRC	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
SRC	NA	hsa04926	Relaxin signaling pathway	Apr-22	130/8848	2.65E-04	0.001164931	4.33E-04	2885/5594/4087/6714	4	GRB2/MAPK1/SMAD2/SRC
SRC	NA	hsa04915	Estrogen signaling pathway	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	2099/2885/5594/6714	4	ESR1/GRB2/MAPK1/SRC
SRC	NA	hsa05152	Tuberculosis	Apr-22	180/8848	9.10E-04	0.003164503	0.00117684	1387/2033/5594/6714	4	CREBBP/EP300/MAPK1/SRC
SRC	NA	hsa01521	EGFR tyrosine kinase inhibitor resistance	Mar-22	80/8848	9.68E-04	0.003300536	0.001227429	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa04510	Focal adhesion	Apr-22	203/8848	0.001422458	0.004657852	0.001732198	2534/2885/5594/6714	4	FYN/GRB2/MAPK1/SRC
SRC	NA	hsa04540	Gap junction	Mar-22	92/8848	0.001451895	0.004662816	0.001734044	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa04912	GnRH signaling pathway	Mar-22	93/8848	0.001497879	0.004719731	0.00175521	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa05208	Chemical carcinogenesis - reactive oxygen species	Apr-22	226/8848	0.00211085	0.006111198	0.00227268	2885/5594/4700/6714	4	GRB2/MAPK1/NDUFA6/SRC
SRC	NA	hsa04137	Mitophagy - animal	Mar-22	105/8848	0.002122452	0.006111198	0.00227268	1457/6714/7157	3	CSNK2A1/SRC/TP53
SRC	NA	hsa04611	Platelet activation	Mar-22	126/8848	0.003562952	0.009596983	0.003569001	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	NA	hsa04921	Oxytocin signaling pathway	Mar-22	154/8848	0.006246197	0.015339925	0.005704731	1026/5594/6714	3	CDKN1A/MAPK1/SRC
SRC	NA	hsa04370	VEGF signaling pathway	Feb-22	60/8848	0.009574006	0.022519142	0.008374594	5594/6714	2	MAPK1/SRC
SRC	NA	hsa04360	Axon guidance	Mar-22	184/8848	0.010185291	0.023624218	0.008785558	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	NA	hsa04613	Neutrophil extracellular trap formation	Mar-22	192/8848	0.011432575	0.024509819	0.009114903	3065/5594/6714	3	HDAC1/MAPK1/SRC
SRC	NA	hsa04062	Chemokine signaling pathway	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	2885/5594/6714	3	GRB2/MAPK1/SRC
SRC	NA	hsa05130	Pathogenic Escherichia coli infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	2534/5594/6714	3	FYN/MAPK1/SRC
SRC	NA	hsa05417	Lipid and atherosclerosis	Mar-22	216/8848	0.015690563	0.030118667	0.011200765	5594/6714/7157	3	MAPK1/SRC/TP53
SRC	NA	hsa05131	Shigellosis	Mar-22	249/8848	0.022840621	0.041014879	0.015252933	5594/6714/7157	3	MAPK1/SRC/TP53
SRC	NA	hsa04144	Endocytosis	Mar-22	252/8848	0.023566067	0.041867374	0.015569966	4087/4088/6714	3	SMAD2/SMAD3/SRC
SRC	NA	hsa04625	C-type lectin receptor signaling pathway	Feb-22	105/8848	0.027611539	0.047537393	0.017678577	5594/6714	2	MAPK1/SRC
TP53	BP	GO:0071560	cellular response to transforming growth factor beta stimulus	Aug-29	274/18614	6.54E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
TP53	BP	GO:0071559	response to transforming growth factor beta	Aug-29	280/18614	7.74E-09	6.26E-06	3.33E-06	1387/2033/2534/3065/4087/4088/6714/7157	8	CREBBP/EP300/FYN/HDAC1/SMAD2/SMAD3/SRC/TP53
TP53	BP	GO:0007179	transforming growth factor beta receptor signaling pathway	Jul-29	218/18614	3.44E-08	9.27E-06	4.93E-06	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
TP53	BP	GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	Jun-29	148/18614	9.32E-08	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
TP53	BP	GO:1903844	regulation of cellular response to transforming growth factor beta stimulus	Jun-29	151/18614	1.05E-07	2.12E-05	1.13E-05	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
TP53	BP	GO:0048511	rhythmic process	Jul-29	303/18614	3.24E-07	4.37E-05	2.32E-05	1387/1457/2033/2099/3065/6714/7157	7	CREBBP/CSNK2A1/EP300/ESR1/HDAC1/SRC/TP53
TP53	BP	GO:2001233	regulation of apoptotic signaling pathway	Jul-29	381/18614	1.51E-06	1.52E-04	8.09E-05	367/1457/1984/3065/9821/6714/7157	7	AR/CSNK2A1/EIF5A/HDAC1/RB1CC1/SRC/TP53
TP53	BP	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	Jul-29	398/18614	2.01E-06	1.81E-04	9.62E-05	1387/2033/3065/4087/4088/6714/7157	7	CREBBP/EP300/HDAC1/SMAD2/SMAD3/SRC/TP53
TP53	BP	GO:1902893	regulation of miRNA transcription	Apr-29	68/18614	3.61E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
TP53	BP	GO:0061614	miRNA transcription	Apr-29	69/18614	3.83E-06	2.92E-04	1.55E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
TP53	BP	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
TP53	BP	GO:0097193	intrinsic apoptotic signaling pathway	Jun-29	301/18614	5.91E-06	3.67E-04	1.95E-04	1026/1984/2033/3065/6714/7157	6	CDKN1A/EIF5A/EP300/HDAC1/SRC/TP53
TP53	BP	GO:2000628	regulation of miRNA metabolic process	Apr-29	81/18614	7.27E-06	4.05E-04	2.15E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
TP53	BP	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	Apr-29	83/18614	8.02E-06	4.18E-04	2.22E-04	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
TP53	BP	GO:0031647	regulation of protein stability	Jun-29	322/18614	8.69E-06	4.25E-04	2.26E-04	1387/2033/5594/4088/6714/7157	6	CREBBP/EP300/MAPK1/SMAD3/SRC/TP53
TP53	BP	GO:0071478	cellular response to radiation	May-29	191/18614	1.05E-05	4.97E-04	2.64E-04	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
TP53	BP	GO:0034644	cellular response to UV	Apr-29	93/18614	1.26E-05	5.62E-04	2.99E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
TP53	BP	GO:0090287	regulation of cellular response to growth factor stimulus	Jun-29	345/18614	1.29E-05	5.62E-04	2.99E-04	1387/2033/3065/4087/4088/7157	6	CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53
TP53	BP	GO:0010586	miRNA metabolic process	Apr-29	97/18614	1.49E-05	6.17E-04	3.28E-04	367/2099/4088/7157	4	AR/ESR1/SMAD3/TP53
TP53	BP	GO:1901653	cellular response to peptide	Jun-29	375/18614	2.06E-05	7.93E-04	4.22E-04	2534/2885/5594/6714/7157/7532	6	FYN/GRB2/MAPK1/SRC/TP53/YWHAG
TP53	BP	GO:2000279	negative regulation of DNA biosynthetic process	Mar-29	37/18614	2.55E-05	9.58E-04	5.09E-04	1026/6714/7157	3	CDKN1A/SRC/TP53
TP53	BP	GO:0001701	in utero embryonic development	Jun-29	398/18614	2.88E-05	0.001012157	5.38E-04	367/2885/5594/4087/4088/7157	6	AR/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	BP	GO:2000278	regulation of DNA biosynthetic process	Apr-29	121/18614	3.56E-05	0.001223397	6.50E-04	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
TP53	BP	GO:0071482	cellular response to light stimulus	Apr-29	127/18614	4.30E-05	0.001422587	7.56E-04	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
TP53	BP	GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Mar-29	44/18614	4.31E-05	0.001422587	7.56E-04	1026/2033/7157	3	CDKN1A/EP300/TP53
TP53	BP	GO:0035196	miRNA processing	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	4087/4088/7157	3	SMAD2/SMAD3/TP53
TP53	BP	GO:0051972	regulation of telomerase activity	Mar-29	47/18614	5.26E-05	0.001605213	8.53E-04	5594/6714/7157	3	MAPK1/SRC/TP53
TP53	BP	GO:1902895	positive regulation of miRNA transcription	Mar-29	51/18614	6.73E-05	0.001908899	0.001014631	367/4088/7157	3	AR/SMAD3/TP53
TP53	BP	GO:0001666	response to hypoxia	May-29	293/18614	8.13E-05	0.00221531	0.001177497	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
TP53	BP	GO:2000377	regulation of reactive oxygen species metabolic process	Apr-29	150/18614	8.23E-05	0.00221531	0.001177497	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
TP53	BP	GO:0009411	response to UV	Apr-29	154/18614	9.11E-05	0.002336435	0.001241878	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
TP53	BP	GO:0034504	protein localization to nucleus	May-29	304/18614	9.68E-05	0.002443574	0.001298825	1026/2534/4088/6714/7157	5	CDKN1A/FYN/SMAD3/SRC/TP53
TP53	BP	GO:0036293	response to decreased oxygen levels	May-29	306/18614	9.98E-05	0.002481349	0.001318903	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
TP53	BP	GO:0051974	negative regulation of telomerase activity	Feb-29	10/18614	1.05E-04	0.002487048	0.001321933	6714/7157	2	SRC/TP53
TP53	BP	GO:2000630	positive regulation of miRNA metabolic process	Mar-29	60/18614	1.10E-04	0.002566918	0.001364386	367/4088/7157	3	AR/SMAD3/TP53
TP53	BP	GO:0072331	signal transduction by p53 class mediator	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1026/1984/2033/7157	4	CDKN1A/EIF5A/EP300/TP53
TP53	BP	GO:2001242	regulation of intrinsic apoptotic signaling pathway	Apr-29	173/18614	1.43E-04	0.003117301	0.001656929	1984/3065/6714/7157	4	EIF5A/HDAC1/SRC/TP53
TP53	BP	GO:0001756	somitogenesis	Mar-29	66/18614	1.46E-04	0.003138186	0.00166803	2033/4088/7157	3	EP300/SMAD3/TP53
TP53	BP	GO:0070482	response to oxygen levels	May-29	333/18614	1.48E-04	0.003154276	0.001676583	1387/2033/4088/6714/7157	5	CREBBP/EP300/SMAD3/SRC/TP53
TP53	BP	GO:0071214	cellular response to abiotic stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
TP53	BP	GO:0104004	cellular response to environmental stimulus	May-29	339/18614	1.61E-04	0.003257009	0.001731188	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
TP53	BP	GO:2000379	positive regulation of reactive oxygen species metabolic process	Mar-29	70/18614	1.74E-04	0.00341922	0.001817407	1026/2885/7157	3	CDKN1A/GRB2/TP53
TP53	BP	GO:0070918	regulatory ncRNA processing	Mar-29	71/18614	1.81E-04	0.003463376	0.001840877	4087/4088/7157	3	SMAD2/SMAD3/TP53
TP53	BP	GO:0070661	leukocyte proliferation	May-29	348/18614	1.82E-04	0.003463376	0.001840877	11119/1026/2534/5594/7157	5	BTN3A1/CDKN1A/FYN/MAPK1/TP53
TP53	BP	GO:0030308	negative regulation of cell growth	Apr-29	191/18614	2.09E-04	0.003876813	0.00206063	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
TP53	BP	GO:0071479	cellular response to ionizing radiation	Mar-29	75/18614	2.13E-04	0.003909723	0.002078123	1026/2885/7157	3	CDKN1A/GRB2/TP53
TP53	BP	GO:0031334	positive regulation of protein-containing complex assembly	Apr-29	195/18614	2.26E-04	0.004102277	0.00218047	2099/2885/6714/7157	4	ESR1/GRB2/SRC/TP53
TP53	BP	GO:0007369	gastrulation	Apr-29	196/18614	2.30E-04	0.004136761	0.0021988	2885/4087/4088/7157	4	GRB2/SMAD2/SMAD3/TP53
TP53	BP	GO:0071897	DNA biosynthetic process	Apr-29	198/18614	2.39E-04	0.004206819	0.002236037	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
TP53	BP	GO:0009952	anterior/posterior pattern specification	Apr-29	209/18614	2.94E-04	0.004803929	0.002553417	2033/4087/4088/7157	4	EP300/SMAD2/SMAD3/TP53
TP53	BP	GO:0090399	replicative senescence	Feb-29	17/18614	3.14E-04	0.004863024	0.002584828	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0061053	somite development	Mar-29	86/18614	3.19E-04	0.004863024	0.002584828	2033/4088/7157	3	EP300/SMAD3/TP53
TP53	BP	GO:0048145	regulation of fibroblast proliferation	Mar-29	87/18614	3.30E-04	0.004984416	0.002649351	1026/2099/7157	3	CDKN1A/ESR1/TP53
TP53	BP	GO:0006977	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0006978	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Feb-29	18/18614	3.53E-04	0.005140322	0.002732219	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0043254	regulation of protein-containing complex assembly	May-29	409/18614	3.84E-04	0.005539882	0.002944596	2033/2099/2885/6714/7157	5	EP300/ESR1/GRB2/SRC/TP53
TP53	BP	GO:0042772	DNA damage response, signal transduction resulting in transcription	Feb-29	19/18614	3.94E-04	0.005539882	0.002944596	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0006140	regulation of nucleotide metabolic process	Mar-29	94/18614	4.14E-04	0.005722622	0.003041727	978/2033/7157	3	CDA/EP300/TP53
TP53	BP	GO:0001558	regulation of cell growth	May-29	420/18614	4.34E-04	0.005893251	0.003132421	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
TP53	BP	GO:0003002	regionalization	May-29	422/18614	4.43E-04	0.005919313	0.003146274	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
TP53	BP	GO:0072593	reactive oxygen species metabolic process	Apr-29	237/18614	4.74E-04	0.006174999	0.003282178	1026/2534/2885/7157	4	CDKN1A/FYN/GRB2/TP53
TP53	BP	GO:0035282	segmentation	Mar-29	100/18614	4.97E-04	0.006370133	0.003385897	2033/4088/7157	3	EP300/SMAD3/TP53
TP53	BP	GO:0006979	response to oxidative stress	May-29	434/18614	5.04E-04	0.006409007	0.003406559	2534/5594/4700/6714/7157	5	FYN/MAPK1/NDUFA6/SRC/TP53
TP53	BP	GO:0008630	intrinsic apoptotic signaling pathway in response to DNA damage	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	1026/2033/7157	3	CDKN1A/EP300/TP53
TP53	BP	GO:0010906	regulation of glucose metabolic process	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0048144	fibroblast proliferation	Mar-29	103/18614	5.42E-04	0.006631889	0.003525027	1026/2099/7157	3	CDKN1A/ESR1/TP53
TP53	BP	GO:0048863	stem cell differentiation	Apr-29	247/18614	5.54E-04	0.00672641	0.003575267	2099/3065/5594/7157	4	ESR1/HDAC1/MAPK1/TP53
TP53	BP	GO:1901796	regulation of signal transduction by p53 class mediator	Mar-29	106/18614	5.89E-04	0.007049017	0.003746742	1984/2033/7157	3	EIF5A/EP300/TP53
TP53	BP	GO:0045926	negative regulation of growth	Apr-29	252/18614	5.97E-04	0.007092315	0.003769756	978/1026/4088/7157	4	CDA/CDKN1A/SMAD3/TP53
TP53	BP	GO:0062014	negative regulation of small molecule metabolic process	Mar-29	107/18614	6.05E-04	0.007094243	0.003770781	978/2033/7157	3	CDA/EP300/TP53
TP53	BP	GO:0009314	response to radiation	May-29	452/18614	6.06E-04	0.007094243	0.003770781	1026/1387/2033/2885/7157	5	CDKN1A/CREBBP/EP300/GRB2/TP53
TP53	BP	GO:0048568	embryonic organ development	May-29	453/18614	6.12E-04	0.007114114	0.003781342	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	BP	GO:0045980	negative regulation of nucleotide metabolic process	Feb-29	25/18614	6.88E-04	0.007825603	0.004159518	978/7157	2	CDA/TP53
TP53	BP	GO:0007389	pattern specification process	May-29	467/18614	7.02E-04	0.007936074	0.004218236	367/2033/4087/4088/7157	5	AR/EP300/SMAD2/SMAD3/TP53
TP53	BP	GO:0071216	cellular response to biotic stimulus	Apr-29	264/18614	7.11E-04	0.007973549	0.004238155	978/5594/6714/7157	4	CDA/MAPK1/SRC/TP53
TP53	BP	GO:0006476	protein deacetylation	Mar-29	116/18614	7.66E-04	0.008303657	0.004413616	2033/3065/7157	3	EP300/HDAC1/TP53
TP53	BP	GO:0045815	transcription initiation-coupled chromatin remodeling	Feb-29	27/18614	8.03E-04	0.008537085	0.00453769	2033/7157	2	EP300/TP53
TP53	BP	GO:0051348	negative regulation of transferase activity	Apr-29	279/18614	8.73E-04	0.00898774	0.004777225	1026/6714/7157/7532	4	CDKN1A/SRC/TP53/YWHAG
TP53	BP	GO:0045165	cell fate commitment	Apr-29	281/18614	8.97E-04	0.00907924	0.00482586	367/3065/4087/7157	4	AR/HDAC1/SMAD2/TP53
TP53	BP	GO:0016049	cell growth	May-29	495/18614	9.13E-04	0.00907924	0.00482586	978/1026/1457/4088/7157	5	CDA/CDKN1A/CSNK2A1/SMAD3/TP53
TP53	BP	GO:0031571	mitotic G1 DNA damage checkpoint signaling	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0044819	mitotic G1/S transition checkpoint signaling	Feb-29	29/18614	9.27E-04	0.00907924	0.00482586	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0071480	cellular response to gamma radiation	Feb-29	30/18614	9.92E-04	0.009519221	0.005059721	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0035601	protein deacylation	Mar-29	127/18614	9.96E-04	0.009519221	0.005059721	2033/3065/7157	3	EP300/HDAC1/TP53
TP53	BP	GO:0034599	cellular response to oxidative stress	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
TP53	BP	GO:0044262	cellular carbohydrate metabolic process	Apr-29	290/18614	0.00100811	0.009526934	0.005063821	2033/9821/6714/7157	4	EP300/RB1CC1/SRC/TP53
TP53	BP	GO:0098732	macromolecule deacylation	Mar-29	131/18614	0.00108881	0.01011217	0.00537489	2033/3065/7157	3	EP300/HDAC1/TP53
TP53	BP	GO:0046651	lymphocyte proliferation	Apr-29	306/18614	0.001229728	0.011040225	0.005868176	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
TP53	BP	GO:0032943	mononuclear cell proliferation	Apr-29	313/18614	0.001336677	0.011549078	0.006138645	11119/1026/2534/7157	4	BTN3A1/CDKN1A/FYN/TP53
TP53	BP	GO:1902253	regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Feb-29	35/18614	0.001350728	0.011549078	0.006138645	1984/7157	2	EIF5A/TP53
TP53	BP	GO:0010212	response to ionizing radiation	Mar-29	143/18614	0.001401358	0.011856515	0.006302056	1026/2885/7157	3	CDKN1A/GRB2/TP53
TP53	BP	GO:0035264	multicellular organism growth	Mar-29	145/18614	0.001458362	0.012274545	0.00652425	367/2033/7157	3	AR/EP300/TP53
TP53	BP	GO:0009416	response to light stimulus	Apr-29	323/18614	0.001500559	0.0124354	0.006609749	1026/1387/2033/7157	4	CDKN1A/CREBBP/EP300/TP53
TP53	BP	GO:0051053	negative regulation of DNA metabolic process	Mar-29	148/18614	0.001546573	0.012751337	0.006777678	1026/6714/7157	3	CDKN1A/SRC/TP53
TP53	BP	GO:0071496	cellular response to external stimulus	Apr-29	327/18614	0.001569882	0.012877816	0.006844905	978/1026/5594/7157	4	CDA/CDKN1A/MAPK1/TP53
TP53	BP	GO:0062012	regulation of small molecule metabolic process	Apr-29	331/18614	0.001641417	0.013354479	0.007098264	978/2033/6714/7157	4	CDA/EP300/SRC/TP53
TP53	BP	GO:0010675	regulation of cellular carbohydrate metabolic process	Mar-29	152/18614	0.00166931	0.013354479	0.007098264	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0007265	Ras protein signal transduction	Apr-29	333/18614	0.001678025	0.013358069	0.007100172	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
TP53	BP	GO:0009895	negative regulation of catabolic process	Apr-29	337/18614	0.001752946	0.013818341	0.007344819	1457/2534/4088/7157	4	CSNK2A1/FYN/SMAD3/TP53
TP53	BP	GO:0062197	cellular response to chemical stress	Apr-29	349/18614	0.001991682	0.015253833	0.008107822	2534/5594/6714/7157	4	FYN/MAPK1/SRC/TP53
TP53	BP	GO:0016052	carbohydrate catabolic process	Mar-29	162/18614	0.002002413	0.015263674	0.008113053	2033/9821/7157	3	EP300/RB1CC1/TP53
TP53	BP	GO:0006606	protein import into nucleus	Mar-29	163/18614	0.00203783	0.015460723	0.008217789	1026/4088/7157	3	CDKN1A/SMAD3/TP53
TP53	BP	GO:0044275	cellular carbohydrate catabolic process	Feb-29	44/18614	0.002128979	0.015927917	0.008466115	9821/7157	2	RB1CC1/TP53
TP53	BP	GO:0051170	import into nucleus	Mar-29	168/18614	0.002220791	0.016424566	0.008730098	1026/4088/7157	3	CDKN1A/SMAD3/TP53
TP53	BP	GO:0009267	cellular response to starvation	Mar-29	170/18614	0.002296745	0.016870633	0.008967194	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	BP	GO:2000378	negative regulation of reactive oxygen species metabolic process	Feb-29	50/18614	0.002740969	0.018945874	0.01007024	2534/7157	2	FYN/TP53
TP53	BP	GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	Mar-29	181/18614	0.0027434	0.018945874	0.01007024	2534/6714/7157	3	FYN/SRC/TP53
TP53	BP	GO:0006109	regulation of carbohydrate metabolic process	Mar-29	183/18614	0.00282996	0.019270953	0.010243029	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0045912	negative regulation of carbohydrate metabolic process	Feb-29	51/18614	0.002850098	0.019270953	0.010243029	2033/7157	2	EP300/TP53
TP53	BP	GO:0042770	signal transduction in response to DNA damage	Mar-29	184/18614	0.002873867	0.019350706	0.010285419	1026/2885/7157	3	CDKN1A/GRB2/TP53
TP53	BP	GO:0006006	glucose metabolic process	Mar-29	187/18614	0.003008113	0.019680611	0.010460773	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0040029	epigenetic regulation of gene expression	Mar-29	188/18614	0.003053708	0.019872984	0.010563024	2033/3065/7157	3	EP300/HDAC1/TP53
TP53	BP	GO:0006338	chromatin remodeling	Apr-29	402/18614	0.003319658	0.021203821	0.0112704	2033/2099/3065/7157	4	EP300/ESR1/HDAC1/TP53
TP53	BP	GO:0002520	immune system development	Mar-29	197/18614	0.003483352	0.022131628	0.011763554	5594/4088/7157	3	MAPK1/SMAD3/TP53
TP53	BP	GO:0010332	response to gamma radiation	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0043470	regulation of carbohydrate catabolic process	Feb-29	57/18614	0.003547086	0.022131628	0.011763554	2033/7157	2	EP300/TP53
TP53	BP	GO:0090311	regulation of protein deacetylation	Feb-29	58/18614	0.003670231	0.022489469	0.011953756	2033/7157	2	EP300/TP53
TP53	BP	GO:0007623	circadian rhythm	Mar-29	207/18614	0.004002267	0.024012739	0.012763415	2033/3065/7157	3	EP300/HDAC1/TP53
TP53	BP	GO:0042594	response to starvation	Mar-29	207/18614	0.004002267	0.024012739	0.012763415	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	BP	GO:0060261	positive regulation of transcription initiation by RNA polymerase II	Feb-29	62/18614	0.004182531	0.02448902	0.013016571	2099/7157	2	ESR1/TP53
TP53	BP	GO:0034470	ncRNA processing	Apr-29	432/18614	0.004291296	0.0249306	0.013251283	23536/4087/4088/7157	4	ADAT1/SMAD2/SMAD3/TP53
TP53	BP	GO:2001244	positive regulation of intrinsic apoptotic signaling pathway	Feb-29	63/18614	0.004315506	0.0249306	0.013251283	1984/7157	2	EIF5A/TP53
TP53	BP	GO:0042098	T cell proliferation	Mar-29	213/18614	0.004335086	0.0249306	0.013251283	11119/2534/7157	3	BTN3A1/FYN/TP53
TP53	BP	GO:0050821	protein stabilization	Mar-29	213/18614	0.004335086	0.0249306	0.013251283	2033/4088/7157	3	EP300/SMAD3/TP53
TP53	BP	GO:0045936	negative regulation of phosphate metabolic process	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
TP53	BP	GO:0010563	negative regulation of phosphorus metabolic process	Apr-29	440/18614	0.004579782	0.025829504	0.013729074	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
TP53	BP	GO:0051123	RNA polymerase II preinitiation complex assembly	Feb-29	68/18614	0.005009484	0.027723717	0.0147359	2099/7157	2	ESR1/TP53
TP53	BP	GO:2000144	positive regulation of DNA-templated transcription initiation	Feb-29	68/18614	0.005009484	0.027723717	0.0147359	2099/7157	2	ESR1/TP53
TP53	BP	GO:0019318	hexose metabolic process	Mar-29	228/18614	0.005239432	0.028508155	0.015152849	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0031669	cellular response to nutrient levels	Mar-29	230/18614	0.005367955	0.02901209	0.015420705	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	BP	GO:0030330	DNA damage response, signal transduction by p53 class mediator	Feb-29	72/18614	0.005599233	0.029569806	0.015717146	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0060260	regulation of transcription initiation by RNA polymerase II	Feb-29	72/18614	0.005599233	0.029569806	0.015717146	2099/7157	2	ESR1/TP53
TP53	BP	GO:0060348	bone development	Mar-29	235/18614	0.00569757	0.029893744	0.015889327	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0071356	cellular response to tumor necrosis factor	Mar-29	235/18614	0.00569757	0.029893744	0.015889327	1984/5594/7157	3	EIF5A/MAPK1/TP53
TP53	BP	GO:0016570	histone modification	Apr-29	475/18614	0.005996982	0.031161166	0.016562996	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
TP53	BP	GO:0031667	response to nutrient levels	Apr-29	477/18614	0.006085872	0.03122149	0.01659506	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
TP53	BP	GO:0007264	small GTPase mediated signal transduction	Apr-29	483/18614	0.006357843	0.032384911	0.017213449	1026/2885/6714/7157	4	CDKN1A/GRB2/SRC/TP53
TP53	BP	GO:2000142	regulation of DNA-templated transcription initiation	Feb-29	80/18614	0.006869314	0.033947437	0.018043974	2099/7157	2	ESR1/TP53
TP53	BP	GO:0044773	mitotic DNA damage checkpoint signaling	Feb-29	81/18614	0.007036453	0.034457298	0.018314979	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0050730	regulation of peptidyl-tyrosine phosphorylation	Mar-29	255/18614	0.007136835	0.034738328	0.018464353	2534/6714/7157	3	FYN/SRC/TP53
TP53	BP	GO:0005996	monosaccharide metabolic process	Mar-29	256/18614	0.007213953	0.035008252	0.018607825	2033/6714/7157	3	EP300/SRC/TP53
TP53	BP	GO:0034612	response to tumor necrosis factor	Mar-29	257/18614	0.007291568	0.035266347	0.01874501	1984/5594/7157	3	EIF5A/MAPK1/TP53
TP53	BP	GO:0070897	transcription preinitiation complex assembly	Feb-29	83/18614	0.007376253	0.035266347	0.01874501	2099/7157	2	ESR1/TP53
TP53	BP	GO:0031668	cellular response to extracellular stimulus	Mar-29	261/18614	0.007607017	0.036049677	0.019161371	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	BP	GO:0003007	heart morphogenesis	Mar-29	262/18614	0.00768713	0.036281916	0.019284812	4087/4088/7157	3	SMAD2/SMAD3/TP53
TP53	BP	GO:0044774	mitotic DNA integrity checkpoint signaling	Feb-29	85/18614	0.007723378	0.036281916	0.019284812	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0034103	regulation of tissue remodeling	Feb-29	86/18614	0.007899673	0.036789256	0.019554477	6714/7157	2	SRC/TP53
TP53	BP	GO:2000134	negative regulation of G1/S transition of mitotic cell cycle	Feb-29	86/18614	0.007899673	0.036789256	0.019554477	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0097194	execution phase of apoptosis	Feb-29	87/18614	0.008077782	0.037403141	0.019880773	662/7157	2	BNIP1/TP53
TP53	BP	GO:0042113	B cell activation	Mar-29	276/18614	0.00886175	0.040568238	0.021563107	1026/2033/7157	3	CDKN1A/EP300/TP53
TP53	BP	GO:0000422	autophagy of mitochondrion	Feb-29	92/18614	0.008995342	0.040832789	0.021703723	9821/7157	2	RB1CC1/TP53
TP53	BP	GO:0061726	mitochondrion disassembly	Feb-29	92/18614	0.008995342	0.040832789	0.021703723	9821/7157	2	RB1CC1/TP53
TP53	BP	GO:1901216	positive regulation of neuron death	Feb-29	92/18614	0.008995342	0.040832789	0.021703723	2534/7157	2	FYN/TP53
TP53	BP	GO:0061912	selective autophagy	Feb-29	93/18614	0.009184217	0.041341769	0.02197426	9821/7157	2	RB1CC1/TP53
TP53	BP	GO:1900542	regulation of purine nucleotide metabolic process	Feb-29	93/18614	0.009184217	0.041341769	0.02197426	2033/7157	2	EP300/TP53
TP53	BP	GO:0016575	histone deacetylation	Feb-29	94/18614	0.009374867	0.042082737	0.022368104	3065/7157	2	HDAC1/TP53
TP53	BP	GO:0048534	hematopoietic or lymphoid organ development	Feb-29	96/18614	0.009761469	0.043099817	0.02290871	5594/7157	2	MAPK1/TP53
TP53	BP	GO:1902807	negative regulation of cell cycle G1/S phase transition	Feb-29	97/18614	0.009957409	0.043607514	0.023178564	1026/7157	2	CDKN1A/TP53
TP53	BP	GO:0030512	negative regulation of transforming growth factor beta receptor signaling pathway	Feb-29	100/18614	0.010555722	0.045246808	0.024049893	3065/7157	2	HDAC1/TP53
TP53	MF	GO:0061629	RNA polymerase II-specific DNA-binding transcription factor binding	Sep-32	348/18369	5.42E-09	9.45E-07	4.03E-07	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
TP53	MF	GO:0140297	DNA-binding transcription factor binding	Sep-32	478/18369	8.36E-08	3.72E-06	1.58E-06	367/1387/2033/2099/3065/4087/4088/6714/7157	9	AR/CREBBP/EP300/ESR1/HDAC1/SMAD2/SMAD3/SRC/TP53
TP53	MF	GO:0002039	p53 binding	Apr-32	67/18369	5.38E-06	1.92E-04	8.16E-05	1387/2033/3065/7157	4	CREBBP/EP300/HDAC1/TP53
TP53	MF	GO:0001091	RNA polymerase II general transcription initiation factor binding	Mar-32	26/18369	1.22E-05	3.37E-04	1.43E-04	367/2099/7157	3	AR/ESR1/TP53
TP53	MF	GO:0019902	phosphatase binding	May-32	187/18369	1.67E-05	3.37E-04	1.43E-04	2885/5594/4087/4088/7157	5	GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	MF	GO:0097718	disordered domain specific binding	Mar-32	36/18369	3.30E-05	5.87E-04	2.50E-04	2534/4087/7157	3	FYN/SMAD2/TP53
TP53	MF	GO:0140296	general transcription initiation factor binding	Mar-32	53/18369	1.06E-04	0.001348122	5.74E-04	367/2099/7157	3	AR/ESR1/TP53
TP53	MF	GO:0001098	basal transcription machinery binding	Mar-32	61/18369	1.61E-04	0.001689597	7.19E-04	367/2099/7157	3	AR/ESR1/TP53
TP53	MF	GO:0001099	basal RNA polymerase II transcription machinery binding	Mar-32	61/18369	1.61E-04	0.001689597	7.19E-04	367/2099/7157	3	AR/ESR1/TP53
TP53	MF	GO:1990841	promoter-specific chromatin binding	Mar-32	63/18369	1.78E-04	0.001756554	7.48E-04	3065/4088/7157	3	HDAC1/SMAD3/TP53
TP53	MF	GO:0030971	receptor tyrosine kinase binding	Mar-32	76/18369	3.10E-04	0.00275597	0.001173447	2885/7157/7532	3	GRB2/TP53/YWHAG
TP53	MF	GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	May-32	468/18369	0.001198605	0.007136975	0.003038807	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
TP53	MF	GO:1990782	protein tyrosine kinase binding	Mar-32	121/18369	0.001202861	0.007136975	0.003038807	2885/7157/7532	3	GRB2/TP53/YWHAG
TP53	MF	GO:0001216	DNA-binding transcription activator activity	May-32	472/18369	0.001244795	0.007145292	0.003042348	367/2099/4087/4088/7157	5	AR/ESR1/SMAD2/SMAD3/TP53
TP53	MF	GO:0031625	ubiquitin protein ligase binding	Apr-32	301/18369	0.001769913	0.008147008	0.003468862	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
TP53	MF	GO:0044389	ubiquitin-like protein ligase binding	Apr-32	320/18369	0.002211874	0.009602771	0.004088702	1026/4087/4088/7157	4	CDKN1A/SMAD2/SMAD3/TP53
TP53	MF	GO:0001046	core promoter sequence-specific DNA binding	Feb-32	43/18369	0.002539157	0.010272045	0.004373668	3065/7157	2	HDAC1/TP53
TP53	MF	GO:0001094	TFIID-class transcription factor complex binding	Jan-32	10/18369	0.017288924	0.04808482	0.020473726	7157	1	TP53
TP53	MF	GO:0097371	MDM2/MDM4 family protein binding	Jan-32	11/18369	0.019001803	0.049740015	0.021178481	7157	1	TP53
TP53	MF	GO:0140666	annealing activity	Jan-32	11/18369	0.019001803	0.049740015	0.021178481	7157	1	TP53
TP53	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
TP53	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
TP53	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
TP53	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
TP53	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
TP53	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
TP53	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
TP53	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
TP53	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
TP53	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
TP53	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
TP53	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
TP53	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
TP53	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
TP53	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
TP53	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
TP53	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
TP53	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
TP53	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
TP53	NA	hsa05216	Thyroid cancer	Mar-22	37/8848	9.82E-05	5.12E-04	1.90E-04	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
TP53	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
TP53	NA	hsa05218	Melanoma	Mar-22	73/8848	7.41E-04	0.002691655	0.001000994	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	NA	hsa01524	Platinum drug resistance	Mar-22	75/8848	8.02E-04	0.002850907	0.001060217	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
TP53	NA	hsa04137	Mitophagy - animal	Mar-22	105/8848	0.002122452	0.006111198	0.00227268	1457/6714/7157	3	CSNK2A1/SRC/TP53
TP53	NA	hsa04722	Neurotrophin signaling pathway	Mar-22	120/8848	0.003103907	0.008639206	0.003212816	2885/5594/7157	3	GRB2/MAPK1/TP53
TP53	NA	hsa05217	Basal cell carcinoma	Feb-22	63/8848	0.010516467	0.02405822	0.008946958	1026/7157	2	CDKN1A/TP53
TP53	NA	hsa05202	Transcriptional misregulation in cancer	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	1026/3065/7157	3	CDKN1A/HDAC1/TP53
TP53	NA	hsa05230	Central carbon metabolism in cancer	Feb-22	71/8848	0.013221774	0.02673445	0.009942216	5594/7157	2	MAPK1/TP53
TP53	NA	hsa05169	Epstein-Barr virus infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	1026/3065/7157	3	CDKN1A/HDAC1/TP53
TP53	NA	hsa04115	p53 signaling pathway	Feb-22	75/8848	0.014676616	0.02849994	0.01059878	1026/7157	2	CDKN1A/TP53
TP53	NA	hsa05417	Lipid and atherosclerosis	Mar-22	216/8848	0.015690563	0.030118667	0.011200765	5594/6714/7157	3	MAPK1/SRC/TP53
TP53	NA	hsa04211	Longevity regulating pathway	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	9821/7157	2	RB1CC1/TP53
TP53	NA	hsa05222	Small cell lung cancer	Feb-22	93/8848	0.022025036	0.039980229	0.01486816	1026/7157	2	CDKN1A/TP53
TP53	NA	hsa05131	Shigellosis	Mar-22	249/8848	0.022840621	0.041014879	0.015252933	5594/6714/7157	3	MAPK1/SRC/TP53
TP53	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
TP53	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
TP53	NA	hsa05215	Prostate cancer	Jul-22	98/8848	2.45E-09	9.58E-08	3.56E-08	367/1026/1387/2033/2885/5594/7157	7	AR/CDKN1A/CREBBP/EP300/GRB2/MAPK1/TP53
TP53	NA	hsa05161	Hepatitis B	Aug-22	163/8848	2.87E-09	9.58E-08	3.56E-08	1026/1387/2033/2885/5594/4088/6714/7157	8	CDKN1A/CREBBP/EP300/GRB2/MAPK1/SMAD3/SRC/TP53
TP53	NA	hsa04919	Thyroid hormone signaling pathway	Jul-22	122/8848	1.15E-08	3.19E-07	1.19E-07	1387/2033/2099/3065/5594/6714/7157	7	CREBBP/EP300/ESR1/HDAC1/MAPK1/SRC/TP53
TP53	NA	hsa05220	Chronic myeloid leukemia	Jun-22	77/8848	2.38E-08	5.68E-07	2.11E-07	1026/2885/3065/5594/4088/7157	6	CDKN1A/GRB2/HDAC1/MAPK1/SMAD3/TP53
TP53	NA	hsa05166	Human T-cell leukemia virus 1 infection	Aug-22	223/8848	3.39E-08	7.07E-07	2.63E-07	246184/1026/1387/2033/5594/4087/4088/7157	8	CDC26/CDKN1A/CREBBP/EP300/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05210	Colorectal cancer	Jun-22	87/8848	4.99E-08	9.26E-07	3.45E-07	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa01522	Endocrine resistance	Jun-22	99/8848	1.09E-07	1.82E-06	6.75E-07	1026/2099/2885/5594/6714/7157	6	CDKN1A/ESR1/GRB2/MAPK1/SRC/TP53
TP53	NA	hsa05205	Proteoglycans in cancer	Jul-22	204/8848	3.97E-07	5.53E-06	2.06E-06	1026/2099/2885/5594/4087/6714/7157	7	CDKN1A/ESR1/GRB2/MAPK1/SMAD2/SRC/TP53
TP53	NA	hsa05212	Pancreatic cancer	May-22	77/8848	1.03E-06	1.14E-05	4.25E-06	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05226	Gastric cancer	Jun-22	150/8848	1.28E-06	1.34E-05	4.97E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05225	Hepatocellular carcinoma	Jun-22	170/8848	2.66E-06	2.54E-05	9.43E-06	1026/2885/5594/4087/4088/7157	6	CDKN1A/GRB2/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05219	Bladder cancer	Apr-22	41/8848	2.73E-06	2.54E-05	9.43E-06	1026/5594/6714/7157	4	CDKN1A/MAPK1/SRC/TP53
TP53	NA	hsa05167	Kaposi sarcoma-associated herpesvirus infection	Jun-22	196/8848	6.08E-06	5.34E-05	1.99E-05	1026/1387/2033/5594/6714/7157	6	CDKN1A/CREBBP/EP300/MAPK1/SRC/TP53
TP53	NA	hsa05206	MicroRNAs in cancer	Jul-22	312/8848	6.85E-06	5.72E-05	2.13E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
TP53	NA	hsa05165	Human papillomavirus infection	Jul-22	333/8848	1.05E-05	8.36E-05	3.11E-05	1026/1387/2033/2885/3065/5594/7157	7	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/TP53
TP53	NA	hsa05213	Endometrial cancer	Apr-22	59/8848	1.19E-05	9.05E-05	3.37E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
TP53	NA	hsa05224	Breast cancer	May-22	148/8848	2.56E-05	1.78E-04	6.63E-05	1026/2099/2885/5594/7157	5	CDKN1A/ESR1/GRB2/MAPK1/TP53
TP53	NA	hsa05223	Non-small cell lung cancer	Apr-22	73/8848	2.79E-05	1.86E-04	6.93E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
TP53	NA	hsa05214	Glioma	Apr-22	76/8848	3.27E-05	2.10E-04	7.81E-05	1026/2885/5594/7157	4	CDKN1A/GRB2/MAPK1/TP53
TP53	NA	hsa04218	Cellular senescence	May-22	157/8848	3.40E-05	2.11E-04	7.83E-05	1026/5594/4087/4088/7157	5	CDKN1A/MAPK1/SMAD2/SMAD3/TP53
TP53	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
TP53	NA	hsa04310	Wnt signaling pathway	May-22	174/8848	5.57E-05	3.10E-04	1.15E-04	1387/1457/2033/4088/7157	5	CREBBP/CSNK2A1/EP300/SMAD3/TP53
TP53	NA	hsa05016	Huntington disease	Jun-22	311/8848	8.32E-05	4.48E-04	1.67E-04	1387/2033/3065/4700/9821/7157	6	CREBBP/EP300/HDAC1/NDUFA6/RB1CC1/TP53
TP53	NA	hsa05216	Thyroid cancer	Mar-22	37/8848	9.82E-05	5.12E-04	1.90E-04	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	NA	hsa05163	Human cytomegalovirus infection	May-22	226/8848	1.92E-04	9.16E-04	3.41E-04	1026/2885/5594/6714/7157	5	CDKN1A/GRB2/MAPK1/SRC/TP53
TP53	NA	hsa04071	Sphingolipid signaling pathway	Apr-22	122/8848	2.08E-04	9.37E-04	3.49E-04	79603/2534/5594/7157	4	CERS4/FYN/MAPK1/TP53
TP53	NA	hsa05218	Melanoma	Mar-22	73/8848	7.41E-04	0.002691655	0.001000994	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	NA	hsa01524	Platinum drug resistance	Mar-22	75/8848	8.02E-04	0.002850907	0.001060217	1026/5594/7157	3	CDKN1A/MAPK1/TP53
TP53	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
TP53	NA	hsa04137	Mitophagy - animal	Mar-22	105/8848	0.002122452	0.006111198	0.00227268	1457/6714/7157	3	CSNK2A1/SRC/TP53
TP53	NA	hsa04722	Neurotrophin signaling pathway	Mar-22	120/8848	0.003103907	0.008639206	0.003212816	2885/5594/7157	3	GRB2/MAPK1/TP53
TP53	NA	hsa05217	Basal cell carcinoma	Feb-22	63/8848	0.010516467	0.02405822	0.008946958	1026/7157	2	CDKN1A/TP53
TP53	NA	hsa05202	Transcriptional misregulation in cancer	Mar-22	193/8848	0.011594465	0.024509819	0.009114903	1026/3065/7157	3	CDKN1A/HDAC1/TP53
TP53	NA	hsa05230	Central carbon metabolism in cancer	Feb-22	71/8848	0.013221774	0.02673445	0.009942216	5594/7157	2	MAPK1/TP53
TP53	NA	hsa05169	Epstein-Barr virus infection	Mar-22	203/8848	0.013287182	0.02673445	0.009942216	1026/3065/7157	3	CDKN1A/HDAC1/TP53
TP53	NA	hsa04115	p53 signaling pathway	Feb-22	75/8848	0.014676616	0.02849994	0.01059878	1026/7157	2	CDKN1A/TP53
TP53	NA	hsa05417	Lipid and atherosclerosis	Mar-22	216/8848	0.015690563	0.030118667	0.011200765	5594/6714/7157	3	MAPK1/SRC/TP53
TP53	NA	hsa04211	Longevity regulating pathway	Feb-22	90/8848	0.02071212	0.038432488	0.014292574	9821/7157	2	RB1CC1/TP53
TP53	NA	hsa05222	Small cell lung cancer	Feb-22	93/8848	0.022025036	0.039980229	0.01486816	1026/7157	2	CDKN1A/TP53
TP53	NA	hsa05131	Shigellosis	Mar-22	249/8848	0.022840621	0.041014879	0.015252933	5594/6714/7157	3	MAPK1/SRC/TP53
YWHAG	BP	GO:1901653	cellular response to peptide	Jun-29	375/18614	2.06E-05	7.93E-04	4.22E-04	2534/2885/5594/6714/7157/7532	6	FYN/GRB2/MAPK1/SRC/TP53/YWHAG
YWHAG	BP	GO:0032869	cellular response to insulin stimulus	Apr-29	211/18614	3.05E-04	0.004863024	0.002584828	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
YWHAG	BP	GO:0032868	response to insulin	Apr-29	272/18614	7.94E-04	0.008500733	0.004518368	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
YWHAG	BP	GO:0051348	negative regulation of transferase activity	Apr-29	279/18614	8.73E-04	0.00898774	0.004777225	1026/6714/7157/7532	4	CDKN1A/SRC/TP53/YWHAG
YWHAG	BP	GO:0071375	cellular response to peptide hormone stimulus	Apr-29	308/18614	0.001259647	0.011135312	0.005918717	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
YWHAG	BP	GO:0043434	response to peptide hormone	Apr-29	427/18614	0.00411742	0.024283759	0.01290747	2885/5594/6714/7532	4	GRB2/MAPK1/SRC/YWHAG
YWHAG	BP	GO:0045936	negative regulation of phosphate metabolic process	Apr-29	439/18614	0.004543022	0.025759729	0.013691987	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
YWHAG	BP	GO:0010563	negative regulation of phosphorus metabolic process	Apr-29	440/18614	0.004579782	0.025829504	0.013729074	978/1026/7157/7532	4	CDA/CDKN1A/TP53/YWHAG
YWHAG	BP	GO:0050804	modulation of chemical synaptic transmission	Apr-29	487/18614	0.006543613	0.032839994	0.017455338	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
YWHAG	BP	GO:0099177	regulation of trans-synaptic signaling	Apr-29	488/18614	0.006590616	0.032871717	0.0174722	2534/5594/6714/7532	4	FYN/MAPK1/SRC/YWHAG
YWHAG	MF	GO:0030971	receptor tyrosine kinase binding	Mar-32	76/18369	3.10E-04	0.00275597	0.001173447	2885/7157/7532	3	GRB2/TP53/YWHAG
YWHAG	MF	GO:1990782	protein tyrosine kinase binding	Mar-32	121/18369	0.001202861	0.007136975	0.003038807	2885/7157/7532	3	GRB2/TP53/YWHAG
YWHAG	MF	GO:0030291	protein serine/threonine kinase inhibitor activity	Feb-32	36/18369	0.001785019	0.008147008	0.003468862	1026/7532	2	CDKN1A/YWHAG
YWHAG	MF	GO:0005080	protein kinase C binding	Feb-32	49/18369	0.003285353	0.011695858	0.004979904	6714/7532	2	SRC/YWHAG
YWHAG	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
YWHAG	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
YWHAG	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
YWHAG	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
YWHAG	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
YWHAG	NA	hsa04390	Hippo signaling pathway	Mar-22	157/8848	0.006589044	0.015947396	0.005930642	4087/4088/7532	3	SMAD2/SMAD3/YWHAG
YWHAG	NA	hsa04110	Cell cycle	Sep-22	158/8848	5.99E-11	1.00E-08	3.72E-09	246184/1026/1387/2033/3065/4087/4088/7157/7532	9	CDC26/CDKN1A/CREBBP/EP300/HDAC1/SMAD2/SMAD3/TP53/YWHAG
YWHAG	NA	hsa05203	Viral carcinogenesis	Sep-22	205/8848	6.19E-10	5.17E-08	1.92E-08	1026/1387/2033/2885/3065/5594/6714/7157/7532	9	CDKN1A/CREBBP/EP300/GRB2/HDAC1/MAPK1/SRC/TP53/YWHAG
YWHAG	NA	hsa05160	Hepatitis C	May-22	159/8848	3.62E-05	2.16E-04	8.03E-05	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
YWHAG	NA	hsa04114	Oocyte meiosis	Apr-22	139/8848	3.42E-04	0.001429688	5.32E-04	367/246184/5594/7532	4	AR/CDC26/MAPK1/YWHAG
YWHAG	NA	hsa04151	PI3K-Akt signaling pathway	May-22	362/8848	0.001650235	0.005103503	0.001897931	1026/2885/5594/7157/7532	5	CDKN1A/GRB2/MAPK1/TP53/YWHAG
YWHAG	NA	hsa04390	Hippo signaling pathway	Mar-22	157/8848	0.006589044	0.015947396	0.005930642	4087/4088/7532	3	SMAD2/SMAD3/YWHAG
